Trans fat intake and risk of lifestyle diseases by Bendsen, Nathalie Tommerup
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Trans fat intake and risk of lifestyle diseases
Bendsen, Nathalie Tommerup
Publication date:
2010
Document version
Peer reviewed version
Citation for published version (APA):
Bendsen, N. T. (2010). Trans fat intake and risk of lifestyle diseases. Department of Human Nutrition, University
of Copenhagen.
Download date: 02. Feb. 2020
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Academic advisors:  Arne Astrup,  
Thomas M. Larsen  
Steen B. Haugaard 
 
Submitted: 30/09/10 
F A C U L T Y  O F  L I F E  S C I E N C E S  
U N I V E R S I T Y  O F  C O P E N H A G E N  
 Trans fat intake and risk of lifestyle diseases 
PhD Thesis by Nathalie Tommerup Bendsen 
 
 
 
Supervisors 
Professor, MD, DMSc Arne Astrup 
Department of Human Nutrition 
Faculty of Life Sciences 
University of Copenhagen, Denmark 
 
Associate Professor, PhD Thomas Meinert Larsen 
Department of Human Nutrition 
Faculty of Life Sciences 
University of Copenhagen, Denmark 
 
MD, DMSc Steen B. Haugaard  
Clinical Research Centre 
Copenhagen University Hospital, Hvidovre, Denmark 
 
 
 
Evaluation Committee 
Associate Professor, PhD Tine Tholstrup 
Department of Human Nutrition 
Faculty of Life Sciences 
University of Copenhagen, Denmark 
 
MD, PhD Jens M. Bruun 
Department of Medicine and Endocrinology C 
Aarhus University Hospital, Denmark 
 
Associate Professor, MD, PhD Ulf Risérus 
Department of Public Health and Caring Sciences 
Clinical Nutrition and Metabolism  
Uppsala University, Sweden 
 
 
 
 
ISBN 9788790505462 
Printed by SL grafik, Frederiksberg, Denmark (www.slgrafik.dk) 
 
 
 
Department of Human Nutrition 
Faculty of Life Sciences, University of Copenhagen 
Rolighedsvej 30 
DK-1958 Frederiksberg C, Denmark 
Tel: +45 3533 2470 
Fax: +45 3533 2483 
E-mail: ihe@life.ku.dk
  
i 
PREFACE AND ACKNOWLEDGEMENTS 
The scope of the present PhD thesis was i) to review the observational evidence for an association be-
tween intake of trans fat and risk of coronary heart disease, including the evidence to distinguish between 
the effects of trans fat of industrial and ruminant origin; and ii) to examine if dietary trans fat from hy-
drogenated vegetable oil affects traditional and emerging cardiovascular risk markers in a vulnerable 
study population.  
The thesis is based on a systematic review and meta-analysis of observational studies as well as a dietary 
intervention study, called  (Copenhagen Obesity Risk Assessment Study) conducted at the De-
partment of Human Nutrition, University of Copenhagen in the time period from September 2007 to Sep-
tember 2010, which has provided the following four manuscripts: 
I. Bendsen NT, Christensen R, Bartels EM & Astrup A. Consumption of industrial and ruminant 
trans fatty acids and risk of coronary heart disease: A systematic review and meta-analysis of co-
hort studies (Submitted).  
II. Bendsen NT, Chabanova C, Thomsen HS, Larsen TM, Newman JW, Stender S, Dyerberg J, Hau-
gaard SB & Astrup A. Effect of trans fatty acid intake on abdominal and liver fat deposition and 
blood lipids - a randomized trial in overweight postmenopausal women (Submitted).  
III. Bendsen NT, Haugaard SB, Larsen TM, Chabanova C, Stender S & Astrup A. Effect of trans fatty 
acid intake on insulin sensitivity and intramuscular lipids – a randomized trial in overweight post-
menopausal women (Submitted). 
IV. Bendsen NT, Stender S, Szecsi PB, Pedersen SB, Basu S, Hellgren LI, Newman JW, Larsen TM, 
Haugaard SB & Astrup A. Trans fatty acid intake induces low-grade systemic inflammation: evi-
dence from a randomized, controlled trial in overweight postmenopausal women (draft). 
The intervention study was carried out as a part of the research program of the Danish Obesity Research 
Centre (DanORC, see www.danorc.dk). DanORC is supported by the Danish Council for Strategic Re-
search (Grant 2101-06-0005). The study was also supported by the Danish Council for Independent Re-
search | Medical Sciences (Grant 271-08-0715), and the Danish Diabetes Association. The test fats were 
kindly provided by AarhusKarlshamn Denmark A/S. The meta-analysis was kindly co-sponsored by Arla 
Foods Amba. 
I owe thanks to many people who have been involved in this project: 
To my supervisors Arne Astrup and Thomas M. Larsen for giving me the opportunity to conduct this 
research; To Arne for supporting me despite his early proclamation saying “trans fat is a dead herring” a 
few months into my PhD; To my external supervisor Steen B. Haugaard for his never ending enthusiasm 
and swift replies to my many scientific questions; To all the technical personnel, lab technicians, dieti-
cians and kitchen staff at the department who were involved in the  study; including Elisabet, 
Charlotte, Sarah, Bettina, Marianne, Birte, Kira and Charlotte; To Anne-Louise and Ida, who provided 
valuable help with all the practical work; To the partners who have contributed to the  study, in 
particular Steen Stender and all his hard-working staff (Copenhagen University Hospital, Gentofte) and 
John D. Newman and colleagues (University of California, Davis); To all the women who participated in 
the  study; To Robin Christensen and Else Bartels for taking the time to introduce me to the field 
of systematic reviews and meta-analyses; To all my colleagues in the obesity group for making this proc-
ess less lonesome; especially my roommates, Lene, Lone and Lesli for great scientific and less scientific 
discussions; to Janne for looking after me; and to Nikolaj for being Nikolaj; To Svedsken, Becs, Bendsen 
and NomsESKARTAR, and not least to my Great White for always supporting me, but also reminding me that 
all work and no play will only make be a dull girl… 
 
 
Nathalie Tommerup Bendsen, 
Frederiksberg, September 2010 
ii 
SUMMARY 
Consumption of trans fatty acids (TFA), which form part of partially hydrogenated edible oils, 
is detrimental to human health. An average daily intake of just ~5 grams of TFA increases the 
risk of coronary heart disease (CHD) by more than 20%, according to data from prospective 
cohort studies. Associations between TFA intake and incidence of type 2 diabetes have also 
been reported. Several studies have attempted to elucidate the causal physiological mechanisms 
of action. However, the documented effects of TFA intake on cardiovascular risk markers, such 
as blood lipids, can explain less than 50% of the increase in risk of CHD found in observational 
studies, leaving a so-called “explanatory gap”.  
The present thesis examines whether there is a scientific basis for differentiating between TFA 
of industrial and ruminant origin in terms of health risk, and whether the TFA-associated in-
crease in CHD risk may be explained by detectable effects on established as well as emerging 
risk factors for lifestyle diseases. To address these issues, the thesis combines a review of the 
scientific literature with i) a systematic review and meta-analysis of published and unpublished 
prospective cohort studies assessing the association between TFA consumption and risk of CHD 
(Paper I); and ii) results of a dietary intervention study called , in which 52 abdominally 
obese, postmenopausal women for 16 weeks were to consume 15 g/day of TFA from partially 
hydrogenated soybean oil or a control fat high in oleic and palmitic acid (Papers II, III and IV).  
The thesis attends to the following questions: 
Question (Q): Is TFA intake associated with increased CHD risk – and may TFA from ruminant 
and industrial sources be regarded as equally harmful? 
Answer (A): The systematic review of cohort studies confirms that TFA intake is associated 
with an increased risk of CHD of the magnitude previously reported (~20% per 5 g/day TFA). 
However, it also highlights the scarcity of this type of studies, which may be due to the difficul-
ties in appropriately assessing TFA intake in observational studies or to publication bias. Never-
theless, evidence from case-control studies, using biomarkers of TFA intake, collectively 
support the notion that TFA intake is associated with increased risk of CHD.  
Based on data from the cohort studies, it appears that the risk associated with TFA intake may 
be ascribable to industrially produced, and not ruminant TFA, possibly due to low intake levels 
of the latter. However, a very limited number of studies prohibits any firm conclusions concern-
ing whether the source of TFA is important. Biomarker studies do not lend support to the notion 
that R-TFA should be less harmful than IP-TFA; neither do intervention studies examining the 
effect on blood lipids. Yet, there is no evidence to support that ruminant TFA increases the risk 
of CHD in the amounts usually consumed.  
Q: Does TFA consumption affect blood lipids? 
A: TFA consumption increases LDL-cholesterol and decreases HDL- cholesterol concentrations 
and thereby induces a more atherogenic blood cholesterol profile than all other fatty acid 
classes. This has been confirmed by numerous intervention studies and appears to apply to TFA 
of both ruminant and industrial origin, at least at high intake levels. The observed increase in the 
ratio of LDL-cholesterol to HDL-cholesterol of 34% (P<0.001) in the  study, can there-
fore be considered an indication of good compliance with the study diets. An increase of the 
size found in the  study may translate into an increase in heart disease risk of ~6% per 5 
g/day TFA. In addition, there is evidence to suggest that TFA intake induces a modest increase 
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in triglyceride and lipoprotein (a) concentrations and gives rise to production of smaller LDL 
particles. 
Q: Does TFA consumption affect markers of low-grade inflammation and endothelial dysfunc-
tion? 
A: The current evidence for an effect of TFA consumption on low-grade systemic inflammation 
and endothelial dysfunction mainly stem from cross-sectional studies. Yet, with the finding of a 
12% increased production of tumor necrosis factor α (P=0.002) and concomitant increases in its 
soluble receptors, the  study supports the notion that dietary TFA promote low-grade 
inflammation. TFA consumption has been found to modestly increase CRP production in a few 
studies, but such an effect could not be detected in the  study.  
Results from the  study tend to confirm prior reports of an E-selectin-increasing effect 
of TFA, indicating that TFA may promote endothelial dysfunction. However, only one study 
(out of two) has pointed towards a negative effect of TFA on more direct measures of endothe-
lial function. 
Q: Does TFA consumption affect body composition and fat deposition? 
A: A few large prospective cohort studies have suggested that TFA intake increases the risk of 
abdominal obesity or weight gain in general, and a 6-year study in monkeys supports these find-
ings. A substantial TFA consumption for 4 months in the  study did not affect the ab-
dominal fat accumulation in postmenopausal women, but weak trends towards a greater whole-
body fat deposition was observed in women exposed to TFA (P=0.12). Whereas the evidence 
for an effect of TFA on body adiposity in rodents is highly conflicting, an increased accumula-
tion of fat in the liver has been an almost consistent finding. The  study failed in the 
attempt to verify this effect in humans. The null-finding may, however, be due to study limita-
tions, such as a high degree of within-subject variability in liver fat content and a lack of stan-
dardization of the study diets. 
Q: Does TFA exposure affect insulin sensitivity? 
A: Most animal studies suggest that TFA intake impairs insulin sensitivity compared with other 
FA classes, whereas evidence from studies in humans is highly conflicting. Whether this dis-
crepancy is due to the longer duration of TFA exposure in animal studies or simply reflects 
metabolic differences between species is unknown. The few indices of a detrimental effect of 
TFA intake on insulinemia in humans come from studies in metabolically vulnerable study 
populations. However, TFA exposure did not result in changes in insulin sensitivity and markers 
of lipolysis in older overweight women in the  study.  
Q: What may be concluded from the  study? 
A: In brief, with the findings of a pro-inflammatory effect of TFA in the  study, our 
research has provided evidence to explain part of the aforementioned “explanatory gap”, al-
though it is difficult to estimate what this effect may translate into in terms of heart disease risk. 
In contrast, induction of ectopic fat deposition or insulin resistance could not be confirmed as 
explanatory factors. 
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SAMMENDRAG 
Indtag af transfedtsyrer (TF), som findes i delvist hærdede spiseolier, er skadeligt for helbredet. 
Et gennemsnitligt dagligt indtag af TF på bare ~5 gram øger risikoen for at udvikle hjertesyg-
dom med mere end 20%, ifølge data fra prospektive kohortestudier. Indtag af TF er ligeledes 
blevet kædet sammen med øget risiko for type 2 sukkersyge. En række interventionsstudier har 
undersøgt, hvilke fysiologiske virkningsmekanismer der kan tænkes at ligge til grund for den 
øgede sygdomsrisiko. Dokumenterede effekter af TF, såsom påvirkning af blodets fedtstoffer, 
kan imidlertid forklare mindre end 50% af den øgede risiko for hjertesygdom fundet i befolk-
ningsundersøgelser. Dermed står vi tilbage med et såkaldt ”forklaringsunderskud”. 
Nærværende PhD-afhandling undersøger, hvorvidt der er videnskabeligt belæg for at skelne 
mellem TF, som stammer fra industriel hærdning og TF, som stammer fra mikrobiel hærdning i 
vommen hos drøvtyggere, med hensyn til risiko for livsstilssygdomme. Desuden undersøges, 
om den øgede sygdomsrisiko kan forklares ved at indtag af TF påvirker en række etablerede 
samt nyere risikofaktorer for hjertesygdom og type 2 sukkersyge. Afhandlingen kombinerer en 
gennemgang af den eksisterende litteratur med i) et systematisk review og meta-analyse af pub-
licerede og ikke-publicerede prospektive kohortestudier, som undersøger sammenhængen mel-
lem indtag af TF og forekomsten af hjertesygdom (Artikel I), og ii) resultaterne fra et 
kostinterventionsstudie, kaldet , hvor 52 postmenopausale kvinder med mavefedme 
blev bedt om at indtage 15 g/dag TF fra delvist hærdet sojabønneolie eller et kontrolfedtstof 
med højt indhold af olie- og palmitinsyre i 16 uger. 
Afhandlingen adresserer følgende spørgsmål: 
Spørgsmål (SP): Er indtag af TF forbundet med øget risiko for hjertesygdom – og kan TF fra 
industriel og mikrobiel hærdning betragtes som lige skadelige? 
Svar (SV): Det systematiske review af kohortestudier bekræfter, at indtag af TF er forbundet 
med øget risiko for hjertesygdom i samme størrelsesorden som tidligere rapporteret (~20% pr. 5 
g/dag TF). Det fremhæver imidlertid også, at der findes ganske få studier af denne type, hvilket 
kan skyldes publicerings-skævhed eller vanskelighederne forbundet med at estimere TF-indtag i 
befolkningsundersøgelser. Ikke desto mindre bliver disse resultater underbygget af data fra case-
kontrol-studier, som har undersøgt sammenhængen mellem biomarkører for indtag af TF og 
hjertesygdom. 
På baggrund af data fra kohortestudier synes den TF-associerede forøgelse af risiko for hjerte-
sygdom at være forårsaget af indtag af industrielt hærdet, ikke mikrobiel hærdet, TF, hvilket 
muligvis skyldes, at sidstnævnte indtages i mindre mængder. Et meget sparsomt antal studier 
forhindrer imidlertid klare konklusioner om, hvorvidt kilden til TF er afgørende. Hverken bio-
markør-undersøgelser eller interventionsstudier har kunnet bekræfte, at TF fra mikrobiel hærd-
ning skulle være mindre skadelig end TF fra industriel hærdning. Der er dog ingen indikationer 
af, at TF fra mikrobiel hærdning øger risikoen for hjertesygdom i de mængder, der normalt ind-
tages.  
SP: Påvirker indtag af TF blodets fedtstoffer? 
SV: Indtag af TF øger blodets koncentration af LDL-kolesterol og sænker koncentrationen af 
HDL-kolesterol. Dermed medfører TF en mere sygdomsfremkaldende blod-fedtprofil end alle 
andre typer fedtsyrer. Dette er blevet bekræftet i talrige interventionsundersøgelser og fore-
kommer at gælde for TF fra såvel industriel som mikrobiel hærdning, i hvert fald ved indtag af 
en vis mængde TF. Den observerede 34% stigning i ratioen mellem LDL- og HDL-kolesterol i 
 studiet kunne derfor betragtes som et tegn på god efterlevelse af kostinterventionen fra 
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forsøgsdeltagernes side. Den fundne stigning i LDL/HDL-kolesterol menes at svare til en ~6% 
øget risiko for hjertesygdom pr. 5 g/dag TF. Desuden tyder resultater fra flere undersøgelser på, 
at indtag af TF medfører en svag øgning af triglycerid og lipoprotein (a) i blodet, ligesom pro-
duktionen af små LDL partikler stiger. 
SP: Påvirker indtag af TF markører for systemisk inflammation og endothel dysfunktion? 
SV: Størstedelen af den foreliggende evidens for en sammenhæng mellem indtag af TF og mild 
systemisk inflammation og endothel dysfunktion stammer fra tværsnitsundersøgelser. Med fun-
det af en 12% stigning i koncentrationen af TNFα (P=0.002), samt en stigning i koncentrationen 
af TNF-receptorer, understøtter  studiet imidlertid formodningen om, at indtag af TF 
fører til øget inflammation. Indtag af TF har desuden i enkelte studier vist at medføre let øget 
produktion af CRP, men en sådan effekt kunne ikke påvises i  studiet 
Resultater fra  studiet gik i retning af at bekræfte tidligere fund af en øget E-selectin 
koncentration som følge af TF-indtag, hvilket indikerer, at indtag af TF medfører endothel dys-
funktion. Imidlertid har kun et enkelt studie (ud af to) peget på, at TF påvirker mere direkte mål 
for endothelfunktion i en negativ retning.  
SP: Påvirker indtag af TF kropssammensætning og fedtdeponering? 
SV: Enkelte store befolkningsundersøgelser har peget på, at indtag af TF øger risikoen for ma-
vefedme og generel vægtforøgelse, og disse fund støttes af et 6-årigt interventionsstudie i aber. 
Et betragteligt indtag af TF over 4 måneder i  studiet havde ingen indvirkning på depo-
nering af fedt på maven hos postmenopausale kvinder, men der var svage tegn på en stigning i 
kroppens samlede fedtindhold (P=0.12). Dyrestudier har vist modstridende resultater, med hen-
syn til om TF medfører øget kropsvægt eller fedmegrad, men de peger samstemmende på en 
øget deponering af fedt i leveren. I  studiet kunne en sådan effekt ikke bekræftes hos 
mennesker. Det negative resultat kan dog skyldes begrænsninger i studiets design, såsom høj 
variabilitet i deltagernes leverfedtindhold og manglende standardisering af deltagernes kost. 
SP: Påvirker indtag af TF insulinfølsomhed? 
SV: De fleste dyrestudier har peget på, at indtag af TF påvirker insulinfølsomheden negativt, 
mens resultater fra undersøgelser i mennesker er modstridende. Det er uvist, om denne diver-
gens skyldes det faktum, at dyreforsøg generelt er af længere varighed, eller om den er et resul-
tat af artsforskelle. De få indikationer af en negativ effekt af TF på insulinæmi i mennesker 
stammer fra studier med metabolisk vulnerable forsøgspersoner. TFA eksponering førte imidler-
tid ikke til ændringer i markører for lipolyse eller insulinfølsomhed hos ældre, overvægtige 
kvinder i  studiet. 
SP: Hvad kan konkluderes på baggrund af  studiet? 
SV: Med opdagelsen af en pro-inflammatorisk effekt af TF i  studiet har vores forsk-
ning bidraget til at mindske det føromtalte ”forklaringsunderskud”, selvom det er vanskeligt at 
estimere, hvor stor betydning denne effekt har på risikoen for hjertesygdom. Derimod fremstod 
hverken insulinresistens eller ektopisk fedtdeponering som bidragende forklaringsfaktorer.  
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 LIST OF ABBREVIATIONS
 
8-iso-PGF2α 8-iso-prostaglandin-F2α  
AT adipose tissue 
AUC  area under the curve 
BMI  body mass index  
CETP cholesteryl ester transfer protein 
CHD  coronary heart disease  
COBRA Copenhagen Obesity Risk Assessment Study 
CRP C-reactive protein 
CTP-1 carnitine pamitoyl transferase 1 
CTR control  
DEXA  dual-energy x-ray absorptiometry  
g/d grams per day 
FA fatty acid(s)  
FFA free fatty acid(s) 
FMD flow mediated vasodilation 
HDL-C high density lipoprotein cholesterol 
HOMA-IR homeostasis model assessment index of insulin resistance 
IAAT intra-abdominal adipose tissue  
IGT impaired glucose tolerance 
IL interleukin  
IP-TFA industrially produced trans fatty acid(s) 
ISR Insulin secretion rate 
IVGTT intravenous glucose tolerance test 
LCAT lecithin:cholesterol acyltransferase  
LDL-C low density lipoprotein cholesterol 
MCP-1 monocyte chemoattractant protein 
MI myocardial infarction 
MRI magnetic resonance imaging 
MRS magnetic resonance spectroscopy 
MTP microsomal triglyceride transfer protein  
MUFA monounsaturated fatty acid(s) 
NAFLD non-alcoholic fatty liver disease 
NF-κB nuclear factor κB  
NGT normal glucose tolerance 
OGTT oral glucose tolerance test 
PLTP phospholipid transfer protein  
PPAR peroxisome proliferator-activated receptor 
PUFA polyunsaturated fatty acid(s) 
RBC red blood cell(s) 
RR relative risk or risk ratio 
R-TFA ruminant trans fatty acid(s) 
SAT subcutaneous adipose tissue  
sE-selectin soluble E-selectin 
SFA saturated fatty acid(s) 
sICAM-1 soluble intercellular adhesion molecule 1  
SREBP-1 sterol regulatory element binding protein 1 
sTNF-R1 soluble tumor necrosis factor receptor 1 
sTNF-R2 soluble tumor necrosis factor receptor 2   
sVCAM-1 soluble vascular cell adhesion molecule 1 
Total-C total cholesterol  
TFA trans fatty acid(s) 
TLR Toll-like receptor 
TNFα tumor necrosis factor α 
VOI volume of interest 
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 INTRODUCTION 
During the last decades, much attention has been paid to the presumed adverse health effects of 
dietary trans fatty acids (TFA). It has been estimated that a TFA intake of merely ~5 grams per 
day (g/d) (or 2% of energy (E%)) increases the risk of coronary heart disease (CHD) by more 
than 20%1. A single fast food meal could readily contain more than 15 g of TFA in 20062.  
The general belief has been that this increase in risk of CHD should be ascribed to TFA derived 
from industrial production (IP-TFA), whereas the evidence for a detrimental effect of those 
produced by ruminants (R-TFA) is less strong3-5. In addition, TFA intake has been positively 
associated with greater risk of type 2 diabetes (T2D)6,7 and weight gain8,9. 
Many intervention studies have been conducted to elucidate the underlying metabolic effects of 
dietary TFA. It has been known for decades now that IP-TFA intake increases plasma low-den-
sity lipoprotein cholesterol concentrations (LDL-C) as well as the ratio between LDL-C and 
high-density lipoprotein cholesterol (HDL-C), as summarized in several meta-analyses1,10-13. 
However, these effects on blood cholesterol levels may only explain a cardiovascular risk in-
crease of ~5% per 2 E% TFA14. Even when taking into account the less well established effects 
of TFA intake on other cardiovascular risk markers, such as lipoprotein a (Lp(a)), the ratio of 
apolipoprotein (Apo)B to ApoA-1 and C-reactive protein (CRP), a considerable explanatory gap 
(of up to ~50%) persist between the risk increase found in observational studies and that which 
can be explained by the assessed cardiovascular risk factors11. Limited evidence suggests that 
TFA intake may induce low-grade systemic inflammation15-19, insulin resistance20,21 and/or ec-
topic fat deposition22, but evidence from controlled intervention studies is scarce.  
Despite the fact that the explanatory mechanisms responsible for the health risk associated with 
dietary TFA have not been fully elucidated, the evidence against TFA has by many governmen-
tal agencies worldwide been considered sufficient to recommend that dietary sources of TFA 
should be reduced as much as possible. Extensive campaigns have been conducted in several 
countries to eliminate TFA from the food supply based on the arguments that i) TFA can be 
considered nutritionally unnecessary and ii) most food products (except those of ruminant ori-
gin) can be produced without TFA23.  
Whereas some countries, such as Denmark and Switzerland, have implemented legislation re-
stricting the use of TFA in fats destined for human consumption23, others, such as the USA, 
Canada, Argentina and Brazil, have enforced limits to the TFA content in restaurant foods 
or/and introduced obligatory labeling of TFA containing foods24. In June 2010, the European 
Parliament voted for a mandatory labeling of TFA content25, but this act has not yet been ap-
proved by the European Commission. These legislative actions, together with voluntary refor-
mulations by industry, have drastically decreased the TFA availability in most foods sold in 
Western countries23,24. 
In most countries, including Denmark23, the TFA intake seems to have followed a downward 
trend during the last decades (reviewed by Craig-Schmidt & Rong26). In 1989-91, the mean 
TFA intake in the US population was 5.3 g/day (2.6 E%) and 10% of the population was esti-
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mated to have an intake above 9.4 g/d27. More recent mean TFA intake estimates from 2002-
2004 range from 1 to 3 E%26. Estimates of TFA intake in Europe has generally been somewhat 
lower with mean intakes in the range of 2.4 to 5.4 g/d (28-79% from R-TFA) in most northern 
European and Nordic countries in 1995-9928, with the 90th percentiles generally being 50-70% 
above the mean values. In Denmark, the R-TFA is believed to constitute almost all of the TFA 
consumed after the trans fat law went into force in 2004, and intake is likely to have remained 
constant since 1999 where the median R-TFA intake was 1.8 g/d (80% central range 0.9-2.9)29.  
Unfortunately, updated reports of population TFA intakes are lacking. It should be kept in mind, 
that mean intake values tend to hide the fact that subpopulations may have considerably higher 
intakes. In 2006, it was possible to obtain an intake of TFA beyond 15 g in a single serving of 
fast food from international fast food restaurants in selected countries2. Since then, McDonald’s 
claim to have substantially reduced the TFA content in their products sold in the US, Australia 
and Europe30 and products from Kentucky Fried Chicken now allegedly contain a maximum of 
1 g of TFA per serving31. A recent assessment of the TFA content in popular foods in Europe, 
confirmed that meals from these two fast food chains were indeed free of TFA in 2009. Yet, in 
Eastern European countries, some snack products, such as cakes and popcorn, contained more 
than 5 g TFA per 100 g (Stender et al. 2010, submitted). 
While the access to TFA has decreased considerable in many countries, populations living in 
some developing countries, may still be exposed to high TFA-foods, because partially hydro-
genated vegetable oils represent inexpensive and stable sources of dietary fat32.  Examples are 
Iran, where the mean TFA intake in 2001-03 was estimated to ~12.3 g/d (4.3 E%)33 and India 
where the intake of vanaspati, a hydrogenated vegetable oil high in TFA, has increased during 
recent years24.  
The fact that some populations or sub-groups may still be exposed to considerable amounts of 
IP-TFA, together with the fact that R-TFA cannot be removed from meat and dairy products, 
makes it pertinent to fully understand the risk associated with intake of TFA from these two 
sources on lifestyle diseases. We found it timely to systematically review all the available ob-
servational evidence on the association between TFA intake and CHD, with specific emphasis 
on differentiating between TFA from ruminant and industrial sources.  
Furthermore, since TFA intake appears to be associated with greater risk or CHD than can be 
explained by established risk markers, and since causal relationships can only be assessed in 
well-designed controlled studies, we performed such a study with the aim to examine the effect 
of a substantial daily intake of TFA on established as well as emerging risk factors for lifestyle 
diseases, including blood lipids, ectopic fat deposition, insulin sensitivity, and markers of endo-
thelial dysfunction and low-grade inflammation. 
In the subsequent chapters, the body of evidence linking dietary TFA with risk of CHD and 
T2D will be discussed and results of the following research will be included where appropriate:  
i. A systematic review and meta-analysis of published and unpublished analyses from pro-
spective cohort studies examining the association of dietary TFA from both industrial and 
ruminant sources on the risk of developing CHD (Paper I). 
ii. A randomized controlled trial (RCT) carrying the acronym  (Copenhagen Obesity 
Risk Assessment Study), which included 52 abdominally obese, postmenopausal women 
with body mass index (BMI) between 25 and 32 kg/m2. The intervention period lasted 16 
weeks, during which the women were exposed to high daily amounts of TFA (~15 g/d 
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corresponding to ~7 E%) from partially hydrogenated soybean oil or a control fat consist-
ing of a blend of palm oil and high oleic sunflower oil. With this choice of control fat, 
TFA were compared to a mix of 23% palmitic (16:0), 67% oleic (cis18:1n-9) and 10% li-
noleic acid (cis18:2n-6). Before and after the intervention, as well as after a subsequent 
12-week weight loss program, a range of measurements were performed as depicted in 
Figure 1. Nineteen normal-weight women (BMI 19 to 24 kg/m2) served as lean references 
and underwent baseline examinations only.  
The endpoints presented to the right in Figure 1 are covered in Paper II (blood lipids, fatty acid 
(FA) profile in red blood cells (RBC), anthropometrics, body composition, liver fat, subcutaneous and 
intraabdominal adipose tissue (AT), and dietary intake); Paper III (insulin sensitivity, glucose tolerance 
and markers of lipolysis); and Paper IV (systemic markers of inflammation and endothelial dysfunc-
tion, subcutaneous AT FA profile, ceramide content and mRNA expression of cytokines, and urinary iso-
prostanes), respectively.  
The intention with the weight loss program was to provide the overweight women with an in-
centive to participate in the TFA intervention as well as to compensate for the putative negative 
TFA-induced health effects. The results of the examinations performed after the weight loss 
period will not be covered in this thesis; neither will data obtained from measurement of heart 
rate variability. 
Figure 1: Design of the  study. Fifty-two abdominally obese, overweight but otherwise healthy postmeno-
pausal women were randomized to the dietary intervention; 25 to the trans fat (TFA) and 27 to the control (CTR) 
group (24 and 25, respectively, completed the intervention). Nineteen lean women underwent baseline examinations 
only. AT; adipose tissue; DEXA; dual-energy x-ray absorptiometry; FA, fatty acids; FFA, free fatty aids; MR, mag-
netic resonance; OGTT, oral glucose tolerance test; RBC, red blood cells. 
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 THE BASICS ABOUT TRANS FAT 
According to the European Food Safety Authority, the term “trans fat”, or more correct “trans 
fatty acids” (TFA), refers to any unsaturated fatty acid (FA) with at least one double bond in the 
trans configuration. The United States Food and Drug Administration and the Codex Alimen-
tarius employ a more exclusive definition, excluding FAs with conjugated double bonds, i.e. 
double bonds not interrupted by at least one methylene group34,35. 
In the trans configuration, the hydrogen 
atoms on either side of the FA’s double 
bond are positioned on opposite sides of the 
carbon chain, resulting in an almost straight 
molecule, which resembles that of a satu-
rated fatty acid (SFA). Since animals and 
most plants lack the enzymatic capacity to 
synthesize double bonds with trans con-
figuration, most naturally occurring unsatu-
rated FAs are cis-FAs. Around cis double 
bonds, the hydrogen atoms are located on 
the same side of the carbon chain imposing 
a kink in the molecule (Figure 2). Due to 
this difference in geometry, TFA have 
higher melting points than their cis-iso-
mers, although not as high as the SFA of 
equal chain length36. The structural differ-
ences between cis and trans FAs affect 
their physiological properties and metabolic 
effects. 
FROM WHERE DO WE GET TRANS FAT? 
TFA in the human food supply come mainly from two sources: One is industrial hydrogenation 
of unsaturated FAs in edible oils, the other biohydrogenation of unsaturated FAs in the rumen of 
ruminants. The first type of hydrogenation gives rise to IP-TFA, the other to R-TFA. Whereas 
IP-TFA are mostly found in processed food products such as margarine/shortenings, fried fast 
foods, snacks and bakery products, R-TFA are naturally incorporated into the fat from rumi-
nants (cows, sheep and goats), and is therefore present in dairy and fatty meat products.  
The two main fat sources of TFA have distinct characteristics. First of all, the concentration of 
TFA can be much higher in partially hydrogenated oils (up to 60%)37, than in ruminant fat (nor-
mally up to 6%)29,38, although the concentration in the latter may be elevated to 20% by manipu-
lating the ruminants’ feed39. Secondly, the TFA isomer distributions differ. Vaccenic acid, 
trans18:1n-7 (or trans11-18:1), is by far the most predominant isomer in ruminant trans fat, 
Figure 2: Structure of cis and trans monounsaturated C18 
fatty acids and the corresponding saturated fatty acid. The 
Δ nomenclature denotes the position of the double bond 
counted from the carboxylic end of the fatty acid, whereas 
the “n-“ nomenclature counts from the methyl end. 
Adapted and modified from Stender & Dyerberg36. 
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constituting up to 50% of total TFA38,39. In contrast, industrially produced trans fat encompasses 
a wide range of positional trans-18:1 isomers with a more even distribution of the Δ8/n-10 to 
Δ11/n-7 isomers (Figure 3)37. Both sources of TFA also contain some TFA with a chain-length 
of 16 carbon atoms as well as some TFA 
with two double bonds (trans18:2), although 
these FA isomers seldom constitute great 
proportion of total TFA (<10% each) 29,38,40.  
In addition, minor amounts of dietary TFA 
may originate from other processes where 
unsaturated FAs are heated in the presence of 
hydrogen, such as deodorization (or refining) 
of vegetable oils and oil-frying of foods41. 
However, whereas the first process gives rise 
to quantitatively negligible amounts of TFA 
(0.1-0.3% in cold pressed vegetable oils) and 
TFA are produced at the low rate of 0.3% per 
hour when frying potatoes in soybean oil at 
180˚C41, a considerable amount of TFA may 
be produced if highly unsaturated frying oil 
is reused and if frying temperature is high 
(>250˚C)42.   
HOW THE STORY OF TRANS FAT BEGAN 
As described in Chapter 1, it is now broadly recognized that dietary IP-TFA are detrimental to 
human health. However, when hydrogenation of edible oils, and thereby trans fat, was first in-
troduced more than a hundred years ago, it was considered a great new invention.  
In the 1890s, the French chemist Paul Sabatier discovered that metal catalysts could be used to 
precipitate hydrogenation reactions. In the beginning of the 20th century, the German chemist 
Wilhelm Normann expanded these findings and in 1903 he received a patent for the hydrogena-
tion of liquid fat. In this process, the unsaturated FAs are converted to a mix of SFA and TFA. 
Since food products containing unsaturated FAs are susceptible to oxygenation and therefore 
have relatively short shelf lives, this new technique was soon adopted by food manufactur-
ers26,41. The first food product developed that contained partially hydrogenated vegetable oil, 
and thereby TFA, was Crisco shortening, introduced in 1911 by Procter & Gamble Company43. 
In the 1950s and 1960s the use of hydrogenation to stabilize the shelf life of food products grew 
rapidly. During the 1960s, margarine became viewed as the healthy alternative to butter because 
it was lower in SFA, and by the 1980s, many food manufacturers and restaurants had replaced 
tallow and lard with TFA-rich products26,44.  
However, already in the late 1970s some researchers began to question the widespread use of 
TFA. In 1979, Kummerow pointed to the facts that heart disease prevalence was higher in coun-
tries with high TFA intake and that margarines high in TFA might increase blood cholesterol 
levels45. Inspired by this work among others, Willet and colleagues, in 1980, initiated the collec-
tion of dietary TFA data in the large prospective Nurses’ Health Study to investigate the asso-
ciation between dietary factors, and among them TFA consumption, and risk of life style 
Figure 3: Typical trans18:1 isomer distribution in trans
fat of ruminant (milk fat) and industrial (marga-
rines/shortening) origin. From Wolff et al.37. 
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diseases44. In 1993, after 10 years of follow-up, Willet et al. could report a positive association 
with risk of CHD across increasing quintiles of TFA intake5.  
Since then much research has been undertaken to confirm these findings and to explore putative 
mechanisms of action of TFA in increasing the risk of CHD and other lifestyle diseases. 
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  TRANS FAT INTAKE AND RISK OF CORONARY HEART DIS-
EASE – EVIDENCE FROM OBSERVATIONAL STUDIES 
Since Willet and coauthors’ first report on the association between TFA intake and incident 
CHD in the Nurses’ Health Study5, several observational analyses on this subject have been 
published. Generally, studies with a prospective design are regarded as superior to studies with 
a case-control design due to i) the recall bias associated with reporting of dietary information 
after a myocardial infarction (MI); ii) the bias introduced when it is the more health-conscious 
controls who chose to participate in a study, and ii) the fact that in a case-control study of CHD, 
usually only non-fatal cases are included, whereas the important fatal cases are not44. Some of 
these shortcomings may be overcome by using biomarkers of TFA intake. 
ASSOCIATION OF TRANS FAT INTAKE WITH RISK OF CORONARY HEART DIS-
EASE IN PROSPECTIVE COHORT STUDIES 
Following the 1993 publication from the Nurses’ Health Study5, similar analyses have been 
published from four other prospective cohort studies: the American Health Professionals’ Fol-
low-up Study3, the Finnish Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study4, the 
Dutch Zutphen Elderly Study46, and the Native American Strong Heart Study47. Positive associa-
tions between TFA intake and risk of CHD events or fatal CHD4,5,46,48 or trends towards the 
same3 were found in most of the studies, but not all47 after adjustment for various confounding 
factors.  
In a variance weighted pooled analysis of the four earliest studies, including data from more 
than 146,000 subjects who experienced a total of 3,170 coronary events, Oomen et al.46 esti-
mated that an isocaloric substitution of 2 E% of carbohydrates with TFA would correspond to 
an increase of 25% (95% confidence interval (CI): 11 to 40) in the risk of coronary events. An 
updated inverse-variance weighted estimate of 23% (CI: 11 to 37) after more years of follow-up 
in two of the included studies (total number of events 4,965), was later provided by Mozaffarian 
et al.1 Recently, based on the same few cohort studies, it was estimated that if TFA replaced 2 
E% of SFA, monounsaturated FA (MUFA) and polyunsaturated FA (PUFA) the corresponding 
risk increases would be 20% (CI: 7 to 34), 27% (CI: 14 to 42) and 32% (CI: 17 to 49), respec-
tively11,49.  
Even fewer observational studies have provided risk-analyses stratified for the source of TFA.  
Whereas two of the cohort studies4,5 together with data from a case-control study50 suggested 
that IP-TFA, rather than R-TFA, intake was responsible for the increased risk associated with 
TFA intake, a third cohort study found no difference in risk between the two sources46. Re-
cently, the risk of CHD associated with intake of R-TFA was assessed in the Danish MONICA 
cohort showing no association in men and a trend towards a negative association in women51. 
However, no pooled estimate of the cardiovascular risk associated with R-TFA and IP-TFA 
intake, respectively, has yet been published. 
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For this reason, and because a very limited number of studies has been included in prior meta-
analyses of the association between TFA from any source (total-TFA) and CHD, we found it 
timely to conduct a systematic review and meta-analysis of the evidence from cohort studies of 
an association between intake of TFA and the risk of fatal and/or non-fatal CHD. Our work had 
a specific emphasis on stratifying the results according to industrial or ruminant origin of the 
TFA (Paper I).    
Our literature search only identified one published study47 that had not been included in the 
meta-analyses by Oomen et al.46 and Mozaffarian et al.1 However, by contacting principal in-
vestigators of five prospective cohort studies, who had not published data on the association 
between TFA intake and CHD, despite having collected relevant data, we identified one unpub-
lished analysis from the Finnish Mobile Clinic Health Examination Survey and an analysis of 
data from the Iowa Womens’ Health Study was performed on our request (Paper I).   
Thereby, we identified at total of five published and two unpublished prospective cohort studies, 
assessing the association between TFA intake and incidence of fatal and/or non-fatal CHD. A 
total of 150,000 subjects experiencing 4,649 CHD events and 105,796 subjects with 2,998 fatal 
MIs, were included in the pooled analysis of total and fatal CHD, respectively. None of the un-
published analyses were stratified for the origin of the TFA, whereby only four and three analy-
ses could be pooled in meta-analyses of the risk associated with intake of ruminant or industrial 
TFA, respectively. 
The pooled relative risk estimates for comparison of extreme quintiles of total-TFA intake (cor-
responding to intake increments ranging from 2.8 to ~10 g/d) were 1.22 (CI: 1.08 to 1.38; P = 
0.002, I2=15%) for CHD events and 1.24 (CI: 1.07 to 1.43; P = 0.003, I2=0%) for fatal CHD 
[Figure 4].  Thereby our estimate of the risk of CHD events was in accordance with that of a 
prior analysis, also comparing extreme quintiles of intake52; whereas the inclusion of the two 
unpublished analyses resulted in a slightly lower risk estimate for fatal CHD, compared to that 
found previously (relative risk (RR)=1.32 (CI: 1.08 to 1.61))52.  
Besides the prospective cohort studies included in the meta-analysis, a few case-control studies 
have examined the association between TFA intake and CHD50,53,54 [see Appendices A, B and 
C for details]. In one study, an increased risk of first MI was evident only among subjects in the 
top quintile of TFA intake (6.5 g/d)50, whereas two other studies (with TFA intakes of 1.4 and 
5.5 g/d in the top quintiles) did not show any association between TFA intake and MI53,54. 
Is the source of TFA important? 
In our analysis [Figure 4], R-TFA intake (increments ranging from 0.5 to 1.9 g/d) was not sig-
nificantly associated with risk of CHD [RR = 0.92 (CI: 0.76 to 1.11); P = 0.36], and neither was 
IP-TFA intake (increments ranging from ~1.3 to 5.0 g/d), although there was a trend towards a 
positive association [RR = 1.21 (CI: 0.97 to 1.50); P = 0.09]. 
 9 
  
Figure 4: Risk ratios and 95% confidence intervals for fully adjusted random-effects models examining the associa-
tions of intake of trans fatty acids from any source (T-TFA) with total coronary heart disease (CHD) events and fatal
CHD (Figure A); for studies examining the associations of intake of ruminant trans fatty acids (R-TFA) with total
CHD events and fatal CHD (Figure B) and  for studies examining the associations of intake of industrially produced
trans fatty acids (IP-TFA) with total CHD events and fatal CHD (Figure C). AT/BC, Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study4; FMC, Finnish Mobile Clinic Health Examination Survey (unpubl.); HPFS, The
Health Professionals' Follow-up Study3; IWHS, the Iowa Womens’ Health Study (unpubl.); MONICA51; NHS, The
Nurses' Health Study5,48; Q, quintile; T, tertile; SHS, The Strong Heart Study47; ZES, The Zutphen Elderly Study46.
Modified from Paper I. 
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Since very few prospective cohort studies have investigated the association between R-TFA or 
IP-TFA intake and CHD, data from other types of studies may add important evidence. Results 
from the case-control study by Ascherio et al.50 are in support of the estimate from our pooled 
analyses by indicating that IP-TFA was associated with increased risk, but only at intake levels 
above 3.3 g/d, whereas R-TFA appeared to be neutral (when comparing intakes up to 1.8 g/d). 
A negative association of R-TFA with undiagnosed CHD was found among men (n=4,490) in a 
cross-sectional analysis of the Scottish Heart Health Study, while total-TFA and IP-TFA were 
neutral, after adjustment for relevant confounders. Among women (n=5,170), no linear dose-
response was found between any source of TFA and CHD, despite a wide range of intakes 
(mean intakes in the first/fifth quintile in men: 1.5/4.9 g/d R-TFA and 1.0/8.8 g/d IP-TFA)55.  
In summary, the observational evidence suggests that in contrast to dietary IP-TFA, R-TFA 
intake does not affect the risk of CHD or may even be slightly protective. However, this may be 
ascribed to either the different FA profile or the fact that R-TFA generally is consumed in much 
lower quantities than IP-TFA.  
Limitations of TFA intake data 
In epidemiological studies, the assessment of intake of TFA is potentially affected by substan-
tial random measurement error due to a number of factors: i) participant recall bias; ii) problems 
with identifying and quantifying hidden fat and fats used for cooking; iii) insufficiently updated 
values in local food composition tables; iv) considerable variation of TFA content within foods 
from the same food category; and v) substantial changes in the TFA content of foods over time.  
As described in Chapter 2, margarine was perceived as the healthy alternative to butter during 
the 1960s44 and in the following decades tallow and lard were widely replaced by TFA-
containing products as these were thought to be healthier due to their lower content of SFA.  
However, during the 1990s the food industry in many countries made efforts to reduce the TFA 
content of margarines and shortenings, and in recent years a drastic decline in the industrial 
TFA content of most foods in Western countries has been reported26. Thereby, values for TFA 
content in food composition tables are outdated quickly.  
Part of these changes over time can be accounted for by performing repeated assessment of 
dietary intake; yet of the studies included in our meta-analysis only one48 performed repeated 
dietary assessments.  However, even though food databases may be adequately updated, the fact 
that similar foods, even from the same manufacturer, may have substantially different TFA con-
tents, compromises the accuracy of TFA intake estimates. Innis et al.56demonstrated a large 
variability in the content of TFA in Canadian food products from the same category; e.g. in 17 
brands of crackers the TFA content varied from 1 to 13 g TFA per 100 g. Moreover, using 
minimum and maximum values for TFA within a given food category, the estimated daily TFA 
intake could range from 1.4 to 25.4 g/d. Also, Stender et al.2 documented how the TFA content 
in the same fast food meal from the same chain of fast food restaurants sampled from 26 coun-
tries around the world varied from 0.3 to 24 g. 
Furthermore, a problem of ‘confounding by indication’ may arise in dietary surveys, and this is 
difficult to correct for: A subject with symptoms of CHD or family history of MI may be more 
aware of consuming a healthy diet, which in the 1980s meant replacing butter with margarine. 
Thereby subjects at higher risk may have increased their margarine and with this their IP-TFA 
consumption while reducing their butter, and R-TFA, consumption.  
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BIOMARKERS OF TRANS FAT INTAKE AND RISK OF CORONARY HEART DIS-
EASE 
Considering the difficulties in assessing TFA intake in free-living populations, biomarkers of 
TFA intake, such as proportions of TFA in blood or adipose tissue (AT), may provide more 
reliable estimates of individual TFA exposure, although this will not correct for the above-
mentioned confounding by indication. As TFA cannot be synthesized in the human body, the 
proportions of TFA in plasma, red blood cells (RBC) and AT are thought to reflect the inte-
grated dietary intake during the last weeks, months and year, respectively26. Assessment of tis-
sue TFA does not allow for separation of the TFA isomers into R-TFA and IP-TFA (since most 
isomers are present in both ruminant and industrial sources). Instead it is possible to separate the 
exposure data into trans16:1, trans18:1 and trans18:2 isomers.  
A number of case-control studies have found increased cardiovascular risk associated with 
blood or AT biomarkers of TFA intake57-62 , whereas many others have not54,63-67. Jakobsen & 
Overvad68 provided a review of the evidence from case-controls studies, suggesting that bio-
markers of trans18:2 intake are associated with increased risk of CHD whereas those of 
trans18:1 are not. However, since many of the published studies include a limited number of 
subjects, they may be underpowered to detect significant associations. A pooled analysis might 
shed more light on this subject.  
We therefore extracted and pooled the data from all the identified case-control studies reporting 
an odds ratio (OR) for the odds of being a case in the highest quantile of tissue TFA compared 
to the lowest (n =12)54,58-60,62-67,69,70 and included data from two additional case-control studies 
published after the literature search by Jakobsen & Overvad57,61 [see study characteristics and 
individual risk estimates in Appendices A, B and C]. The concentration of the sum of all TFA 
isomers (total-TFA) in AT and blood was positively associated with increased risk of CHD, 
although the heterogeneity was considerable [OR=1.33; CI: 1.01 to 1.74; P=0.04, I2= 76%; see 
Forest plot in Appendix D]. The level of trans18:1 in AT and blood was also significantly asso-
ciated with risk of CHD [OR=1.16; CI: 1.04 to 1.29; P=0.008, I2= 75%], and the level of 
trans18:2 even more so [OR=1.30; CI: 1.14 to 1.47; P<0.0001, I2= 68%]. However, caution 
should be taken in concluding too strongly on a meta-analysis compiling data with different end 
points (such as sudden cardiac death and non-fatal MI). 
Yet, if the risk of CHD associated with intake of trans18:2 isomers is indeed greater than for 
trans18:1, this may help to explain why the prospective studies indicated a higher risk associ-
ated with IP-TFA intake compared to R-TFA; the content of trans18:2 is generally higher in IP-
TFA compared to R-TFA. Alternatively, the tendency for a risk reduction seen with R-TFA, 
may relate to the fact that vaccenic acid (the predominant TFA isomer in R-TFA) may be con-
verted endogenously to the conjugated linoleic acid (CLA) isomer cis9, trans11-18:271. The 
adipose tissue content of this CLA isomer has been shown to be inversely associated with MI 
risk72. It is also possible that R-TFA intake may simply reflect milk fat intake just as the FAs 
15:0 and 17:0. The content of these in plasma phospholipids was recently shown to correlate 
negatively to the risk of MI73.  
Of all the case-control studies, only three presented analyses for specific positional trans18:1 
isomers. Lemaitre et al.60 found no association of the RBC proportions of trans18:1n-7 (vacce-
nic acid), trans18:1n-8 or trans18:1n-9 with risk of sudden cardiac death, whereas Sun et al.62 
showed that trans18:1n-7, trans18:1n-9 and trans18:1n-12 were all significantly positively as-
sociated to risk of CHD after adjusting for potential confounders. Clifton et al.53,74 observed that 
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AT trans18:1n-7 was an independent predictor of first MI. Taken together; these studies do not 
support a weaker association between vaccenic acid and risk of heart disease than estimated for 
other trans18:1 isomers. However, since vaccenic acid is also present in IP-TFA, it may be an 
invalid marker of R-TFA intake, as suggested recently75. 
In our pooled analysis of case-control studies, the trans16:1 concentration in AT and blood was 
not significantly associated with incident CHD, but few studies were included in this analysis, 
and tissue concentrations were low [OR = 1.09; CI: 0.82 to 1.46; P=0.55, I2= 52%]. It must be 
acknowledged that the results from half of the case-control studies were not isomer-specific 
which would have complicated the interpretation of any significant finding reported in these 
studies59,65, e.g. the trans16:1n-7 isomer is thought to reflect the intake of R-TFA and has been 
shown to correlate with dairy and red meat intake, the trans16:1n-9 isomer correlates with mar-
garine intake75.  
SUMMARY: TRANS FAT INTAKE AND RISK OF CORONARY HEART DISEASE 
The evidence against TFA as a risk factor for CHD from prospective studies seems strong, al-
though causality cannot be inferred from this type of study. It is however noteworthy that a very 
limited number of prospective cohort studies have published analyses of the association be-
tween TFA intake and incident CHD. Publication bias may be a contributory factor. Yet, studies 
examining the association of biomarkers of TFA intake with risk of CHD collectively confirm 
that TFA exposure is associated with an increased risk of CHD. This appears to be the case for 
TFA with one or two double bonds, though the latter may be associated with higher CHD risk.  
The pooled analysis of prospective cohort studies suggests that the risk associated with TFA 
intake may be ascribable to IP-TFA, not R-TFA. However, the very limited number of studies 
prohibits any firm conclusions concerning whether the source of TFA is important. The bio-
marker studies do not lend support to the notion that R-TFA should be less harmful than IP-
TFA. This subject will be further addressed in Chapter 5. 
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 TRANS FAT INTAKE AND RISK OF TYPE 2 DIABETES – EVI-
DENCE FROM OBSERVATIONAL STUDIES 
Very few studies have reported on the association between dietary TFA and risk of T2D. Data 
from the Nurses’ Health Study suggest that TFA intake is positively associated with incidence 
of T2D. In an analysis including 84,204 women with 2,507 incident cases of T2D during 14 
years of follow-up, Salmeron et al.7 reported a dose-response related increase in risk across 
quintiles of TFA intake, with women in the highest quintile having a 31% (CI: 10 to 56) greater 
risk of T2D than those in the lowest quintile after adjustment for various confounders; the corre-
sponding estimate was 40% after 16 years of follow-up6. Furthermore, Salmeron et al.7 esti-
mated that replacement of 2 E% TFA by PUFA would decrease the risk of T2D by 40% (CI: 
25-52). Moreover, the association between TFA intake and T2D risk was strongest among obese 
and physically inactive women7. In support of these findings, an Iranian cross-sectional study in 
486 women found a positive association between intake of partially hydrogenated oil (generally 
containing 25-35% TFA) and insulin resistance (assessed by homeostasis model assessment 
index of insulin resistance (HOMA-IR) after adjustment for relevant confounders76. 
However, no association with risk of T2D was found in two other large prospective cohort stud-
ies. After 12 years of follow-up in 42,504 men (1,321 incident cases) in the Health Profession-
als’ Follow-up Study, there was a risk increase across quintiles of TFA intake in multivariate 
analysis, but it disappeared after adjustment for other dietary variables and BMI [RR for ex-
treme quintiles: 0.90 (CI: 0.74 to 1.10); P for trend = 0.33]. After 11 years of follow-up in 
35,988 older women in the Iowa Womens’ Health Study (n=1,890 incident cases), intake of TFA 
was inversely related to T2D risk in multivariate analysis, but not after additional adjustment for 
other dietary variables [RR for extreme quintiles: 0.92 (CI: 0.75 to 1.11); P for trend = 0.20]77. 
Importantly, however, in the two latter studies the median TFA intakes were slightly lower 
(~1.3 and 1.6 E%, respectively) compared to the Nurses’ Health Study (2 E%). Also, in the 
Iowa Womens’ Health Study repeated dietary measurements were not obtained and the self-
reported T2D incidence was invalid in one third of the cases77. 
In a recent study, TFA intake in the first trimester of pregnancy and incidence of gestational 
diabetes or glucose intolerance (assessed by oral glucose tolerance tests) were not associated in 
a sample of 1,733 women. The odds ratio was 0.87 (CI: 0.51 to 1.49) for developing gestational 
diabetes and 0.93 (CI: 0.66 to 1.31) for glucose intolerance per 1 E% increase in TFA intake78.  
SUMMARY: TRANS FAT INTAKE AND RISK OF TYPE 2 DIABETES 
Collectively, the observational evidence connecting TFA intake to risk of T2D must be consid-
ered weak. However, the strong association seen in the large high-quality Nurses’ Health Study 
calls for more analyses in other cohorts. 
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 DIETARY TRANS FAT & BLOOD LIPIDS 
The causality of the observational associations between dietary TFA and risk of CHD, and the 
putative association with T2D, has been investigated in a number of randomized controlled tri-
als (RCTs) examining the effect of TFA intake on various disease risk markers. TFA may affect 
several steps in the atherosclerotic process, which ultimately leads to heart disease, either by 
acting directly on the endothelium, or indirectly by affecting metabolism and signaling in sev-
eral tissues, such as muscle, liver and adipose tissue (AT).  
ROLE OF LIPOPROTEINS IN THE ATHEROSCLEROTIC PROCESS 
Lipoprotein particles play an important role in the atherosclerotic process. In early plaque for-
mation, immune cells and lipid droplets accumulate in the intima, which is the innermost layer 
of the artery. The concentration of LDL in the circulation as well as the permeability of the en-
dothelium is believed to accelerate the development of atherosclerosis79.   
Infiltration and retention of LDL particles in the arterial intima causes activation of the endothe-
lium80. In the intima, LDL particles undergo oxidative modifications, whereby a mixture of 
heterogeneously modified particles is formed. The mechanism by which LDL is oxidized is not 
clear, but oxidative stress-induced lipid-peroxidation as well as enzymatic modification of both 
lipid and protein moieties may be involved81. The modifications give rise to production and 
release of oxidized phospholipids and possibly other lipid mediators, which initiate an inflam-
matory response in the arterial wall. The modified LDL particles are taken up by macrophages, 
whereby foam cells loaded with cholesterol ester containing droplets are formed and cytokine 
release is stimulated82-84 (see Chapter 6 for more detail). 
In contrast, HDL particles, and particularly large HDL particles, are thought to be anti-athero-
genic due to their reverse transport of cholesterol from the artery and peripheral tissues to the 
liver, and possibly also due to anti-oxidative and anti-inflammatory properties85.  
LDL- and HDL-cholesterol - risk factors or risk markers? 
In a major meta-analysis including 68 long-term prospective trials and more than 300,000 sub-
jects, the HDL-C and the non-HDL-C concentrations were independent predictors of CHD, 
whereas the triglyceride concentration was not. An increase in the HDL-C concentration of 0.39 
mmol/l (corresponding to 1 standard deviation) was associated with a hazard ratio for CHD of 
0.78 (CI: 0.74 to 0.82) and an increase in non-HDL-C concentration of 1.11 mmol/l with a haz-
ard ratio of 1.50 (CI: 1.39 to 1.61) after controlling for standard risk factors. The risk associated 
with LDL-C (only measured in some of the included studies; n=44,234) was similar to that of 
non-HDL-C. Moreover, the HDL-C and non-HDL-C associated risk estimates were largely 
independent from each other86. Another comprehensive meta-analysis (61 trials and 900,000 
subjects) largely supported these findings, and additionally indicated that the ratio of total-
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cholesterol (total-C) to HDL-C was the strongest predictor of CHD mortality (40% more infor-
mative than non-HDL-C and more than twice as informative as total-C)14.  
A beneficial effect of lowering non-HDL-C, or LDL-C, has been firmly established, as both 
primary and secondary prevention trials with LDL-C-lowering statins consistently have shown 
that LDL-C reductions are accompanied by a decreased risk of CHD events87. In contrary, the 
general view of HDL-C as an anti-atherogenic factor85 has been questioned, since HDL-increa-
sing therapy has failed to decrease CHD mortality independently of LDL-C levels, as shown in 
a recent meta-analysis of RCTs88.  
TRANS FAT INTAKE AND BLOOD CHOLESTEROL 
Today, ample evidence to substantiate a pro-atherogenic effect of TFA on blood lipid levels 
exists. A handful of metabolic studies conducted in the 1960s and 1970s examined the effect of 
partially hydrogenated fats on serum cholesterol levels. These studies were of varying quality 
and produced conflicting results as reviewed by Katan et al.89  
However, when instead cholesterol content in different lipoprotein classes was measured, first 
in the beginning of the 1980s by Laine et al.90 and later in 1990 by Mensink and Katan91, detri-
mental effects of TFA became evident. The latter study, in which 59 subjects were fed 3 differ-
ent diets for 3 weeks each, showed that TFA (11 E%) compared to oleic acid (18:1n-9) in-
creased serum LDL-C and decreased HDL-C. Thereby, TFA had an even more unfavorable 
effect on the lipoprotein profile than SFA (a mix of lauric (12:0), myristitic (14:0) and palmitic 
acid (16:0))91.  
Since then, a number of human intervention studies have investigated the effect of TFA from 
hydrogenated vegetable or fish oils on blood lipid levels, collectively confirming that in com-
parison to all other FA classes, TFA dose-dependently increase the concentration of LDL-C and 
decrease HDL-C92-109. Several meta-analyses, based on 8 to 13 of these studies, have been pub-
lished within the last two decades1,10-12,110. Mozaffarian & Clarke11 performed the most recent 
and inclusive of these, and the main results are presented in Table 1.   
Isocaloric replacement of 1 E% of MUFA with TFA was estimated to increase the ratio of total-
C to HDL-C by 0.054 units (with smaller and greater estimated changes ensuing from replace-
ment of SFA and PUFA, respectively). An increase of 0.054 may translate into an increased risk 
of CHD of approximately 2.0-2.5%14. Or in other terms, an increase in TFA intake of 2 E%, in 
exchange for MUFA, may increase the risk of CHD of ~5% based on the impact on blood cho-
lesterol levels alone. 
Table 1: Changes in blood cholesterol (C) concentrations associated with replacement of 1 E% intake of  
industrially produced trans fatty acids (IP-TFA) with saturated (SFA), monounsaturated (MUFA) or 
polyunsaturated fatty acids (PUFA). 
 Δ Total-C/HDL-C Δ Total-C  
(mmol/l) 
Δ LDL-C 
(mmol/l) 
Δ HDL-C 
(mmol/l) 
TFA replaces SFA (per E%) 0.031* (0.007) -0.006   (0.006) 0.008   (0.005) -0.013* (0.002) 
TFA replaces MUFA (per E%) 0.054* (0.009)   0.032* (0.008) 0.038* (0.007) -0.010* (0.003) 
TFA replaces PUFA (per E%) 0.067* (0.009)   0.047* (0.008) 0.051* (0.007) -0.013* (0.003) 
Values are changes (SE), calculated from a meta-analysis of 13 randomized controlled dietary trials including 41 
diets, adjusted for the effects of the other types of fat, dietary cholesterol, protein intake, duration of diet, total calo-
ries, weight and age. *Indicates corresponding P-value is <0.05. Adapted from11. 
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In the  study, we found that intake of 7 E% TFA decreased plasma HDL-C by 10% and 
increased LDL-C by 18% (Paper II). The mean difference between diet groups in the ratio of 
total-C to HDL-C of 0.45 (CI: 0.24 to 0.65; P<0.001), was somewhat larger than what could 
have been expected from the meta-analysis by Mozaffarian & Clarke11. We used a blend of 
palm oil and high oleic sunflower oil as a control fat, whereby 7 E% from TFA in the TFA 
group was compared to an intake of 1.6 E% from SFA, 4.7 E% from MUFA and 0.7 E% from 
PUFA in the CTR group. According to the estimates proposed by Mozaffarian & Clarke (Table 
1) a difference in the total-C to HDL-C ratio of 0.35 between the TFA and CTR diet groups was 
expected.  
The effect of TFA on blood lipids in the  study was also considerably greater than that 
observed in our previous 8-wk study with similar design but in normal-weight young men111. 
The fact that a more metabolically vulnerable study population of moderately overweight, ab-
dominally obese and older women (> 45 y), was enrolled in the  study may help to ex-
plain the more pronounced effect of TFA on plasma cholesterol.  
The adverse change in blood lipids after consumption of ~7 E% TFA, observed in the  
study, may translate into an increase in the risk of CHD of approximately 20%14. A TFA intake 
this high (15 g/d) is likely to be consumed by very few people in Western countries today. 
However, as described in Chapter 1, the TFA intake may very well still reach this level among 
subgroups in some developing countries32.  
EFFECT OF TRANS FAT ON BLOOD LIPIDS AND LIPOPROTEINS BEYOND 
CHANGES IN LDL-C AND HDL-C 
Besides affecting the cholesterol-content of the different lipoprotein classes, TFA intake has 
also been shown to affect the number of lipoprotein particles, as reflected by increased ApoB 
(reflecting number of ApoB-containing particles) and decreased ApoA1 (reflecting HDL parti-
cle number) concentrations in a number of studies91,93,95,99,103,106,112. These effects are attenuated, 
but not eliminated, when adjusting for the total-C to HDL-C ratio11. A clear association between 
the ApoB to A1 ratio and risk of MI has been shown113 although this ratio may not add substan-
tial information beyond that obtained from the total-C to HDL-C ratio114. 
In addition, TFA intake has been shown to increase fasting plasma Lp(a) in several stu-
dies92,93,99,102,103,115, whereas in other studies such an effect was only observed in subgroups of 
participants with high baseline Lp(a) concentrations96,116 or not at all98,112. The Lp(a) particle is a 
lipoprotein similar to LDL that has an extra glycoprotein apoprotein(a). Plasma Lp(a) has been 
shown to be an independent marker of CHD risk with a ~50 mg/l higher Lp(a) concentration 
corresponding to a RR of 1.7 (CI: 1.4 to 1.9)117. In the meta-analysis by Mozaffarian & Clarke11 
a change in the TFA intake of 1 E% was estimated to increase the concentration of Lp(a) by 3.8, 
1.4 and 1.1 mg/l when compared to SFA, MUFA and PUFA, respectively, suggesting that re-
placement of TFA by SFA would more favorably affect Lp(a) concentrations than replacement 
by MUFA or PUFA. Neither Apo-lipoprotein, nor Lp(a) concentrations were measured in the 
 study. 
Whereas the effect of TFA on fasting triglyceride concentrations was not significantly different 
from that of SFA in the same meta-analysis, a change in the TFA intake of 1 E% was estimated 
to modestly increase the concentration by 0.014 -0.015 mmol/l when replacing either MUFA or 
PUFA11. Using these estimates, a difference between diet groups of 0.08 mmol/l in triglyceride 
concentrations could have been expected in the  study. We found a non-significant in-
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crease of 0.11 ± 0.06 mmol/l (P=0.09) from baseline in the TFA group, but also a slight increase 
of 0.05 ± 0.07 mmol/l (P=0.54) in the CTR group, resulting in no significant difference between 
diet groups (Paper II). 
A few studies have examined the effect of TFA intake on lipoprotein particle sizes. TFA de-
creased the LDL particle size in a dose-dependent, but subtle, manner in one study118 and a ten-
dency towards the same was observed in another119. It has been suggested that smaller LDL 
particles may be more susceptible to oxidation120 and thereby more atherogenic. However, TFA 
intake was found not to increase the vulnerability of LDL to oxidative change102,119. 
DO ALL TRANS FATTY ACID ISOMERS ELICIT THE SAME EFFECT ON BLOOD 
LIPIDS? 
Since all of the above-mentioned effects of TFA have been observed in studies where subjects 
were supplied with elaidic acid (trans18:1n-9) or mixtures of TFA isomers ensuing from hydro-
genation of different vegetable oils (mainly trans18:1), very little is know about the effects of 
individual TFA isomers. Moreover, the effect of TFA with more than one double bond remains 
elusive. A study by Vermunt et al.121 showed that low amounts of trans18:3 (1.4 g/d or < 1 E%) 
caused an increase in the LDL-C to HDL-C ratio of more than 8%, suggesting a greater effect of 
this TFA isomer compared to equivalent intakes of TFA from hydrogenated oils. Also, it ap-
pears that TFA from hydrogenated fish oil, containing C20 and C22 TFA isomers, may be more 
harmful than those from hydrogenated vegetable oils92,101,112.  
The effect of TFA from ruminant sources has long been unknown. A study in hamsters sug-
gested that the effect of vaccenic acid, the predominant isomer in R-TFA, was comparable to, or 
slightly worse, than that of elaidic acid, the isomer typical of IP-TFA, when evaluating different 
blood lipid parameters122. Recently, a few intervention studies comparing industrial and rumi-
nant sources of TFA have been published shedding some more light on this issue in 
humans107,123,124.  
Motard-Belanger et al.107 showed that when men consumed R-TFA in high amounts (3.7 E%) 
the effect on blood lipids was comparable to the effects of IP-TFA, increasing the LDL-C and 
decreasing the HDL-C concentrations in plasma. However, when R-TFA was consumed in 
moderate amounts (1.5 E%) the effect on blood lipids was not significantly different from that 
of a control diet with low TFA content (0.8 E% from any source). In accordance, Tardy et al.124 
found no difference in LDL-C or HDL-C after consumption of diets with ~2 E% TFA from 
either of the two sources, when compared to a control fat (TFA replaced by oleic and palmitic 
acid) in overweight women124.  
A study by Chardigny et al.123 indicated that women may respond differently to TFA from the 
two sources, while men do not. Concentrations of both HDL-C and LDL-C were higher in 
women after intake of 5 E% R-TFA compared to equivalent intakes of IP-TFA, resulting in no 
difference in the total-C to HDL-C ratio. No significant differences were observed in men123. In 
this regard it is noteworthy, than we in our meta-analysis (Paper I) found that in analyses strati-
fying for sex, a negative association of R-TFA with CHD, was present in women [RR=0.73 (CI: 
0.54 to 0.99); P = 0.05], but not in men [RR=1.01 (CI: 0.87 to 1.17); P = 0.91]. However, the 
sample size may be inadequate for these stratified analyses, since only two and three cohort 
studies reported separate analysis for women and men, respectively,. 
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In summary, these studies indicate that adverse effects of TFA on blood lipids are related to the 
amount of TFA rather than to the dietary source. The suggested sex difference in response to 
high intakes of TFA call for confirmation in future studies.   
MECHANISMS BY WHICH TRANS FATTY ACIDS MAY AFFECT BLOOD LIPID 
METABOLISM 
Different classes of FA may differently influence blood lipid levels by affecting various steps in 
lipid metabolism, including LDL-receptor production, abundance and activity; hepatic very-
low-density lipoprotein (VLDL) secretion; and catabolism of triglyceride-rich lipoproteins.  
Lipoprotein production versus catabolism 
The elevation in circulating levels of cholesterol seen after TFA exposure was shown to be ac-
companied by a rise in endogenous cholesterol synthesis in one study 108 but this was not the 
case in others119,125.  
A study in hamsters suggested that increases in LDL-C were due to suppression of hepatic LDL 
receptor activity126. In support of this notion, the catabolic rate of LDL was decreased in humans 
after consumption of TFA from hydrogenated soybean oil compared to un-hydrogenated oil. 
Also, the catabolic rate of HDL was increased, while the production rates of neither HDL nor 
LDL were affected127. An increased catabolism of HDL was likewise seen in a study in cibus 
monkeys fed elaidic acid128. Moreover, one study indicated that TFA-induced increases in LDL-
C concentrations were not caused by changes in the conversion rate of triglyceride-rich lipopro-
teins to intermediate-density lipoproteins (IDL) or IDL to LDL. LDL clearance appeared to be 
the only explanatory factor127. 
CETP enzyme activity 
The effect of TFA intake on LDL-C and HDL-C concentrations likely involves cholesteryl ester 
transfer protein (CETP), a protein in human plasma that transfers esterified cholesterol from 
HDL to lipoproteins of lower density in exchange for triglycerides. In vitro, an increased trans-
fer of HDL-C to LDL due to increased activity of CETP was shown in response to elaidic acid 
but not oleic acid129. An increased postprandial transfer of cholesterol from high to low density 
lipoproteins130 and an increased fasting activity of CETP was subsequently confirmed in 
some131-133 but not all109 human TFA feeding studies as well as in Cibus monkeys128. However, 
no effect on CETP activity was seen, despite significant TFA-induced reduction in HDL-C, 
when compared to a myristitic/palmitic acid-rich baseline diet in a study by Aro et al.93. Also, 
results by Lichtenstein et al.133 indicated that the observed changes in HDL-C were unlikely due 
to changes in CETP activity alone.  
Additional putative mechanisms 
Increased phospholipid transfer protein (PLTP) activity in response to TFA intake was observed 
in two studies93,133. However, the role of PLTP in lipoprotein modulation in humans appears to 
be dual. On one hand, PLTP increases the production of atherogenic apoB-containing lipopro-
teins, on the other, PLTP is thought to be anti-atherogenic by contributing to the formation of 
new HDL-particles, thereby increasing reverse-cholesterol transport134. It is therefore somewhat 
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surprising that the increase in PLTP activity was accompanied by a concomitant decrease in 
HDL-C in the two TFA intervention studies93,133.  
Matthan and colleagues135 have explored additional pathways by which TFA may affect lipo-
protein levels, and they suggested that the observed decrease in plasma concentrations of acyla-
tion-stimulated protein (a determinant of the rate of adipocyte triglyceride uptake) and a con-
comitant increase in free FAs (FFA) after TFA feeding, would cause a higher flux of FFA to the 
liver and subsequent increased production of VLDL135. Also, an observed decrease in the esteri-
fication of cholesterol was suggested to partly explain the lowering of HDL, since HDL is the 
predominant site for this esterification via lecithin:cholesterol acyltransferase (LCAT). How-
ever, this interpretation seems to contradict the null-effect on the esterification rate of choles-
terol in HDL observed in a larger sample of subjects from the same study133. 
The cellular mechanisms behind the effect of TFA on blood lipids remain elusive, but the pro-
posed effect of TFA on LDL receptor activity may occur via modulation of membrane fluidity. 
Also, the fact that different FAs have different ligand affinities for various nuclear transcription 
factors may explain other metabolic effects. These subjects will be further discussed in Chapter 
9.  
SUMMARY: TRANS FAT & BLOOD LIPIDS 
Is has been firmly established that TFA consumption increases LDL-C and decreases HDL-C 
concentrations and thereby induces a more atherogenic blood lipid profile than all other FA 
classes. This appears to apply to TFA of both ruminant and industrial origin, at least at high 
intake levels. The observed changes in blood lipids in the  study could therefore be 
considered an indication of good compliance with the study diets. TFA may induce a modest 
increase in triglyceride levels compared to MUFA and PUFA, but this is not a consistent find-
ing, maybe owing to lack of power in individual studies. TFA intake also appears to increase 
Lp(a) and may give rise to production of smaller LDL particles.  
In the  study, we did not examine putative mechanism by which TFA may exert these 
changes. The available evidence suggests that TFA intake neither affects the synthesis of cho-
lesterol nor the production rate of LDL or HDL particles. Instead, TFA may decrease the activ-
ity of the LDL-receptor and thereby the catabolic rate of LDL. In parallel, HDL particles may be 
catabolized at a higher rate. A stimulating effect of TFA on CETP activity likely explains part 
of the increase in LDL-C and decrease in HDL-C, whereas putative effects on other enzyme 
activities have not been substantiated. Moreover, the cellular mechanism by which TFA intake 
may convey these effects, have not been established. 
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 DIETARY TRANS FAT & OXIDATIVE STRESS, ENDOTHELIAL 
DYSFUNCTION AND CHRONIC LOW-GRADE INFLAMMATION  
It has been suggested that TFA intake may increase the risk of CHD and T2D via induction of 
oxidative stress, endothelial dysfunction and systemic inflammation18,19,136-140. These distur-
bances are tightly implicated in development of insulin resistance and in the atherosclerotic 
process. The initiation and progression of atherosclerosis has been reviewed by Libby & Hans-
son83,141 and will not be covered in detail in this thesis. However, an understanding of some key 
steps is important for the appreciation of how TFA might affect the process. The involvement of 
blood lipids in the progression of atherosclerosis has been dealt with in Chapter 5; in this chap-
ter, the concepts of oxidative stress, endothelial dysfunction, and chronic low-grade inflamma-
tion will be briefly described.   
ATHEROSCLEROSIS AS AN INFLAMMATORY DISEASE 
As already described, infiltration and retention of LDL particles in the arterial intima causes 
activation of the endothelium80. Cytokines, such as tumor necrosis factor α (TNFα) and inter-
leukin (IL)1β, induce increased expression of leukocyte adhesion molecules on the surface of 
the activated endothelial cells84,142,143. Selectins (such as E-selectin) on endothelial cells are es-
sential for the initiation of leucocyte rolling along the endothelium, and adhesion molecules, 
(vascular cell adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-
1)), cause the blood cells to adhere at the site of activation143. The blood cells are stimulated to 
migrate into the subendothelial space by adhesion molecules and chemokines, such as monocyte 
chemoattractant protein 1 (MCP-1), produced in the intima and by vascular cells, and here they 
differentiate into macrophages141. The modified LDL particles are taken up by scavenger recep-
tors or toll-like receptors (TLR) of the macrophages, with ensuing development of foam cells, 
stimulation of cytokine release82-84 and secretion of reactive oxygen species144. T-cells are at-
tracted and activated by antigens presented by macrophages and dendritic cells and they pro-
gressively infiltrate the atheroma. The activated T-cells produce cytokines (e.g. TNFα and 
interferon-γ) which again activates macrophages and vascular cells, initiating a potent inflam-
matory cascade83.  
Initially, the activated immune cells produce TNFα and IL1β, which induce the production of 
IL6. IL6 may then be released into the circulation and stimulate production of the acute phase 
reactants CRP and fibrinogen in the liver141. The pro-inflammatory cytokines and proteases 
released from the activated immune cells can reduce collagen formation and attack the fibrous 
cap that covers the atheroma. This weakens the stability of the plaque and makes it more vul-
nerable to rupture83. 
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MARKERS OF LOW-GRADE SYSTEMIC INFLAMMATION 
The identification of an exact cause of a rise in the systemic level of a given inflammatory 
marker is not straightforward, as they may stem from processes in the vascular endothelium, but 
also from local inflammatory processes in adipose tissue, muscle and/or liver. Also, cytokines 
may have different effects in different tissues or in different conditions145,146. However, systemic 
cytokine or CRP concentrations are thought to be reflective of spontaneously ongoing inflam-
matory responses in vivo and thereby mirror the overall inflammatory state of an individual147.  
As described above, it is progressively recognized that inflammatory processes are involved in 
the initiation and progression of atherosclerosis83,141 and insulin resistance148-150. Furthermore, 
obesity is a disorder characterized by chronic mild inflammation, with increased adipose tissue 
expression, production and release of various cytokines, including TNFα, IL6 and MCP-1 as 
well as a decrease in adiponectin. This is thought to be partly due to macrophage infiltration as 
well as the hypoxia ensuing from tissue mass expansion151.  
TNFα and TNF receptors 
TNFα is a pro-inflammatory cytokine, which is ubiquitously expressed in multiple cell types. 
TNFα is elevated in obesity and is thought to be one of many causal factors in obesity-induced 
insulin resistance152,153. As already described, TNFα in also highly involved in the atheroscle-
rotic process by triggering vascular inflammation via activation of specific membrane-bound 
receptors146. TNFα triggers the production of IL6154 and suppresses that of adiponectin in 
vitro155. The cytokine is short-lived in the circulation and concentrations may reflect local TNFα 
activation or mirror overall systemic inflammation156.  
TNF receptors are shed as a consequence of exposure to TNFα and other cytokines156. Soluble 
TNF receptors are thought to have a buffering function, either as inhibitors or as carrier proteins 
for TNFα156. An endotoxin-stimulated increase in TNFα has been shown to be followed by a 
prolonged rise in both TNF receptor 1 and 2 (TNF-R1 and TNF-R2)157. 
Rather than exerting pro-inflammatory effects in themselves, the soluble receptors are thought 
to be more easily measurable markers of TNF system activity than systemic TNFα, since the 
latter is present in plasma in very low concentrations. Also, the natural variability over time is 
higher for TNFα than for TNF receptors158.  
TNFα and TNF-receptor concentrations are elevated in heart failure patients, as reviewed by 
Bozkurt et al.159, and high systemic TNFα concentration was shown to increase the risk of re-
current coronary events after a MI160. However, adjustment for lipid risk markers may attenuate 
the association of TNF receptors with risk of CHD161. 
IL6 
IL6 is another cytokine reported to be elevated in obese subjects153. The physiological role of 
IL6 is, however, controversial. Some investigators have argued for a pro-inflammatory and in-
sulin resistance-inducing effect, largely based on evidence from observational or animal 
studies153,162. Based on data from trials in humans, others154 have argued that IL6 has insulin 
sensitizing and anti-inflammatory properties and that high systemic levels of IL6 simply reflect 
a stimulation by locally produced TNFα. In humans, IL6 has been shown to stimulate anti-
inflammatory cytokines and suppress TNFα production154. Nevertheless, the systemic concen-
tration of IL6 has been shown to be an independent predictor of cardiovascular events163. 
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Adiponectin 
Adiponectin is an adipokine produced by adipocytes and present in the circulation in high con-
centrations164. In contrast to other adipokines, adiponectin secretion and circulating levels are 
inversely proportional to body fat content165. Adiponectin increases hepatic insulin sensitivity, 
decreases vascular inflammation and antagonizes many effects of TNFα164. Furthermore, TNFα 
gene expression is inversely related to that of adiponectin in human AT166. Adiponectin levels 
may not independently predict cardiovascular risk167 but they are inversely associated with risk 
of T2D168. 
CRP 
The bulk of circulating CRP is produced by hepatocytes largely under regulatory control of IL6 
and IL1, but CRP may also be produced in the atherosclerotic lesion by smooth muscle cells and 
macrophages169,170. As recently reviewed by Devaraj et al.169, evidence is now emerging to sup-
port the notion that CRP is indeed an active factor and not just a marker of atherogenesis, al-
though the function of CRP in human physiology remains uncertain. Effects of CRP are thought 
to include inhibition of fibrinolysis, promotion of endothelial dysfunction (reduction of endothe-
lial nitric oxide and elevated levels of cellular adhesion molecules), increased production of pro-
inflammatory cytokines by macrophages and monocytes and release of reactive oxygen 
species169. Systemic concentrations of CRP have been found to predict the risk of cardiovascular 
events independent of other risk markers114. 
TFA intake and markers of low-grade systemic inflammation – evidence from observa-
tional studies 
A few cross-sectional analyses in healthy subjects and heart failure patients have reported in-
creasing concentrations of markers of low-grade systemic inflammation, such as CRP, TNFα 
and soluble TNF-receptors with higher intake of TFA18,19,136,137, or partially hydrogenated vege-
table oils139[Table 2].  
In healthy women from the Nurses’ Health Study, the concentrations of  sTNF-R1 and sTNF-R2 
were 9% and 12% higher in the highest quintile of TFA intake compared to the lowest (inter-
quintile range ~2.1 g/d TFA)19. Also in heart failure patients, the proportion of TFA in RBC 
membranes or intake of TFA has been associated with increased concentrations of TNFα and its 
soluble receptors137, 136. 
Positive associations between intake of TFA (or partially hydrogenated oil) and IL6 and CRP 
were found in populations of moderately overweight women18,139. In one study, positive associa-
tions were only seen in women with higher BMI19, whereas in another, stratification by BMI 
showed similar associations in women with BMI higher or lower than the median value18. 
Thereby, limited data support the hypothesis proposed by Mozaffarian et al.19 that the effect of 
TFA intake of IL6 and CRP production is modified by body weight.  
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Table 2: Cross-sectional studies examining the association between trans fatty acid (TFA) intake and 
markers of endothelial dysfunction and inflammation 
  Effect of TFA 
Reference Subjects Comparison TNFα TNF-
R1 
TNF-
R2 
CRP IL6 E-Se-
lectin 
I-
CAM 
V-
CAM
Mozaffarian 
et al. (2004)19 
823 F from 
NHS; healthy, 
61 y; BMI 24.6 
kg/m2 
Quintiles of TFA intake 
(FFQ) 1  
Mean TFA intake: 2.7 g/d)  
 ↑ 
9% 
↑ 
12% 
↔2 ↔2 
   
Mozaffarian 
et al. 
(2004)137 3 
86 F+M; heart 
failure; ~53 y; 
BMI ~30 kg/m2 
1% diff in TFA in RBC 
membranes 4 
Mean TFA in RBC: 1.8% 
(range: 0.7-2.9%)  
↑ 
249%
↑ 
41% 
↑ 
247%
↓ 
-48%
↑ 
123%    
Lennie et al. 
(2005)136 
42 F+M; heart 
failure; 61 y; no 
BMI data. 
High vs. low TFA intake, 
cut-off 3.3 g/d (4d food 
records) 
Mean TFA intake: 4.0 g/d) 
↑ 
51% 
↔ ↔  ↔ 
   
Lopez-Garcia 
et al. (2005)18 
730 F from 
NHS; healthy;  
56 y; BMI ~26 
kg/m2  
Quintiles of TFA intake 
(FFQ) 5  
Mean TFA intake: 2.4 g/d 
  ↑ 
5% 
↑ 
73%
↑ 
17% 
↑ 
20% 
↑ 
10% 
↑ 
10% 
Esmaillzadeh 
et al. 
(2008)139 
486 F; healthy; 
40-60 y; BMI 
~27 kg/m2 
Quintiles of PHVO intake 
(FFQ) 6  
Mean PHVO intake: 23 g/d, 
or ~7.5 g TFA 
↑ 
56% 
  ↑ 
29%
↑ 
59% 
↔ ↑ 
16% 
↔ 
↑ and ↓ represent higher and lower concentration of this marker with increasing TFA intake. ↔, no significant effect 
of TFA. NHS, the Nurses’ Health Study; PHVO, Partially hydrogenated vegetable oil. 1 adjusted for age; BMI; smok-
ing; physical activity; intake of energy, alcohol, SFA, PUFA, protein and fiber; use of aspirin and anti-inflammatory 
drugs, 2Positively associated with TFA intake only in women with higher body mass index; 3 TFA was also positively 
associated with interleukin (IL)1β, IL1 receptor antagonist, IL10, monocyte chemoattractant protein 1, and brain 
natriuretic peptide; 4 adjusted for age, sex, BMI, smoking, ejection fraction, New York Heart Association class, 
ischemic etiology, statin use and serum glucose; 5 adjusted for age, BMI, physical activity, smoking, intake of alco-
hol, MUFA, PUFA, SFA and postmenopausal hormone therapy;  6 adjusted for, age, smoking, physical activity, es-
trogen use, dietary intakes, BMI, plasma glucose and lipids and other confounders. 
The findings from these cross-sectional analyses have not been substantiated by prospective 
analysis looking at associations between changes in TFA intake and markers of inflammation. 
Moreover, supporting evidence from RCTs is sparse [Table 3]. 
TFA intake and inflammatory markers - Intervention studies 
Han et al.171 showed increased production of TNFα and IL6 in stimulated mononuclear cells of 
mildly hypercholesterolemic, older and overweight subjects after 32 days of 7 E% TFA intake 
from stick margarine compared to soybean oil. In contrast, in two studies in young, lean and 
healthy subjects, supplementation with a mix of trans18:1n-7 and trans18:1n-6 (~3 E%) for 6 
weeks had no effect on plasma concentrations of TNFα, IL6, IL8 or adiponectin172, and 5 weeks 
consumption of 10 E% TFA from hydrogenated soybean oil did not affect the serum TNFα or 
IL6 concentration when compared to palm stearin or high oleic palm olein17.  
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Table 3: Intervention studies examining the effect of trans fatty acid (TFA) intake on markers of endo-
thelial dysfunction and inflammation 
    Effect of TFA 
Reference Subjects Design Diets Meas-
ured in 
TNFα CRP IL6 E-Se-
lectin
Han et al. 
(2002)171 
19 F+M 
(hyperchol., 
mean age 65 y, 
mean BMI 29 
kg/m2) 
Cross-
over 
(32d) 
Isoenergetic, 30 E% from fat. 
1) Stick marg. (7 E%TFA);   
2) Soybean oil;  
3) Butter (1 E% TFA) 
LPS 
stimulated 
PBMCs 
↑ 
58%1 
 ↑ 
36%1 
 
Lichten-
stein et al. 
(2003)173 
36 F+M 
(hyperchol., 
mean age 63 y, 
mean BMI 27 
kg/m2) 
Cross-
over 
(35d) 
Isoenergetic, 30 E% from fat. 
1) Soft marg. (3 E% TFA); 
2) Shortening (4 E% TFA); 
3) Stick marg. (7 E% TFA); 
4) Soybean oil;  
5) Semi-liquid marg.;   
6) Butter (1 E% TFA) 
Plasma  ↔   
Baer et al. 
(2004)15 
50 M 
(healthy, mean 
age 42 y, mean 
BMI 26 kg/m2) 
Cross-
over 
(5wk) 
Isoenergetic, 39 E% from fat. 
1) Carbohydrate (31E% from fat); 
2) OA;  
3) SA;  
4) TFA (8 E%);  
5) 50/50 SA+TFA  
6) Medium-chain SFA 
Plasma  ↑  
21%2 
↔3 ↑  
14%4
Kuhnt et 
al. 
(2007)172 
24 F+M 
(healthy, mean 
age 25 y, BMI 
20-22 kg/m2) 
Parallel 
(6wk) 
Isoenergetic, 30 E% from fat. 
1) TFA (t11/t12-18:1; 3 E%)  
2) Palm/rapeseed oil (PUFA) 
Plasma ↔  ↔ 5  
Motard-
Belanger et 
al. 
(2008)107 
38 M (healthy, 
mean age 33 y, 
mean BMI 24 
kg/m2)  
Cross-
over 
(4wk) 
Isoenergetic, 37 E% from fat. 
1) R-TFA (~4 E%); 
2) R-TFA (1.5 E%); 
3) IP-TFA (~4 E%); 
4) Butter/canola/peanut oil (OA) 
na  ↔   
Tardy et al. 
(2009)124 
57 F (healthy, 
18-50 y, mean 
BMI 32.5 
kg/m2, abd. 
obese) 
Parallel 
(5wk) 
Isoenergetic, 42-45 E% from fat. 
1) IP-TFA (~2 E%);  
2) R-TFA(~2 E%); 
3) Palm oil (PA/OA) 
Plasma  ↔   
Vega-
Lopez et 
al. 
(2009)174 
30 F 
(hyperchol., 
mean age 64 y, 
mean BMI 26 
kg/m2) 
Cross-
over 
(35d) 
Isoenergetic, 25-26 E% from fat. 
1) Part. hydr. soybean oil (4 E% 
TFA);  
2) Corn oil (PUFA) 
Plasma  ↔   
Teng et al. 
(2010)17 
41F+M 
(healthy, mean 
age 29 y, mean 
BMI 22 kg/m2 ) 
Cross-
over 
(5wk) 
Isoenergetic, 32-34 E% from fat. 
1) Part. hydr. soybean oil (10 E% 
TFA);  
2) Palm stearin (PA/OA);  
3) High OA palm oil 
(OA/LA/ALA) 
Serum ↔ ↑  
22%6 
↔ 7  
↑ and ↓ represent higher and lower concentration of this marker with increasing TFA intake. ↔, no significant effect 
of TFA. ALA, alpha-linolenic acid; LA, linoleic acid; OA, oleic acid; PA, palmitic acid; SA, stearic acid; 1Compared 
to soybean oil, not different from butter diet; 2 Compared to OA or carbohydrate, not different from SA or medium-
chain SFA; 3 Lower after OA compared to all other diets; 4 Compared to OA, 6-9 % higher compared to all other 
diets; 5 Also no effect on IL1β, IL8, IL10, IL12, leptin or adiponectin; 6 Compared to palm steartin, 25% compared to 
high OA palm oil. 7 Also no effect on IL1β, but lower IL8 after TFA compared to palm stearin diet. 
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It is possible that the TNF system is more susceptible to TFA-induced activation in older and 
overweight subjects. This would explain why we in the  study were able to show a 12% 
(CI: 5 to 20; P=0.002) higher TNFα concentration in TFA-exposed abdominally obese post-
menopausal women compared to controls (Paper IV). We substantiated our findings by show-
ing concomitant increases in sTNF-R1 and sTNF-R2 plasma concentrations in the TFA group of 
22 ± 7% and 14 ± 3%, respectively [Figure 5]. The TNFα concentration was significantly corre-
lated with both sTNF-R1 (r=0.31, P=0.03) and sTNF-R2 (r=0.48; P<0.001) concentrations after 
the intervention. Also, it is worth noting that we, in accordance with others175, observed higher 
TNF receptor concentrations in the overweight women compared to the lean references, sup-
porting the notion that these receptors may be markers of an overall dysmetabolic state and low-
grade inflammation. 
It would be interesting to assess whether subjects with high incorporation of TFA into RBC 
membranes were more likely to experience a high TNFα response. Unfortunately, due to meth-
odological shortcomings, the RBC FA composition analyses did not allow for exact quantifica-
tion of RBC TFA content (Paper II), rendering such analyses impossible. 
Although TFA intake has been associated with IL6 concentrations in cross-sectional anal-
ysis18,139, no RCT has been able to demonstrate an effect of TFA intake on systemic concentra-
tions of IL615,17,172. In the  study, we did not see an effect of the intervention on 
circulating IL6 either, although IL6 is stimulated by TNFα. This may be due to the fact that the 
natural variability in circulating levels of IL6 is significantly higher than that of TNFα, and con-
siderably higher than that of TNF receptors158. Thereby, TFA-induced changes, if present, may 
only be detected in stimulated cells171. However, in vitro results indicate that TFA indeed affects 
TNFα production more so than that of IL6. Incubation of murine Kupffer cells with trans18:1 or 
trans18:2 isomer-containing medium resulted in higher lipopolysaccharide-stimulated TNFα, 
but not IL6, production compared to incubation with the corresponding cis isomers176. 
Previous intervention studies examining the effect of TFA on systemic CRP concentrations are 
limited and contradictory. In studies providing healthy subjects with 8 or 10 E% TFA, the con-
Figure 5: Serum concentration of tumor necrosis factor (TNF)α assessed by ELISA and plasma concentrations of
soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1 and sTNF-R2) assessed by Bead array technology before
and after 8 and 16 weeks (wk) of supplementation with 15.7 g/d trans fatty acids (dark grey bars; n=24) or a control
oil (white bars; n=25), and in lean references (light grey bars; n = 19). From Paper IV.  
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centration of CRP increased compared to provision of carbohydrate or oleic acid15 or compared 
to oleic acid/PUFA or palmitic/oleic acid17. In contrast, CRP was unaffected by dietary TFA in 
doses of 3.6 to 5.2 E%173, 174, 107 [Table 3]. It is possible that very high dietary TFA levels are 
needed before CRP is affected, or more likely, that most studies have simply been under-
powered to detect the small changes induced by TFA. In the two crossover studies showing 
significant effects of TFA on CRP, the difference between diets was only 0.12 mg/l (n=41)17 
and 0.20 mg/l (n=50)15, respectively. In the  study, the baseline-adjusted mean CRP 
concentrations were 1.93 (CI: 1.53 to 2.43) and 1.91 (CI: 1.50 to 2.42), in the TFA and CTR 
groups, respectively. Consistent with the width of these confidence intervals, we were not able 
to detect a difference between diet groups of the size previously reported.  
Few studies have examined the effect of TFA consumption on adiponectin levels. Consumption 
of hydrogenated soybean oil (4 E% TFA) resulted in a significant increase of ~2% in adi-
ponectin levels in postmenopausal women compared to corn oil109. In contrast, the serum adi-
ponectin concentration was not affected in the  study [mean relative difference between 
diet groups: 11% (CI: -32 to 15); P= 0.37] (Paper IV). The evidence from rodent studies is 
equally conflicting, with one study showing an adiponectin-increasing effect of TFA compared 
to MUFA177, and another finding the exact opposite when TFA was compared to PUFA178. 
TFA intake and mRNA expression of inflammatory markers in adipose tissue 
The higher circulating concentrations of TNFα and its soluble receptors after TFA consumption 
in the  study was not reflected by increased mRNA expression in subcutaneous ab-
dominal AT (SAT) (Paper IV). In accordance, no effect of 6 years of TFA-feeding was seen on 
AT TNFα protein concentration in monkeys22.  
In the  study, neither serum TNFα, IL6 nor adiponectin concentrations were correlated 
with mRNA expressions in SAT (Paper IV). This is no too surprising, given that TNFα and IL6 
are also produced by other tissues/cells, e.g. the vascular endothelium and skeletal muscle83,179, 
and the fact that transcript and protein turnover is different in various tissues. 
The fact that serum TNFα but not AT mRNA was affected by TFA intake in the  study, 
may also be due to limited incorporation of TFA into AT during the 16 weeks of intervention. 
The AT content of the two predominant TFA isomers increased two-fold in the TFA group, but 
still only constituted ~1% of total FA. This low degree of TFA incorporation is not unexpected 
given the half life of SAT FA of 6-18 months180-182.  
However, as the intra-abdominal AT (IAAT) depot FA turnover is higher than that of the 
SAT183 and since meal FA uptake is relatively larger in the former depot184, more TFA may 
have been incorporated here. Previously, the TFA concentration was shown to be higher in 
IAAT compared to SAT185. Also, the SAT depot may not adequately reflect an effect of TFA on 
AT inflammation; in overweight subjects, the mRNA of TNFα was found to be considerable 
higher in IAAT compared to SAT186.  
In the  study, we did not see a difference in AT mRNA expression of TNFα or adi-
ponectin between the overweight women (BMI ~28 kg/m2) and lean references (BMI ~21 
kg/m2). Again, this may be due to the sampling of SAT and not IAAT. Previously, higher TNFα 
and lower adiponectin expression in IAAT was observed in overweight (BMI 28 kg/m2) com-
pared to lean subjects. In contrast, no difference in adiponectin mRNA was seen in SAT, 
whereas TNFα mRNA was even higher in lean subjects in this depot186.  
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The evidence from rodent studies looking at effects of TFA-feeding on cytokine or adipokine 
mRNA expression is somewhat conflicting [Appendix E]. In rats fed TFA-diets until 120 days-
of-age, the mRNA expression of TNFα was higher and the expression of adiponectin lower in 
retroperitoneal AT compared to PUFA-fed rats178. In another study in rats, AT mRNA expres-
sion of adiponectin was decreased by SFA, but not TFA187. Also, TFA-feeding of rats and mice 
did not affect hepatic expression of TNFα and IL6176,188, but expression of IL-1β was higher 
than in mice fed SFA188.  
MARKERS OF ENDOTHELIAL DYSFUNCTION 
Disturbance of the normal function of the vessel endothelium, so-called endothelial dysfunction, 
triggers the initiation of atherogenesis, as described in the beginning of this chapter. Endothelial 
dysfunction is characterized by an activation of endothelial cells leading to increased adhesion 
of leucocytes to the activated endothelium, but also by a disturbed regulation of vessel tone and 
blood pressure due to a disturbed balance in the release of relaxing and constricting factors189. 
Despite clear roles for adhesion molecules in the pathogenesis of atherosclerosis, the association 
between plasma levels of these molecules and cardiovascular risk is less apparent. Whereas 
levels of soluble ICAM-1 (sICAM-1) have been associated with risk of cardiovascular disease 
in large observational studies190-193, the findings for soluble VCAM-1 (sVCAM-1), and soluble 
E-Selectin (sE-selectin)190,191 are inconsistent. It has been proposed that sICAM-1 is the most 
powerful predictor of events in healthy populations, whereas sVCAM-1 may be a prognostic 
marker in patients with established atherosclerotic disease194. One study suggested that the com-
bination of high levels of both sICAM-1 and sVCAM-1 might be associated with the develop-
ment of CHD, independent of other CHD risk factors195. 
TFA intake and endothelial dysfunction 
In a cross-sectional analysis in overweight women, concentrations of sE-selectin, sICAM-1 and 
sVCAM-1 were positively associated with TFA intake18, while only sICAM-1 was associated 
with intake of hydrogenated vegetable oil in another study139 [Tabel 2]. Again, the supporting 
evidence from randomized studies is limited. An increase in E-selectin after 5 weeks of 8 E% 
TFA consumption (compared to carbohydrate, stearic acid, oleic acid and a mix of lauric, myris-
titic and palmitic acid) has been reported in a crossover study in 50 men15. In the  study, 
we confirmed these findings by showing increases in serum sE-selectin of 19 ± 4% in the TFA 
group (P= 0.004 for within-group change). The effect of diet reached significance when sE-
selectin was measured in plasma [mean difference 10% (CI: 1 to 21); P=0.04], but not in serum 
[8% (CI: -2 to 19); P=0.13]. In contrast, there was no effect of diet on sICAM-1 and sVCAM-1 
(Paper IV). Of note, only sE-selectin, not sICAM-1 and sVCAM-1, was lower in overweight 
compared to lean subjects, indicating that the former may be a better marker of obesity-related 
endothelial disturbances. 
Given the questionable validity of these systemic markers of endothelial dysfunction in predict-
ing disease risk in healthy subjects, more direct measures of endothelial dysfunction, such as 
flow-mediated vasodilation (FMD), may convey more useful information. In 29 lean young 
subjects, high TFA consumption (9 E% or 23 g/d) for 3-4 weeks was shown to negatively affect 
FMD of the brachial artery compared to a diet high in lauric, myristitic and palmitic acid (FMD: 
4.4 ± 2.3% after TFA compared to 6.2 ± 3.0% after SFA; P=0.02)196. However, this finding 
could not be confirmed in a study in 75 lean and young men consuming TFA (6 E% or 20 g/d), 
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palmitic acid or fish oil (12 g/d) for 8 weeks111. The power of the latter study was lower, due to 
a parallel study design, but no trends in either direction were observed. 
A few in vitro experiments support the notion that TFA may more potently induce endothelial 
dysfunction than the corresponding cis FA. Human aortic endothelial cells exposed to trans18:2 
significantly increased the expression of endothelial adhesion molecules, including ICAM-1, 
compared to cis18:2197. Moreover, the trans18:2 isomer increased the release of MCP-1 and 
resulted in increased adhesion of monocytes to cell monolayers198. In another study, elaidic acid 
was shown to maintain the TNFα-stimulated level of ICAM-1 and VCAM-1 in human bone 
marrow endothelial cells, whereas oleic acid suppressed the expression199. Finally, incorporation 
of TFA into endothelial cell membrane phospholipids has also been shown to suppress the se-
cretion of prostacyclin, which is a potent vasodilator and inhibitor of platelet aggregation and 
leukocyte adhesion200. 
MARKERS OF OXIDATIVE STRESS 
Oxidative stress occurs when the body experiences potentially deleterious distress due to forma-
tion of reactive radical species in levels that exceed those that can be controlled by the body’s 
antioxidant defense systems. Lipid peroxidation can occur via enzymatic or non-enzymatic 
pathways. Arachidonic acid (20:4n-6) can be enzymatically oxidized via cyclooxygenase and 
lipooxygenase mediated pathways to form bioactive leukotrienes, prostaglandins and lipoxins, 
which are highly involved in inflammatory pathways201. Non-enzymatic oxidation is induced by 
free radicals, and the ensuing oxidized lipids, so-called isoprostanes, can modify the cell mem-
brane fluidity and induce inflammation in neighboring cells202. Urinary 8-iso-prostaglandin-F2α 
(8-iso-PGF2α), which is the product of free radical catalyzed peroxidation of arachidonic acid, is 
a validated marker of non-enzymatic lipid peroxidation and overall in vivo oxidative stress203. 
Elevated levels are found in many conditions, such as chronic inflammation, diabetes and 
atherosclerosis (reviewed by Basu et al.202).  
TFA intake and markers of oxidative stress 
Intake of vaccenic acid or a mixture of vaccenic acid and trans18:1n-6 has been shown to in-
crease the urinary excretion of the isoprostane 8-iso-PGF2α71,138, although this was not found 
after intake of vaccenic acid-rich butter204.  However, a mixture of TFA isomers from partially 
hydrogenated vegetable oils, as provided to the subjects in the  study, had no detectable 
effect on the urinary concentration of 8-iso-PGF2α (Paper IV). Whether consumption of vacce-
nic acid per se may induce oxidative stress or whether the observed effect in prior studies 
should rather be ascribed to the endogenous conversion of vaccenic acid to CLA71, is not 
known. Supplementation with CLA has consistently been shown to cause elevated urinary iso-
prostane excretion205-207.  
Yet, there is some evidence suggesting that TFA, as such, may increase oxidative stress. TFA 
intake was positively correlated with urinary 8-iso-PGF2α in a 5-year follow-up of 1,610 
women140, and increased plasma levels of F2-isoprostanes were found after hydrogenated vege-
table oil-feeding in mice208. Also, human aortic endothelial cells incubated with trans18.2 
showed signs of oxidative stress as indicated by increased nitrosylation of proteins197. 
It has been proposed that induction of oxidative stress may be an intermediary step by which 
dietary FA may adversely affect insulin sensitivity. A negative effect of CLA supplements on 
insulin sensitivity was abolished when adjusting for concomitant increases in urinary excretion 
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of isoprostanes205. In the  study, the changes in urinary isoprostane excretion did not 
correlate with changes in insulin sensitivity, as assessed by oral glucose tolerance tests (Paper 
III). 
MECHANISMS BY WHICH TRANS FATTY ACIDS MAY AFFECT INFLAMMA-
TORY PROCESSES 
The molecular mechanisms implicated in the apparent pro-inflammatory effect of TFA remain 
speculative. First, TFA incorporation into phospholipids may affect membrane properties209, and 
thereby the function of membrane-bound receptors that mediate the transduction of inflamma-
tory stimuli, such as TNF-receptors and TLR210. Second, TFA may interfere with the metabo-
lism of essential FAs and thereby the production of various pro- or anti-inflammatory lipid 
mediators201. Finally, TFA may stimulate the expression of pro-inflammatory cytokines by acti-
vating TLR signaling, as seen for SFA211,212. This will be covered in more detail in Chapter 9. 
SUMMARY: DIETARY TRANS FAT & SYSTEMIC INFLAMMATION, ENDOTHE-
LIAL DYSFUNCTION AND OXIDATIVE STRESS 
The evidence for an effect of TFA consumption on low-grade systemic inflammation, endothe-
lial dysfunction and oxidative stress must be considered limited. Our findings of an increased 
production of TNFα and its soluble receptors after TFA intake do, however, lend convincing 
support to the notion that dietary TFA promote low-grade inflammation. If TFA consumption 
affects CRP production, the effect appears to be modest, which may explain why we failed to 
detect it in the  study. Reports on the effect of TFA intake on IL6 or adiponectin pro-
duction are few and inconsistent. Our research showed that TFA does not affect the mRNA 
expression of TNFα, IL6 and adiponectin in subcutaneous adipose tissue within 16 weeks. 
Thereby, it remains to be answered which tissue(s) may be responsible for the increase in sys-
temic TNFα. 
Furthermore, the evidence for a TFA-induced adverse effect on oxidative stress and endothelial 
dysfunction is far from convincing. Results from our study tended to confirm prior reports of a 
sE-selectin-increasing effect of TFA, indicating that TFA may indeed promote endothelial dys-
function. However, only one study has provided evidence for a negative effect of TFA on the 
more direct measure of endothelial function, flow-mediated vasodilation; a finding that could 
not be confirmed by others.  
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  DIETARY TRANS FAT & FAT DEPOSITION 
Increased BMI and especially increased abdominal fat deposition, as reflected by increased 
waist circumference, are positively associated with risk of T2D213 and CHD113,214. In women, a 
waist circumference of ≥76.2 cm was associated with a more than 2-fold higher risk of CHD, 
after adjustment for other established risk factors214.  
A few years ago, a 15 year prospective analysis in 3,031 young adults showed that fast food 
consumption was strongly associated to weight gain215. Frequent fast food consumption might 
simply reflect a generally unhealthy lifestyle, or fast food may cause obesity due to high energy 
density and large serving sizes. But it has also been suggested, that the high content of TFA in 
fast food contributes to this obesogenic effect. 
TRANS FAT AND OBESITY – EVIDENCE FROM OBSERVATIONAL STUDIES 
Observational studies have indicated that TFA intake is positively associated with obesity indi-
ces, such as weight, waist circumference, skinfold thickness and percent body fat 8,9,216,217, al-
though this is not a consistent finding185,218. 
In cross-sectional baseline analyses from the Nurses’ Health study (n=31,940), the strongest 
positive association between intake of a single nutrient and BMI (adjusting for age and energy 
intake) was found for TFA219. When using prospective data from the same cohort (n=41,518), 
Field et al.8 showed that change in TFA intake, was stronger associated to weight gain than 
change in any of the other FA classes. Moreover, the association was particularly strong among 
overweight women; for every 1% increase in E% from TFA, they gained an additional 1.0 kg 
(CI: 0.8 to 1.3) during 8 years of follow-up. Data from the Health Professional’s Follow-up 
Study (n=16,587) indicated that TFA intake may specifically increase abdominal obesity. A 2% 
increment in energy intake from TFA, isocalorically substituted for PUFA or carbohydrates, 
was associated with a 0.77 cm waist gain in multivariate analyses during 9 years of follow-up. 
This association was only modestly reduced after adjustment for BMI. Furthermore, in an 
analysis adjusting for measurement error, it was calculated that isocaloric replacement of 2 E% 
of TFA with PUFA would result in a 2.7 cm decrease in waist circumference over 9 years (P < 
0.001)9.  
In contrast, observational studies with much smaller study populations have not been able to 
confirm these findings. In a case-control study of 34 obese Spanish children and 20 lean con-
trols, neither TFA intake nor plasma TFA concentration differed between obese and lean chil-
dren220. Likewise, in a cross-sectional study among 617 Canadians, intake of TFA was not 
associated with waist-to-hip ratio218, yet TFA intake was quite low in both populations (<1 g/d). 
Also, in Brazilian subjects there was no difference in AT TFA concentration between non-obese 
(BMI<30 kg/m2) and obese (BMI>40 kg/m2) subjects, despite very high AT TFA levels (6-9% 
of FA)185. A recent cross-sectional study in 1,785 subjects suggested that individual TFA iso-
mers may have divergent effects on adiposity. Whereas the concentration of trans18:2 in AT 
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was positively associated with BMI, waist circumference and skinfold thickness, inverse asso-
ciations were seen for trans18:1 in multivariate analyses217.  
Two studies in American women have suggested that high TFA intakes may be associated with 
increased maternal postpartum weight or body fat percentage216,221. In 902 women, the odds 
ratio of retaining at least 5 kg at 1 year postpartum was 1.32 (CI: 1.08 to 1.62) per 0.5 E% TFA 
increment in an analysis adjusting for pre-pregnancy BMI, gestational weight gain and a range 
of other putatively explanatory variables221. Likewise, in 96 mothers, the odds of having >30% 
body fat at three months postpartum was 5.81 (CI: 1.05 to 32.32) in women consuming >4.5 g/d 
TFA compared to those consuming less in multivariate analysis. Maternal TFA intake also 
tended to predict 3-month-old infant adiposity, but not after adjusting for possible confound-
ders216. 
TRANS FAT AND BODY FAT DEPOSITION  
A few years ago, a long-term TFA-feeding study in non-human primates received considerable 
attention as it was the first dietary intervention to document a fattening effect of TFA intake in a 
non-rodent animal model. Despite the fact that energy supply was targeted at body weight main-
tenance (and based on baseline body weight), African green monkeys fed a diet enriched with 8 
E% TFA for 6 years (equivalent to ~15 years in humans) gained significantly more body weight 
(7.2 ± 2.7% increase) than a control group (1.8 ± 2.0% increase) whose diet was rich in cis-
MUFA (P=0.05). Moreover, monkeys fed TFA had deposited more fat in both the subcutaneous 
and the intra-abdominal regions (non-significant (ns)) and had a significantly higher ratio of 
intra-abdominal AT (IAAT) to subcutaneous abdominal AT (SAT) after adjusting for body 
weight (P=0.02)22.  
With the  study we are the first to examine the effect of TFA consumption on fat depo-
sition in a human intervention. We observed weak trends towards greater increases in waist 
circumference and total fat mass (assessed by DEXA) in the TFA group compared to controls 
independent of body weight changes. Waist circumference tended to increase more in the TFA 
group [baseline-adjusted mean difference between diet groups: 1.1 cm (CI: -0.1 to 2.4); P =0.08] 
and so did body fat: The baseline-adjusted change in body fat mass was 1.2 kg (CI: 0.7 to 1.8) 
in the TFA group and 0.8 kg (CI: 0.3 to 1.3) in the CTR group with an estimated 0.5 kg (CI: -
0.1 to 1.2; P=0.16) difference between diet groups at the end of the intervention (P=0.12 in an 
analysis adjusting for weight change).  
However, these trends were not reflected in the observed changes in abdominal fat deposition 
(assessed by single-slice magnetic resonance imaging (MRI)). After the intervention, the total 
abdominal AT volume was an estimated 2 cm3 lower (CI: -25 to 21; P=0.85) in the TFA group 
compared to controls; the SAT volume was 3 cm3  lower (CI: -15 to 9; P=0.58), and the IAAT 
volume was 7 cm3  higher (CI: -12 to 26; P=0.46), with no effect of adjusting for weight change 
[Figure 6]. The width of these confidence intervals suggests that we would have been able to 
detect differences between diets corresponding to ~5% of the baseline AT, 7% of the SAT and 
9% of the IAAT volume. The observed within-group changes were of somewhat smaller magni-
tude;  the increase in total AT was 2.9 ± 1.9% in the TFA group and 4.4 ± 1.9% in the CTR 
group, with corresponding increases in IAAT of 2.1 ± 2.4% and 3.2 ± 2.2%, and in SAT of 4.9 
± 2.8% and 5.9 ± 4.6%, in the two groups respectively.  
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Thereby, our data did not show any trend towards confirming the effect of TFA on the ratio of 
IAAT to SAT, as seen in monkeys22. The difference between diet groups in this ratio was 0.01 
(CI: -0.06 to 0.07; P=0.87) in our study 
(Paper II). However, others have observed 
considerable changes in abdominal AT as a 
consequence of altering the dietary fat com-
position. After consumption of a diet high 
in PUFA for 5 weeks, the SAT volume 
(assessed by single-slice MRI) was ~30% 
lower compared to after a diet high in SFA, 
despite no differences in body weight in 17 
men and women222.  
It cannot be discounted that our lack of 
control of the diets in the  study 
may have limited the strength of the study 
to detect TFA-related changes in fat deposi-
tion. Our subjects were given two bread 
rolls per day, containing a total of 26 g of 
fat (TFA or CTR) and 2500 kJ, which they 
were instructed how to substitute iso-
calorically for food items from their habit-
ual diets. The rest of their diets was not 
controlled. However, results of 3-day food records from the week before the last MRI indicated 
no significant differences between diet groups in intake of either energy or any of the macronu-
trients. The only differences were a higher TFA intake in the TFA group and a higher MUFA 
intake in the controls (Paper II). Yet, minor differences may not have been picked up by this 
dietary assessment.   
It may also be considered a limitation of the  study that AT volumes were assessed by 
single trans-axial images (single-slice MRI), and not by examination of the entire abdominal 
region. We obtained images at the level of the third lumbar vertebrae, which has been shown to 
be the single slice volume (or area) to correlate best with the IAAT of the whole abdominal 
region in women (R2 = 0.94-0.97)16,223,224. For SAT, the correlation between single- and multi-
ple-slice MRI is high regardless of the position of the single-slice measurement224. However, 
single-slice methods may be less likely to detect small changes in abdominal adiposity. One 
study estimated that ~6% more women would be needed in a trial using single-slice as com-
pared to multiple-slice measurements to reach the same power223 and another showed that the 
variability in exercise-induced changes in IAAT was somewhat larger when measured with the 
former compared to the latter method225.  
Apart from methodological limitations, the fact that we did not see an effect of the TFA inter-
vention on abdominal fat deposition may be due to the relatively short intervention period. It is 
likely that 16 weeks of exposure was too short a period of time to detect changes in abdominal 
fat independent of body weight even with high daily TFA intakes. Indeed, body weight gain 
may be an intermediary step leading to TFA induced increases in abdominal fat deposition, 
which we may not have been able to detect with our isocaloric study design. In monkeys fed a 
weight-maintenance diet with 8 E% TFA, the abdominal fat deposition was 31% greater than in 
monkeys fed cisMUFA and the weight gain was ~5.4% after 6 years (when subtracting the 
Figure 6: Changes in whole-body fat mass and percentage 
body fat assessed by DEXA and changes in subcutaneous 
(sc.) and intra-abdominal (abd.) adipose tissue (AT) during 
16 weeks in the TFA group (black bars) and in the CTR 
group (white bars). Bars represent baseline-adjusted means 
and SEM. P-values were obtained by baseline-adjusted 
ANCOVA. 
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weight gain in the control group)22. This would correspond to a weight gain of only 0.24 kg in 
an 80 kg woman during 16 weeks. Moreover, the difference in weight between diet groups in 
the study in monkeys did not appear to emerge before after one year22.  
Yet, as mentioned above, 5 weeks of intervention was long enough to show significant diet-
induced changes in abdominal AT deposition in 17 subjects222, and CLA supplementation of 4.5 
g/d has been shown to significantly decrease fat mass (assessed by DEXA) in postmenopausal 
women within 16 weeks on iso-caloric diets226. This confirms that abdominal fat distribution 
can be highly affected by dietary fat manipulations within the timeframe of our study.  
TFA and fat deposition in rodent models 
Due to the limited data available from human studies on the effect of TFA on adiposity, data 
from rodent models may shed some more light on this subject. However, results from studies in 
rabbits, rats and mice are highly conflicting [Appendix E] and may not predict effects in hu-
mans. Most rodent studies examining the metabolic effect of a high TFA intake as part of high-
fat diets have found no effect on body weight compared to stearic acid, SFA, MUFA or 
PUFA177,227-231 or even lower body weight compared to a mixture of other FAs188, oleic acid232 
or SFA 233. Whereas, the lower body weight after TFA-feeding was followed by lower adiposity 
in some studies232-234, the opposite was seen in one study where epididymal AT weight (mimick-
ing IAAT in humans) was 86% higher in TFA-fed rats compared to rats fed a MUFA/PUFA 
mix227.  
It appears that the fat load may modify the effect of TFA feeding on adiposity in rodents. In rats 
fed TFA-enriched diets with moderate fat content (~10-16 E%), body weight, fat mass, and liver 
fat were significantly elevated compared to rats fed SFA, MUFA or PUFA, but not palmitic acid 
235,236. In one study, abdominal fat was preferentially deposited intra-abdominally after con-
sumption of a low-fat TFA-enriched diet, and liver fat accumulation was comparable to that in 
rats fed high-fat SFA diets235. An increased accumulation of triglyceride in the liver after TFA 
feeding, compared to SFA, MUFA or PUFA, has been observed in several other rodent studies, 
despite no effect on body weight176,227-229,231,234. 
TRANS FAT AND LIVER FAT DEPOSITION  
In humans, liver fat accumulation is considered the hepatic manifestation of metabolic dysfunc-
tion237,238 and is associated with intra-abdominal fat deposition239 and insulin resistance240-242. 
Liver fat may be a more important risk factor for obesity-related metabolic disorders than 
IAAT241,243. Based on data from healthy normal weight (BMI<25 kg/m2) subjects in the Dallas 
Heart Study, an upper limit of normal liver fat content of 5.5% was established. Using this cut-
off, the prevalence of hepatic steatosis (also called non-alcoholic fatty liver disease (NAFLD)) 
in the general population (of whom 76% had a BMI >25 kg/m2 and 43% had a BMI >30 kg/m2) 
was estimated to be as high as 33.6%244. NAFLD is linked to an increased risk of cardiovascular 
disease in otherwise healthy subjects, independently of underlying cardiometabolic risk fac-
tors245.  
Few studies in humans have investigated the impact of dietary fat quality on liver fat deposition. 
Intake of SFA has been associated with increased liver fat242, and long-chain n-3 PUFA supple-
ments have been shown to reduce liver fat deposition246,247.  
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With the  study, we were the first to examine the effect of a high TFA intake on liver 
fat deposition in humans and we did not see a significant effect. After the intervention, the base-
line-adjusted liver fat content was 7% 
lower (CI: -61 to 120; P=0.87) in the 
TFA group compared to controls (Paper 
II). Given the geometric mean liver fat 
concentration of approximately 2.5% at 
baseline, these confidence limits may 
translate into an absolute mean decrease 
in liver fat of 1.5% or an absolute in-
crease of 3.5%. Therefore, our results 
cannot discount the possibility that TFA 
intake may exert effects on liver fat 
smaller than this, prohibiting firm con-
clusions on minor changes.  However, no 
detectable trend in liver fat was observed 
in either direction in either diet group 
and plasma liver enzymes remained un-
changed, arguing that if TFA induced 
changes in liver fat concentration, they 
were small indeed.  
We measured liver fat by proton magnetic resonance spectroscopy (1H-MRS), which is the most 
accurate non-invasive technique available248. However, as seen in Figure 7, the between-subject 
variability in baseline liver fat was large (range 0.1 to 73.0%), which also has been found in 
other populations of overweight subjects 241,249. It is questionable if subjects with very high liver 
fat content will be susceptible to further increases due to dietary manipulations. In retrospect, a 
screening for liver fat content should have been considered, since a modest diet-induced change 
may be more easily detected in a study population with more homogeneous liver fat levels. 
Also, it may be a limitation of the  study that we only measured liver fat in a single 
volume of interest (VOI). A voxel size of 11x11x11 mm was found to be optimal in the 
 study as the scanner was sufficiently sensitive to obtain a good signal from this vol-
ume. It was anticipated that a larger voxel size (as the 20 or 30 mm used by others244,249) would 
cause uncertainty in water/fat ratio due to presence of large blood vessels in the VOI. However, 
a single small VOI may not adequately reflect the average change in liver fat. Differences in fat 
content of up to 50% between different regions of the liver have been observed in some sub-
jects249, but modest within-liver coefficients of variation (CV) of 11.0-14.5% have also been 
reported244,248. Moreover, reproducibility of single-voxel measurements is acceptable, with CVs 
of 4.5-8.5% for measurements performed within the same day244,248,249 and of 9.5% for meas-
urements performed weeks apart without standardization of diet or exercise248.  
In the  study we aimed to standardize the liver fat assessments by controlling alcohol 
intake, physical activity and diet from the evening before the examination. However, the fact 
that the diets were not controlled for longer periods before the scans may have limited our abil-
ity to detect small TFA-induced-changes in liver fat. Recently, it was found that the total dietary 
fat intake during the prior ten days, and not that of the previous day, is correlated to liver fat 
content240. It has been documented that liver fat deposition in humans can increase as much as 
100% (from 2 to 4% and from 11 to 22%) after 3-4 days on hyper-caloric high-fat diets250,251. 
Figure 7: Liver fat % in the trans fat group (TFA; n=23) and 
in the control group (CTR; n=23) before and after 16 wk of 
dietary intervention and in lean references (n=19) obtained by 
1H MR spectroscopy. Bars represent geometric means (95% 
confidence intervals). P=0.87 for baseline-adjusted differ-
ences between diet groups at wk 16, by ANCOVA. Liver fat 
% was significantly lower in lean references than in over-
weight subjects (diet groups combined); P<0.01. From Paper 
II. 
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Also, an increase in liver fat of 35% (from 10 to 14%) was seen after 14 days on an eu-caloric 
high-fat diet (56 E% from fat)252. The mean fat intake was 34-37 E% in the  study, as-
sessed by 3-day food records (Paper II). It can be speculated that high-fat diets would have 
been required for us to show effects of TFA on liver fat deposition, as indicated by some176, but 
not all229,235, rodent studies.  
MECHANISMS BY WHICH TRANS FATTY ACIDS MAY AFFECT BODY FAT 
DEPOSITION 
There is very limited data from studies in humans to elucidate how TFA may affect body weight 
and fat deposition. Neither effects on appetite nor energy expenditure could be detected in an 
acute study comparing meals enriched in MUFA, PUFA or TFA (57 E%) in overweight human 
subjects253. The effect of long-term TFA exposure on appetite and energy expenditure has not 
been assessed. A few studies have suggested that TFA may be more prone to oxidation than to 
storage compared to other FA, and thereby less likely to lead to obesity. Fat oxidation was 
higher after a 4-week diet enriched with 9 E% TFA (31.4 ± 1.5 g/d) compared to MUFA (26.0 ± 
1.5 g/d)100, and a meal study showed that elaidic acid is oxidized to a greater degree than oleic, 
palmitic, stearic and linoleic acid for 9 hours postprandially254. In contrast, no difference in the 
total fat oxidation was observed for 8 hours after high-fat meals enriched with 10 E% TFA or 
cis-MUFA in an acute meal study21.  
Generally, if in fact TFA has a long-term impact on body adiposity in humans, this effect may 
be mediated through modulation of the expression of genes involved in the regulation of fat 
metabolism in a number of tissues. Given the seemingly reducing effect of n-3 long-chain 
PUFA on adiposity and liver fat deposition246,247,255, one may hypothesize that the effect of TFA 
on expression of some of these genes, opposes that observed for n-3 long-chain PUFA. For ex-
ample, TFA-feeding has been shown to stimulate the hepatic mRNA expression of steroyl regu-
latory element binding protein (SREBP)-1 in mice256, which may result in increased tran-
scription of lipogenic genes as well as increased cholesterol synthesis in the liver. In contrast, 
PUFA have been shown to suppress SREBP-1257. 
The etiology of fatty liver disease is complex and not fully understood. Liver fat  accumulation 
results from an imbalance between lipid availability (from circulating lipid uptake or de novo 
lipogenesis) and lipid disposal (via β-oxidation of fatty acids or VLDL secretion)258, and both 
sides of the equation may be affected by dietary fat intake. A study in rats found a decreased 
hepatic expression of microsomal triglyceride transfer protein (MTP), suggesting a diminished 
transfer of triglycerides to nascent ApoB particles and thereby impaired VLDL assembly and 
secretion234. However, no effect on hepatic MTP expression was found in mice176. 
These issues will be further discussed in Chapter 9.   
SUMMARY: DIETARY TRANS FAT & FAT DEPOSITION 
In summary, there is limited data available to assess whether TFA consumption is associated to 
increased risk of obesity. However, if in fact TFA intake increases the risk of abdominal obesity 
or general weight gain, as suggested by a few large prospective cohort studies, this is likely to 
occur gradually over a long time-span, as also seen in monkeys. This field of research in 
strongly hampered by the lack of RCTs, possibly due to the difficulties in conducting interven-
tion studies with sufficiently long-term TFA exposure. Even very high TFA consumption for 4 
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months does not appear to affect the abdominal fat deposition in postmenopausal women. How-
ever, our research cannot exclude that whole-body fat accumulation may be slightly stimulated.  
Whereas the evidence for an effect of TFA on body adiposity in rodents is highly conflicting, an 
increased accumulation of fat in the liver has been an almost consistent finding. To what extent 
these findings can be translated into humans, remains to be answered. Our attempt to verify this 
effect in humans failed. This may be due to i) a high degree of within-subject variability in liver 
fat content in our study population, ii) a lack of standardization of the study diets, or iii) a true 
lack of an effect of TFA exposure on liver fat deposition in humans. 
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 DIETARY TRANS FAT & INSULIN SENSITIVITY  
Impaired insulin sensitivity is the underlying abnormality in most people who develop T2D. As 
a compensation for insulin resistance (defined as a smaller than expected biological response to 
a given dose of insulin), the pancreatic β-cells increase the secretion of insulin to maintain blood 
glucose homeostasis. If the compensatory secretion is insufficient, blood glucose increases in 
the fasting and/or postprandial state259. Insulin resistance in AT, and thereby a diminished abil-
ity of insulin to suppress lipolysis, results in increased plasma FFA concentrations, which in the 
long term cause insulin resistance in muscle and liver and impair insulin secretion. An elevated 
FFA concentration is also thought to be a causal factor in excess hepatic and muscle lipid accu-
mulation258, which again is positively associated with hepatic237 and peripheral260 insulin resis-
tance.  
Thereby, increased levels of insulin, glucose and FFA both in the fasted state and after glucose 
challenges, as well as indices of insulin-mediated glucose disposal, insulin secretion and tissue 
insulin resistance, measured by more invasive techniques (e.g. clamps), may be used as early 
markers of an increased risk of developing T2D259. 
TRANS FAT AND INDICES OF INSULIN RESISTANCE – INTERVENTION STUD-
IES 
Very few controlled intervention studies have examined if the positive association between in-
take of TFA and risk of T2D observed in the Nurses’ Health Study7 may be explained by ad-
verse effects on measures of glucose homeostasis and insulin sensitivity. Moreover, the results 
are inconclusive [Table 4]. In lean and healthy young subjects, a high intake of industrial TFA 
(5-9 E%) during 4 weeks does not seem to impair insulin and glucose metabolism measured by 
the intravenous glucose tolerance test (IVGTT)100,261 and TFA of ruminant or industrial origin 
does not affect fasting insulin or glucose concentrations173,204. Recently, it was shown that ~2 
E% of TFA (ruminant as well as industrial) during 5 weeks did not affect peripheral insulin 
sensitivity, assessed by hyperinsulinemic euglycemic clamps, in moderately overweight women 
either124.  
In contrast, in overweight subjects and type 2 diabetic patients, meals with high TFA contents 
have been shown to produce higher postprandial insulin and C-peptide concentrations than simi-
lar meals with cis FAs20,21. Christiansen et al.20 showed a 59% increase in postprandial insulin 
area under the curve (AUC) (240 min) and a 42% increase in C-peptide after consumption of a 
diet with 20 E% TFA for 6 weeks compared to MUFA. The authors hypothesized that since the 
intervention had no effect on postprandial glycemia, the insulinemia most likely reflected an 
increased peripheral insulin resistance and not an impairment of β-cell function. However, the 
design of the study did not allow for interpretation of whether the changes in postprandial insu-
linemia were due to an acute meal effect of TFA as found by others21, or an effect of an in-
creased TFA intake for the prior 6 weeks. In any case, it is somewhat surprising that no effect of 
the quite substantial dietary intervention was seen on blood lipid levels in this study20. 
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Table 4: Intervention studies examining the effect of trans fatty acid (TFA) intake on insulin resistance 
or related outcomes 
Refer-
ence 
Subjects Design Diets Me-
thod 
Effect of TFA on insulin resistance and 
other outcomes 
Louhe-
ranta et 
al. 
(1999)261 
14 F; 
healthy; 
mean age 
23 y; mean 
BMI 20.6 
kg/m2 
Cross-
over  
(4 wk) 
Isoenergetic, 36 E% from fat. 
1) Marg. w. TFA (5 E%);  
2) Olive oil (OA) 
IVGTT ↔ Fasting insulin ↑ ~9% after TFA 
(P=0.09); Fasting glucose ↔; Insu-
lin sensitivity ↔; Glucose effec-
tiveness ↔; Acute insulin response 
↔; total to HDL-cholesterol ↑ after 
TFA. 
Lovejoy 
et al. 
(2002) 
100 
25 M+F; 
healthy; 
mean age 
28 y,; 
mean BMI 
23.5 kg/m2 
Cross-
over  
(4 wk) 
Isoenergetic, 28 E% from fat. 
1) TFA (~9 E%); 
2) OA;  
3) PA 
IVGTT ↔ Fasting insulin and glucose ↔; 
Insulin sensitivity ↔; Glucose 
effectiveness ↔; Acute insulin 
response ↔; Disposition index ↔; 
total-, LDL- and HDL-cholesterol 
↔ vs. OA; Insulin sensitivity ↓ 11% 
(ns) for n=6  with BMI>25 after 
TFA vs. OA. 
Tardy et 
al. 
(2009) 
124 
57 F; 
healthy, 
18-50 y; 
mean BMI 
32.5 kg/m2; 
Parallel 
(5 wk) 
Isoenergetic, 42-45 E% from 
fat. 
1) IP-TFA (~2 E%);  
2) R-TFA(~2 E%); 
3) Palm oil (PA/OA) 
Hyper-
in-
sulemic
euglyc. 
clamp 
↔ Fasting insulin, glucose and HOMA 
↔; Steady state glucose infusion 
rate ↔; Insulin sensitivity ↔; HDL-
C ↓ on all diets. 
Christi-
ansen et 
al. 
(1997)  
20 
25 M+ F; 
T2D; mean 
age 55 y; 
mean BMI 
33.5 kg/m2 
Cross-
over 
 (6 wk) 
Isoenergetic, 30 E% from fat. 
1) TFA (20 E%); 
2) MUFA;  
3) SFA 
4h meal 
test 
↑ 4h insulin AUC ↑ 59% and C-
peptide AUC ↑ 27% after TFA 
meal/diet compared to MUFA but 
not SFA; 4h glucose AUC ↔ : 
fasting insulin and C-peptide ↔; 
LDL-, HDL- and LDL/HDL- C ↔. 
Lefevre 
et al. 
(2005) 21 
22 M + F; 
healthy;  
mean age 
40y; mean 
BMI 25.7 
kg/m2 
Cross-
over 
(meal) 
Breakfast meal with 40% of 
daily energy, 50 E% from fat. 
1) TFA (10E%); 
2) MUFA 
8h meal 
test 
↑ Insulin * glucose at each time point 
and 8h AUC ↑ and  8-h insulin AUC 
↑ after TFA compared to MUFA; 8-
h glucose AUC ↔ 
Lichten-
stein et 
al. 
(2003)  
173 
36 F+M; 
hyperchol.; 
mean age 
63 y; mean 
BMI 27 
kg/m2 
Cross-
over 
(35d) 
Isoenergetic, 30 E% from fat. 
1) Soybean oil;  
2) Semi-liquid marg.;  
3) Soft marg. (3 E% TFA);  
4) Shortening (4 E% TFA);  
5) Stick marg. (7 E% TFA);  
6) Butter (1 E% TFA) 
fasting ↔ Minor diff. between diets in glu-
cose, insulin and HOMA and nei-
ther increased with increasing TFA 
Thol-
strup et 
al. 
(2006) 
204 
42 M; 
healthy, 
mean age 
25 y;  
mean BMI 
23 kg/m2 
Parallel 
(5 wk) 
Isoenergetic, 42-44 E% from 
fat. 
1) Butter enriched in R-TFA (5 
g/d) 
2) Butter without TFA 
fasting ↔ Fasting insulin and glucose ↔. 
Vega-
Lopez et 
al. 
(2006) 
109 
15 F+ M; 
hyperchol.; 
mean age 
64y; mean 
BMI 26 
kg/m2 
Cross-
over 
 (5 wk) 
Isoenergetic, 28-30 E% from 
fat. 
1) Part. hydr. soybean oil 
(TFA, 4 E%);  
2) Soybean oil (LA/ALA);  
3) Palm oil (PA/OA) 
fasting ↑ HOMA and insulin, but not glucose, 
↑ 20-28% after TFA compared to 
soybean, but not palm oil; total- and 
LDL-cholesterol ↑ compared to 
soybean, but not palm oil,  to-
tal/HDL- cholesterol ↔. 
↑ and ↓ represent higher and lower level of insulin resistance (IR)-related outcomes with increasing TFA intake. ↔, 
no significant effect of TFA. ALA, alpha-linolenic acid; IP-TFA, industrially produced TFA; IVGTT, intravenous 
glucose tolerance test; LA, linoleic acid; OA, oleic acid; PA, palmitic acid; R-TFA, ruminant TFA; SA, stearic acid. 
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It appears that the effect of TFA may be modified by an underlying predisposition to insulin 
resistance. In support of this notion, intake of partially hydrogenated soybean oil (4 E% TFA) 
for 5 weeks resulted in increased fasting insulin and HOMA-IR compared to soybean or canola 
oil in overweight, hypercholesterolemic and older women (mean age 64 y)109. Also, in the study 
by Lovejoy et al.100 a decrease in insulin sensitivity (IVGTT) of 11% (ns) after TFA consump-
tion compared to MUFA was seen in a sub-group of overweight women (n=6) only.  
These results led us to hypothesize that the failure of previous studies in showing an effect of 
TFA on insulin sensitivity was either due to i) too short study durations not allowing time for 
TFA to be incorporated into myocellular membrane lipids with possible influence on insulin 
sensitivity262, ii) too low TFA intake levels, and/or iii) too young and healthy study populations.  
However, in the  study we failed to detect an effect of the 7 E% TFA intervention on 
insulin sensitivity, β-cell effectiveness and markers of lipolysis (all assessed by oral glucose 
tolerance test) in abdominally obese, postmenopausal women (Paper III).  
This could be due to lack of power. Indeed, after the dietary intervention, the relative mean dif-
ference between diet groups in insulin sensitivity index was -4% (CI: -23 to 20), indicating that 
we would not have been able to detect TFA-induced changes smaller than ~20%. However, the 
Figure 8: Glucose and insulin metabolism during oral glucose tolerance test. Mean (±SEM)
glucose (A), insulin (B) and C-peptide (C) concentrations and insulin secretion rates (ISR)
during the 3-hour OGTT performed at baseline (week 0; dotted lines) and after the dietary
intervention (week 16; solid lines), in subjects who consumed 15.7 g/d trans fatty acids (TFA;
n=24; black squares); and a control oil (CTR; n=25; white triangles). The corresponding areas
under the curves (AUC) are also depicted (black bars = TFA; white bars = control. From
Paper III. 
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glucose, insulin and C-peptide responses to a glucose challenge were practically unaltered in 
both diet groups after the 16-weeks of intervention (Figure 8), strongly suggesting that a larger 
sample size would not have led to different conclusions. It is however possible, that the higher 
intake of palmitic acid in the CTR group may have attenuated putative differences between diet 
groups, as palmitic acid has been shown to induce insulin resistance in muscle263.  
Yet, the null-findings in the  study regarding insulin sensitivity are supported by the 
fact that we, in contrast to Christiansen et al.20 were able to detect substantial negative effects of 
the TFA intervention on cholesterol levels (Paper II). This, along with the TFA-induced in-
crease in TNFα levels (Paper IV), confirms that our intervention indeed was capable of provok-
ing a negative metabolic impact in our study population. 
Subgroup analysis 
As stated above, it may be that TFA intake induces insulin resistance in subjects with a predis-
position to T2D only. Of the 49 women who completed the  study, 30 had normal glu-
cose tolerance (NGT) and 19 had impaired glucose tolerance (IGT) or T2D (based on the 
baseline 2-hour glucose values and using the criteria proposed by The American Diabetes Asso-
ciation264). When excluding the women with NGT, the insulin sensitivity index was 15% higher 
(CI: -22 to 68; P=0.46) in the TFA group compared to controls after the intervention, leaving no 
indication of a more negative effect of TFA in these women. However, this analysis included 
only 13 and 6 women in the TFA and CTR groups, respectively. 
Does dietary fat quality affect insulin sensitivity? 
Maybe it is not too surprising that we did not see an effect of TFA on insulin sensitivity in the 
 study. In general, there is sparse evidence from high quality human RCTs to suggest an 
impact of dietary fat quality on insulin sensitivity, even in large scale studies. The KANWU 
multicentre study showed a decrease in insulin sensitivity of 10% (by IVGTT) after 3 months of 
high SFA consumption (18 E% SFA, 13 E% MUFA) compared to high MUFA (21 E% MUFA, 
10 E% SFA) in 162 healthy subjects. However, the difference between diets only reached sig-
nificance in subjects consuming diets with < 37 E% fat265. These results are in accordance with 
recent data from the large multicentre study LIPGENE that included more than 100 subjects 
with the metabolic syndrome in each study arm. This study failed to show a significant effect of 
diets high in SFA (16 E% SFA, 12 E% MUFA) compared to MUFA (20 E% MUFA, 8 E% 
SFA) for 12 weeks on insulin sensitivity (by IVGTT), whereas in subjects with low habitual fat 
intake, SFA intake decreased insulin sensitivity266. Also recently, in the multi-centre study 
RISCK, 24-week diets high in SFA (16E% SFA, 11.5 E% MUFA, n=79 completers) were com-
pared to diets high in MUFA (16 E% MUFA, 10 E% SFA, n=103), and no difference in insulin 
sensitivity (by IVGTT) was detected267. 
Long-term exposure may be required 
It cannot be ruled out, that TFA intake only will exert adverse effects on glucose metabolism at 
unrealistically high intake levels (>10 E%) and only when compared to MUFA (or PUFA), not 
SFA, as seen in the study by Christiansen et al.20 Alternatively, very long exposures may be 
required. After 6 years on a diet with 8 E% TFA, increased fructosamine concentrations, in-
creased postprandial insulin concentrations as well as decreased insulin-activation of muscle 
Akt, were found in green monkeys, compared to monkeys fed MUFA22. Since Akt (a kinase) 
mediates the signal transduction from the insulin receptor to translocation of glucose transporter 
4 (GLUT4) to the muscle cell membrane, these findings indicate that TFA may impair post-
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receptor signaling. A decreased phosphorylation status of Akt was also found in livers of 
mice176 but not in rat myotubes230 after TFA exposure.  
TFA and insulin sensitivity in rodent models 
Generally, rodent models allow for examination of longer durations of TFA exposure, at least 
relative to life span, and most studies indicate that long-term TFA intake impairs insulin sensi-
tivity [Appendix E]. Ibrahim and colleagues showed that feeding rats 3 E% TFA for 3 months 
had multiple adverse effects, such as i) decreased insulin-stimulated glucose transport in both 
diaphragm muscle268 and epididymal adipocytes; ii) decreased anti-lipolytic effect of insulin in 
adipocytes; and iii) increased insulin AUC after an oral glucose load (ns) when compared to 
PUFA or a mix of palmitic and oleic acid269. Moderate intake levels of TFA (4-5 E%) has also 
been shown to decrease the whole-body glucose disposal rate (assessed by clamp) compared to 
SFA in rats235, whereas insulin sensitivity (assessed by intra-peritoneal glucose tolerance tests) 
was not different compared to MUFA230. In mice, high TFA intakes (12-20 E%) have been 
found to increase fasting insulin and insulin resistance188,234. Finally, a few studies in rodents 
indicate that early life TFA-exposure (intra-uterine and/or during lactation) may predispose to 
insulin resistance in adulthood270-272 although this is not a consistent finding273. 
MECHANISMS BY WHICH TRANS FATTY ACIDS MAY AFFECT INSULIN SENSI-
TIVITY 
Not much is known about how TFA exposure may affect insulin sensitivity. Since the FA com-
position of phospholipids of skeletal muscle has been shown to be an important predictor of 
insulin sensitivity, with higher degree of unsaturation being associated with increased sensitiv-
ity262,274-276, it has been hypothesized that FA-induced changes in membrane properties are of 
importance. Insulin signaling and translocation of GLUT4 to the skeletal muscle cell membrane 
are both membrane-associated events; therefore membrane characteristics are likely to influence 
insulin sensitivity269.  
Also, insulin resistance has been associated with accumulation of body fat, particularly intra-
myocellularly260. Dietary fat load has been shown to affect the amount of lipid deposited here. 
In humans, three days of high-fat feeding (45-60 E% from fat) was shown to increase the intra-
myocellular lipid deposition in muscle by ~25-50%277,278, and a lipid infusion-stimulated in-
crease in intramyocellular lipid deposition was shown to inversely correlate to insulin sensitivity 
277. A study in rats indicated that TFA may indeed affect glucose metabolism via stimulation of 
intramuscular lipid accumulation (in diaphragm muscle, in which insulin-stimulated glucose 
uptake supposedly reflects whole-body insulin sensitivity)268. In contrast, this was not confirmed 
in another rat study examining the lipid deposition in tibialis and soleus muscle235. In the 
 study lipid deposition in psoas major muscle was not affected by TFA (Paper III), and 
no other human studies appear to have examined the effect of FA quality on this endpoint. 
However, in growing pigs, 12 weeks of supplementation with CLA (1.2 weight%) was shown to 
significantly increase the intramuscular fat content in longissimus dorsi by 19%279. This indi-
cates that relatively small amounts of specific FA may affect muscle lipid accumulation, at least 
during growth; unfortunately insulin sensitivity was not assessed in this study. 
Triglyceride accumulation in muscle cells does, however, not seem to be detrimental per se, but 
may serve as a surrogate marker for the build-up of other lipid species within the muscle. FA 
intake appears to determine the FA composition of the intramyocellular triglyceride pool and 
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thereby the identity of intramyocellular lipid metabolites. Palmitate and stearate stimulate the 
synthesis of diacylglycerol (DAG) and ceramide that have been suggested to play roles as pri-
mary mediators in lipid-induced insulin resistance263,280. In rats, TFA consumption decreased 
whole-body glucose disposal and increased the DAG content in soleus muscle 2-fold, but the 
glucose disposal did not appear diminished in this specific muscle235.  
Finally, TFA may affect insulin sensitivity via induction of inflammation. TNFα and pro-
inflammatory lipid mediators are known to be involved in development of insulin 
resistance152,201,212 (see Chapter 9 for more detail). 
SUMMARY: DIETARY TRANS FAT & INSULIN SENSITIVITY 
Most animal studies suggest that TFA intake impairs insulin sensitivity compared with other FA 
classes, whereas evidence from studies in humans is highly conflicting. Whether this discrep-
ancy is due to the longer duration of TFA exposure in animal studies or simply reflects meta-
bolic differences between species is unknown. The few indices of a detrimental effect of TFA 
intake on insulinemia in humans come from studies in metabolically vulnerable study popula-
tions. Yet, there was an absence of change in any of the glucose homeostatic parameters meas-
ured in older overweight women in the  study, also when analyzing a subgroup with 
impaired glucose tolerance at baseline.  
In the future, it would, however, be interesting to see if an effect of TFA intake may be detected 
in a larger sample from a more homogenous study population, i.e. glucose intolerant subjects 
only. In addition, such a study could include skeletal muscle biopsies to identify changes in 
insulin signal transduction and membrane phospholipid FA composition. 
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  PUTATIVE CELLULAR MECHANISMS BY WHICH DIETARY 
TRANS FATTY ACIDS MAY AFFECT METABOLIC PATHWAYS 
The precise molecular mechanisms by which TFA exert the documented metabolic effects have 
yet to be unraveled. Although not much is known about the cellular actions of TFA per se, they 
may involve some of those, which have been elucidated for other dietary FA. Therefore, in this 
chapter, the primary ways in which dietary FAs may modulate cell function in general will be 
briefly discussed. FAs are known to affect cell function i) by determining the FA composition 
of phospholipids in cell membranes and thereby the membrane properties and function of mem-
brane-bound proteins; ii) by influencing essential FA metabolism and thereby formation of a 
variety of lipid mediators; iii) by binding to and modulating nuclear receptors that regulate gene 
transcription; and iv) by activating cell-surface receptors such as TLR. 
Membrane properties 
Since individual FAs differ by spatial configuration and thus chemical property, they may dif-
ferently affect the fluidity and rigidity of the cell membrane that they make up281. The efficiency 
of molecular signal transduction is highly dependent on the orientation and positioning of vari-
ous proteins within the cell membrane. Thereby, the FA composition of cellular membranes, 
and of lipid rafts within the membrane, may for instance play pivotal roles in insulin signaling 
and transduction of inflammatory stimuli. 
TFA are readily incorporated into phospholipids in cell membranes. Their trans double bonds 
result in a more rigid packing than for cis residues, conveying membrane properties more simi-
lar to those of SFA209. Thereby, incorporation of TFA into the phospholipid bilayer of cell 
membranes induces a structural change that may alter cellular function210,281. The activity of 
rhodopsin (a prototypical member of the G protein-coupled receptor family) was decreased by 
incorporation of TFA into model membrane phospholipids compared to MUFA281. Activation of 
membrane-spanning G protein-coupled receptors is the initial event in various signaling cas-
cades. 
However, in vivo evidence in support of this hypothesis is limited. Whereas TFA-feeding (3 
E%) led to decreased membrane fluidity and impaired insulin-stimulated glucose transport in rat 
adipocytes, irrespective of dietary linoleic acid level269, no effect of erythrocyte membrane flu-
idity was seen in humans after 5 weeks intake of 6.6 E% TFA282. In monkeys, 18-weeks of 
TFA-feeding resulted in decreased insulin receptor number and increased insulin binding affin-
ity, but membrane fluidity of erythrocytes was not affected despite incorporation of 11% 
trans18:1283. Yet, it is possible that local (lipid raft), more than global, membrane fluidity is 
important for receptor functions.  
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Formation of lipid mediators 
Changes in membrane phospholipid FA composition may also affect the production of a range 
of lipid mediators, which are involved in cell signaling processes. Essential FA may be con-
verted to lipid mediators, such as eicosanoids, and depending on the precursor FA the lipid me-
diator may have pro- or anti-inflammatory properties. Arachidonic acid can be enzymatically 
oxidized (by enzymes such as lipooxygenase and cyclooxygenase) to form bioactive leukotrie-
nes, prostaglandins and lipoxins, while essential long-chain n-3 PUFA may be converted to anti-
inflammatory protectins and resolvins201. The overall pattern of lipid-derived compounds may 
be modulated by dietary fats.  
It has been suggested that TFA interfere with essential FA metabolism, and thereby the produc-
tion of lipid mediators. TFA-feeding has been shown to decrease the ratio of arachidonic to 
linoleic acid in AT of mice269 and rats269 and in the phospholipids of piglet arterial cells284, sug-
gesting that TFA inhibit the metabolic conversion of linoleic acid to arachidonic acid. In accor-
dance, incorporation of TFA into endothelial cell membrane phospholipids appeared to inhibit 
the synthesis of linoleic acid to arachidonic acid and lowered the secretion of prostacyclin200. 
Transcription factors 
It is possible that TFA, like other dietary FAs, bind to nuclear receptors that regulate the tran-
scription of various genes involved in numerous cellular processes. FAs are known to be natural 
ligands of peroxisome proliferator-activated receptors (PPARs), SREBP-1 and liver X receptor 
α (LXRα). PPARs act as key regulators of the expression of genes involved in both lipid and 
glucose metabolism and inflammatory pathways, and SREBP-1 and LXRα are mainly impli-
cated in transcription of genes implicated in hepatic lipid metabolism.  
However, not much is known about how, or if, TFA affects these transcription factors. Whereas 
elaidic and oleic acid showed similar potency to bind to and activate PPARα as compared to 
PUFA in vitro, they were both poorer ligands for PPARβ and PPARγ than PUFA285. TFA may, 
however, also affect transcription factors by modulating the production of lipid mediators, as 
described above. Several of these act as transcription factor ligands286. 
There is some evidence to suggest that the metabolic effects of TFA involve a change in the 
expression level of some of these transcription factors, both in liver and AT, although results are 
somewhat conflicting. An increase in the mRNA expression of SREBP-1 and PPARγ in livers 
of TFA-fed mice was suggested as a an explanatory factor for the observed increase in hepatic 
lipid accumulation176. SREBP-1 and PPARγ are known to stimulate the transcription of lipo-
genic genes, such as fatty acid synthase and acetyl-CoA carboxylase, and these were indeed 
expressed in excess compared to mice fed cis-unsaturated FA176. In contrast, acetyl-CoA car-
boxylase and diacylglycerol acyltransferase, the enzyme mediating triglyceride formation, were 
not affected in rats fed TFA in another study228. 
Activation of hepatic PPARα results in increased uptake and oxidation of FFA through mito-
chondrial and peroxisomal β-oxidation partly via activation of carnitine palmitoyl transferase I 
(CTP-I), which is the main control point for mitochondrial β-oxidation of FAs258. A decrease in 
the activity of CTP-I was seen in livers of rats fed TFA228 and the activity of the lipogenic cit-
rate carrier enzyme was increased228. However in mice, TFA-feeding did not affect the hepatic 
expression of PPARα and CTP-1176.   
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Different effects have been observed in AT. Here, PPARγ plays a role in increasing insulin sen-
sitivity as well as in promoting fatty acid uptake into adipocytes, via regulation of lipoprotein 
lipase (LPL)287. Thereby, activation of PPARγ in AT results in an increased triglyceride storage 
in subcutaneous adipocytes and a reduced FFA delivery to the liver258. In TFA-fed rats, PPARγ 
and LPL expression was decreased in AT, but AT mass was not affected, compared to rats fed 
soybean oil178, palm oil or groundnut oil187. Furthermore, increased body weight and fat accu-
mulation in TFA-fed rats, compared to rats fed a mix of MUFA and PUFA, could not be ex-
plained by differences in LPL activity in another study236. 
Overall, the evidence from rodent studies of an effect of TFA-feeding on expression of tran-
scription factors, and the enzymes they regulate, is far from coherent. 
Cell-surface receptors  
FAs are capable of inducing pro-inflammatory cytokine expression in macrophages and adipo-
cytes via activating TLR4212. TLR4 activation triggers a downstream signaling cascade, leading 
to activation of the nuclear factor κB (NF-κB) pathway, which then promotes the transcription 
of many genes that encode pro-inflammatory molecules including cytokines and chemokines. 
Recently, it was shown that the stimulatory effect of high-fat diets rich in SFA on expression of 
pro-inflammatory cytokines in AT and liver, was diminished in TLR4 knock-out mice (ab-
stract)288. In addition, TLR4 knock-out mice appeared to be protected from the increase in liver 
fat deposition seen in wild-type mice. 
TLR4 mediated activation of NF-κB may also be involved in FFA-induced insulin resistance in 
adipocytes and in vivo after high-fat diets212,288. NF-κB activation impairs insulin signaling by 
increasing the inhibitory serine phosphorylation of insulin receptor substrates and thus decreas-
ing phosphatidylinositol 3-kinase activity and Akt phosphorylation. Lower Akt phosphorylation 
after TFA-feeding has been shown in mice176 and monkeys22 but not in myocytes after incuba-
tion with TFA230,289 
However, the potency of TFA to activate TLR4 or NF-κB is uncertain. Whereas palmitate 
potently activated the NF-κB transcription factor and induced IL6 and TNFα expression in adi-
pocytes and macrophages, the TFA isomers elaidic and vaccenic acid had only minor stimula-
tory effects on macrophage IL6 mRNA expression in vitro212. In contrast, physiological concen-
trations of elaidic acid was shown to activate NF-κB in cultured skeletal muscle cells although 
this did not result in decreased insulin-stimulated glucose uptake or translocation of GLUT4289. 
However, if TFA exposure induces insulin resistance, this may occur via stimulation of TNFα, 
which also activates the NF-κB pathway146.  
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 CONCLUSIONS & PERSPECTIVES 
Based on our systematic review and meta-analysis of cohort studies (Paper I) and review of the 
additional scientific literature, the following may be concluded:  
• Our meta-analysis of published and unpublished prospective cohort studies suggested that 
TFA intake is associated with an increased risk of heart disease of the magnitude previ-
ously reported (~20% increased risk per 2 E% TFA). However, it also highlighted the 
scarcity of this type of studies, which may be due to the difficulties in appropriately as-
sessing TFA intake in observational studies or to publication bias. Nevertheless, the avail-
able case-control studies, using biomarkers of TFA intake, collectively supported the 
findings from the pooled analysis of prospective studies.  
• From the pooled analysis it appeared that the risk of CHD associated with TFA intake 
may be ascribable to industrial, not ruminant, TFA, possibly due to low intake levels of 
the latter. Of note, however, a very limited number of studies addressing differential ef-
fects of industrial and ruminant TFA prohibited any firm conclusions concerning the im-
portance of the source of TFA in risk prediction. The biomarker studies did not lend 
support to the notion that R-TFA should be less harmful than IP-TFA; neither did inter-
vention studies examining the effect on blood lipids.  
• There is, however, no evidence to support that R-TFA increases the risk of CHD in the 
amounts usually consumed.  
In addition, a number of conclusions may be drawn from our intervention study : 
• We confirmed, that induction of dyslipidemia may partly explain the TFA-associated in-
crease in the risk of cardiovascular disease estimated from the meta-analysis. The ob-
served increase in the total-C to HDL-C ratio may translate into an increase in heart 
disease risk of ~6% per 2 E% TFA. The greater increase, compared to that seen in previ-
ous studies after TFA consumption, suggests that older and overweight populations may 
be more susceptible to TFA-induced metabolic changes than young and lean ones, at least 
when it comes to adverse effects on lipoproteins.  
• Our findings of an increased production of TNFα and its soluble receptors after TFA ex-
posure support the notion that dietary TFA promote low-grade inflammation. It is, how-
ever, difficult to estimate what this effect may translate into in terms of heart disease risk.  
• Results from our study tended to confirm prior reports of a sE-selectin-increasing effect of 
TFA, indicating that TFA consumption may promote endothelial dysfunction.  
• Even a high TFA consumption for 4 months does not appear to affect the abdominal fat 
deposition in postmenopausal women; yet whole-body fat accumulation may be slightly 
increased.  
• We did not see an increase in liver fat deposition in response to TFA exposure, although 
increased liver triglyceride accumulation has been shown consistently in rodent models. 
Whether this null-finding should be ascribed to limitations of the study, including a high 
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degree of within-subject variability in liver fat content as well as lack of standardization 
of diets, or if it reflects a true lack of an effect of TFA exposure on liver fat deposition in 
humans, is, however, not clear. 
• Finally, we found no evidence for a detrimental effect of TFA intake on insulin sensitiv-
ity, β-cell function and markers of lipolysis within 4 months in a metabolically vulnerable 
study population.  
With the findings of a pro-inflammatory effect of TFA in the  study, we have provided 
evidence that narrows the explanatory gap within the TFA research area, as presented in Chap-
ter 1. For the curious scientist, some unresolved issues could be pursued in the future: 
• The trend towards a greater whole-body fat deposition after TFA consumption in the 
 study merits further investigations. A larger sample size as well as a fully con-
trolled study diet may improve the chances of detecting a significant effect. Yet, great 
challenges lie in conducting long-term trials with highly controlled diets.  
• Further characterization of the lipoproteins after TFA exposure, i.e. in terms of content of 
oxidized lipids, may provide new insights into the pathway by which TFA affects in-
flammatory processes.  
• The indication of a sex-difference in the physiological response to TFA of ruminant and 
industrial origin is interesting, and this should be further examined. 
• The evidence for a TFA-mediated induction of endothelial dysfunction is still weak, and 
should be substantiated. Assessment of flow-mediated vasodilation would have cast more 
light on whether the increased sE-selectin production after TFA consumption in the 
 study was reflective of impaired endothelial function. Measurement of endothe-
lial nitric oxide production, as reflected by plasma nitrite/nitrate (NOx), could also be 
considered in future studies. 
Yet, for the pragmatic scientist, research funding is probably better spent on resolving other 
issues of greater relevance to public health. It is no longer possible to argue for a lack of evi-
dence of the adverse health effects associated with TFA consumption. Thereby, it is hard to 
question that action towards eliminating TFA from the food supply worldwide should be taken. 
Our research highly supports this notion, and the elimination of TFA fortunately appears to be a 
work in progress.  
The low risk of achieving high daily intakes of TFA from ruminant sources when consuming 
normal foods, along with the difficulties in removing ruminant TFA from natural food sources, 
gives less priority to reduction efforts in this field.  
It is worrisome, however, that alternatives to the inexpensive hydrogenated vegetable oils may 
not be readily available in developing countries where TFA intake is likely to be high. On a 
positive note, industry appears to be working with, not against, the out-facing of TFA. Thereby, 
future challenges lie in resolving the difficulties associated with substituting the world supply of 
partially hydrogenated fats with appropriate alternatives low in saturated fat. Interesterified fats 
are being developed as alternatives to hydrogenated oils, but the health effects associated with 
consumption of these still remain largely unknown; this should be the subject of future dietary 
investigations. 
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Appendix A:  Characteristics of case-control studies examining the association between trans fatty acid (TFA) intake or biomarkers of intake on risk of coronary heart 
disease (CHD) 
 
Refer-
ence 
Study 
design 
Study 
year 
Country of 
origin 
No 
of 
cases
No of 
con-
trols 
Participant eligibility criteria Controls 
matched 
for 
Exposure Out-
come 
TFA level 
Ascherio 
et al. 
1994 50 
Retro-
spec-
tive 
1982-
83 
USA 239 282 White men and women. Ex-
cluded if: age > 75 y; history of 
MI, angina, diabetes, high cho-
lesterol. 
Age, sex, 
town of 
residence. 
TFA intake 
previous 
year (116 
item FFQ) 
First 
AMI 
Median TFA intake: 4.4 g/d 
Aro et al. 
1995 63 
Multi-
centre 
retro-
spec-
tive 
(ERAM
IC) 
1991-
92 
9 European 
countries 
671 717 Men. Excluded if: age > 70 y; 
change of diet for health rea-
sons; weight loss> 5kg during 
previous year; history of alcohol 
or drug abuse; major psychiatric 
disorders, institutionalization. 
Age, 
catchment 
area. 
TFA in AT AMI Median AT conc. in controls: t18:1 = 1.59% 
   Finland 57 59     Median AT conc. in controls: t18:1 = 1.51% 
   Germany 56 95     Median AT conc. in controls: t18:1 = 1.38% 
   Israel 50 58     Median AT conc. in controls: t18:1 = 2.15% 
   Netherlands 67 58     Median AT conc. in controls: t18:1 = 2.43% 
   Norway 98 100     Median AT conc. in controls: t18:1 = 2.15% 
   Russia 87 94     Median AT conc. in controls: t18:1 = 1.68% 
   UK 58 41     Median AT conc. in controls: t18:1 = 2.22% 
   Spain, Gra-
nada 
54 52     Median AT conc. in controls: t18:1 = 0.43% 
   Spain, 
Malaga 
91 96     Median AT conc. in controls: t18:1 = 0.47% 
   Switzerland 53 64     Median AT conc. in controls: t18:1 = 1.72 % 
          (Continued) 
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Appendix A (continued)         
Refer-
ence 
Study 
design 
Study 
year 
Country of 
origin 
No 
of 
cases
No of 
con-
trols 
Participant eligibility criteria Controls 
matched 
for 
Exposure Out-
come 
TFA level 
Roberts et 
al. 1995 67
Retro-
spec-
tive 
1990-
91 
UK 66 286 Men. Excluded if: age > 64 y; 
history of CHD. 
Age, sex, 
general 
practitio-
ner. 
TFA in AT SCD Median AT conc. in controls: Total-TFA = 
2.9%; t18:1 =2.3%; t18:2 = 0.6% 
Pedersen 
et al. 
2000 66  
Retro-
spec-
tive 
1996 Norway 100 98 Men and postmenopausal 
women. Excluded if: age <45 y 
and > 75 y; history of MI, diabe-
tes, cancer, major psychiatric 
disease, abuse of alcohol or 
drugs; weight change > 5 kg 
during previous year; use of 
hypolipidemic drugs. 
Age, sex, 
geografic 
area. 
TFA in AT First 
AMI 
Median AT conc. in controls: total-TFA = 
4.1 %, t18:1 = 2.6%. 
Lemaitre 
et al. 
2002 60 
Retro-
spec-
tive 
1988-
99 
USA 179 285 Married men and women. Ex-
cluded if: age <25 y and > 74 y; 
history of CHD or life-
threatening co-morbidities; use 
of fish oil supplements. 
Age, sex, 
commu-
nity. 
TFA in 
blood (RBC 
PL) 
Primary 
cardiac 
arrest 
Median RBC conc. in controls: total-TFA = 
2.0 %, t16:1 = 0.17%; t18:1 = 1.64%; t18:2 = 
0.20%. 
Baylin et 
al. 2003 69
Retro-
spec-
tive 
1994-
98 
Costa Rica 482 482 Men and women. Excluded if: 
age ≥ 75 y; died during hospi-
talization; previous hospital 
admission related to CVD; 
unable to answer questionnaire. 
Age, sex, 
area of 
residence 
TFA in AT First 
non-
fatal 
MI 
Median AT conc. in controls: t161 =0.08% 
Clifton et 
al. 2004 53
Retro-
spec-
tive 
1995-
97 
Australia 209 174 Men and women. Excluded if: 
age ≥ 75 y; previous diagnosis 
of MI, angina, hyper-
cholesterolemia, hypertriglyc-
eridemia or diabetes. 
Age, sex, 
postal 
code. 
TFA intake 
(300-item 
FFQ) 
first MI Median TFA intake: 3.0 g/d 
 
 
 
         (Continued) 
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Appendix A (continued)         
Refer-
ence 
Study 
design 
Study 
year 
Country of 
origin 
No 
of 
cases
No of 
con-
trols 
Participant eligibility criteria Controls 
matched 
for 
Exposure Out-
come 
TFA level 
Colon-
Ramos et 
al. 2006, I 
58 
Retro-
spec-
tive 
1994-
99 
Costa Rica 477 477 Men and women. Excluded if: 
age ≥ 75 y; died during hospi-
talization; previous hospital 
admission related to CVD; 
unable to answer questions. 
Age, sex, 
area of 
residence 
TFA in AT First 
non-
fatal 
AMI 
Median TFA intake: 4.1 g/d. Median AT 
conc. in entire population: Total-TFA = 
2.99%; t18:1 =1.61%; t18:2 = 1.20% 
Colon-
Ramos et 
al. 2006, 
II 58 
Retro-
spec-
tive 
2000-
03 
Costa Rica 1320 1320 
” ” 
TFA in AT First 
non-
fatal 
AMI 
Median AT conc. in entire population: Total-
TFA = 2.57%; t18:1 =1.29%; t18:2 = 1.05% 
Lemaitre 
et al. 
2006 65 
Prospec
tive; 
nested 
in 
CHS; 
mean 
follow-
up 3 y 
1992-
93 
USA 214 214 Men and women, age ≥ 65 y at 
baseline. Excluded if: died in 
nursing home; use of fish oil 
supplements. 
Age, sex, 
cohort, 
clinic site, 
time of 
blood 
draw (± 
90 days); 
presence 
of ab-
sence of 
CVD at 
time of 
blood 
draw; 
follow-up 
duration. 
TFA in 
blood 
(plasma PL) 
Fatal 
IHD 
Median RBC PL conc. in controls: t16:1 = 
0.28%; t18:1 =2.01%; t18:2 = 0.30% 
Harris et 
al. 2007 64
Retro-
spec-
tive 
2001-
02 
USA 94 94 Men and women; "younger age" 
(mean age 46 y). 
Age, sex, 
race. 
TFA in 
blood 
(whole 
blood) 
Acute 
coro-
nary 
syn-
drome 
Mean whole blood conc. in controls: total-
TFA = 1.98%; t18:1 =1.63%; t18:2 = 0.35% 
          (Continued) 
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Appendix A (continued)         
Refer-
ence 
Study 
design 
Study 
year 
Country of 
origin 
No 
of 
cases
No of 
con-
trols 
Participant eligibility criteria Controls 
matched 
for 
Exposure Out-
come 
TFA level 
Lopes et 
al. 2007 54
Retro-
spec-
tive 
NA Portugal 49 
(AT)
; 297 
(in-
take)
49 (AT 
data); 
301 
(intake 
data) 
Men. Excluded if: age<40 y and 
if ≥ 65 y in combination with 
low mental score; change of 
food habits during prior year; 
unable to answer questionnaire; 
history of MI. 
Catch-
ment area 
TFA intake 
(82-item 
FFQ)and 
TFA in AT 
First 
AMI 
Median TFA intake in controls: 1.2 g/d: 
Median AT conc. in controls: total-TFA = 
0.79% 
Sun et al. 
2007a 62 
& 
Sun et al. 
2007b 70 
Prospec
tive;  
nested 
in 
NHS, 
mean 
follow-
up 6 y 
Base-
line: 
1989-
90 
USA 166 327 Women;Excluded if: diagnosed 
with cancer or CVD  
Age, 
smoking 
status, 
date of 
blood 
draw, 
fasting 
status. 
TFA in RBC Inci-
dent 
CHD 
Mean RBC conc. in controls: total-TFA = 
1.66%; t16:1n-7 = 0.14%;  t18:1 =1.16%; 
t18:2 = 0.36% 
Ghahre-
manpour 
et al. 
2008 59 
Retro-
spec-
tive 
NA Iran 105 68 Men and women. Excluded if: ≥ 
75 y; previous hospital admis-
sion for CVD; previous diagno-
sis of angina, hyperchol. or 
diabetes. 
Age, sex. TFA in AT CAD Mean AT conc. in controls: total-TFA = 
8.02%; t16:1 = 0.50%;  t18:1 =6.01%; t18:2 
= 1.50% 
Block et 
al. 2008 57
Retro-
spec-
tive 
2004-
05 
USA 768 768 Men and women. History of 
CHD did NOT exclude cases or 
controls. 
Age, sex, 
race. 
TFA in 
blood cells 
Acute 
coro-
nary 
syn-
drome 
Mean AT conc. in controls: total-TFA = 
3.34%; t16:1n-7 = 0.70%;  t18:1 =2.48%; 
t18:2 = 0.15% 
Park et al. 
2009 61 
Retro-
spec-
tive 
2006-
08 
South Korea 50 50 Men and women. Excluded if: 
history of CHD, cancer, hyper-
lipidemia or diabetes. 
Age, sex. TFA in RBC Non-
fatal 
AMI 
RBC conc. in controls: total-TFA = 1.01% 
1 The study by Baylin et al.69 and the study by Colon-Ramos et al. 58 are partly based on the data from the same subjects and can therefore not be considered independent. From Baylin et 
al.69 we extracted results for trans16:1 only, as these are not presented in Colon-Ramos et al.58. 2 The study by Colon-Ramos et al.58 reported results from examination performed between 
1996-1999 and 2001-2003 (before and after reduction of TFA in foods) separately, whereby the results from the two different time periods can be considered independent and thereby 
regarded as two separate studies, Colon-Ramos I and II. AMI; acute myocardial infarction; AT, adipose tissue; CAD, coronary artery disease; CHD, coronary heart disease; CHS, Car-
diovascular Health Study; CVD, cardiovascular disease; FFQ, food frequency questionnaire;  ICH, ischemic heart disease; NA, not available; NHS, Nurses’ Health Study; RBC, red 
blood cells; SCD, sudden cardiac death; t, trans.
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Appendix B: Relative risk estimates for the association of TFA intake or biomarkers or intake with risk of CHD in case-control studies 
Reference End point Exposure OR 95%CI Comparison Comparison 
span 
Unit of measurement 
Case-control studies with intake of TFA      
Ascherio et al. 1994 50 First MI Total-TFA 2.03 0.98 4.22 Q1 (1.7 g/d) vs Q5 (6.5 g/d) 4.8 g/d Energy-adjusted g/d 
” First MI R-TFA 1.02 0.43 2.41 Q1 (0.5 g/d) vs Q5 (1.8 g/d) 1.3 g/d Energy-adjusted g/d 
” First MI IP-TFA 1.94 0.93 4.04 Q1 (0.8g/d) vs Q5 (5.0 g/d) 4.2 g/d Energy-adjusted g/d 
Clifton et al. 2004 74 First MI Total-TFA 2.25 1.16 4.32 Q1 (1.6 g/d) vs Q5 (5.5 g/d) 3.9 g/d g/d 
” First MI Total-TFA 0.98 NA NA Q1 (1.6 g/d) vs Q5 (5.5 g/d) 3.9 g/d g/d adj. for energy and SFA 
Lopes et al. 2007 54 First MI Total-TFA 0.81 0.48 1.37 Q1 (0.3 g/d) vs Q4 (1.4 g/d) 1.1 g/d g/d 
Case-control studies with total TFA, t16:1, t18:1, or t18:2 in adipose tissue       
Aro et al. 1995 63 First MI Trans18:1 0.97 0.56 1.67 Q1 (0.5%) vs Q4 (2.5%) 2.0% point  % of FAs in sc AT (buttock) 
Norway First MI Trans18:1 5.4 1.5 13.1 Q1  vs Q4  1.24% point  % of FAs in sc. AT (buttock) 
Finland First MI Trans18:1 5.0 1.3 19.6 Q1  vs Q4  1.49% point  % of FAs in sc. AT (buttock) 
Germany First MI Trans18:1 1.8 0.7 5.2 Q1  vs Q4 0.71% point  % of FAs in sc. AT (buttock) 
UK First MI Trans18:1 1.6 0.4 6.6 Q1  vs Q4 1.29% point  % of FAs in sc. AT (buttock) 
Switzerland First MI Trans18:1 1.5 0.5 4.9 Q1  vs Q4 0.98% point % of FAs in sc. AT (buttock) 
Israel First MI Trans18:1 0.8 0.2 3.2 Q1  vs Q4 1.78% point  % of FAs in sc. AT (buttock) 
Netherlands First MI Trans18:1 0.8 0.2 2.6 Q1  vs Q4 2.02% point  % of FAs in sc. AT (buttock) 
Spain, Malaga First MI Trans18:1 0.3 0.1 1 Q1  vs Q4 0.52% point  % of FAs in sc. AT (buttock) 
Russia First MI Trans18:1 0.2 0.1 0.7 Q1  vs Q4 1.36% point  % of FAs in sc. AT (buttock) 
Spain, Granada First MI Trans18:1 0.2 0 0.6 Q1  vs Q4 0.51% point  % of FAs in sc. AT (buttock) 
Baylin et al. 2003 69 First AMI Trans16:1 2.58 1.22 5.43 Q1 (0.0%) vs Q5 (0.1%) 0.1% point  % of FAs in sc. AT (buttock) 
Colon-Ramos et al. 2006, I 58 First AMI Total-TFA 3.28 1.68 6.42 Q1 (1.9%) vs Q5 (4.4%) 2.5% point  % of FAs in sc. AT (buttock) 
“ First AMI Trans18:1 1.75 0.97 3.15 Q1 (0.9%) vs Q5 (2.5%) 1.6% point  % of FAs in sc. AT (buttock) 
“ First AMI Trans18:2 4.76 2.24 10.11 Q1 (0.8%) vs Q5 (2.0%) 1.2% point  % of FAs in sc. AT (buttock) 
Colon-Ramos et al. 2006, II 58 First AMI Total-TFA 1.03 0.75 1.42 Q1 (1.8%) vs Q5 (3.4%) 1.6% point  % of FAs in sc. AT (buttock) 
“ First AMI Trans18:1 1.02 0.75 1.37 Q1 (0.9%) vs Q5 (1.9%) 1.0% point  % of FAs in sc. AT (buttock) 
“ First AMI Trans18:2 1.15 0.8 1.64 Q1 (0.7%) vs Q5 (1.4%) 0.7% point  % of FAs in sc. AT (buttock) 
Ghahremanpour et al. 2008 59 IHD Total-TFA 1.41 1 1.8 Q1  vs Q5  13.7% point  % of FAs in sc. AT (buttock) 
” IHD Trans16:1 0.8 0.3 1.9 Q1  vs Q5  1.5% point  % of FAs in sc. AT (buttock) 
” IHD Trans18:1 1.32 1 1.8 Q1  vs Q5  11.3% point  % of FAs in sc. AT (buttock) 
” IHD Trans18:2 1.85 0.6 4.8 Q1  vs Q5  4.6% point  % of FAs in sc. AT (buttock) 
        (Continued) 
  
A
6 
Appendix B (continued)        
Reference End point Exposure OR 95%CI Comparison Comparison 
span 
Unit of measurement 
Lopes et al. 2007 54 First AMI Total-TFA 0.04 0.01 0.32 T1 (0.6%) vs T3 (0.9%) 0.3% point  % of FAs in sc. AT (buttock) 
Pedersen et al. 2000 66 First AMI Total-TFA 1.49 0.47 4.69 Q1 (2.9%) vs Q5 (5.5%) 2.6% point  % of FAs in sc. AT (buttock) 
Roberts et al. 1995 67 SCD Total-TFA 0.63 0.22 1.84 Q1 (≤2.3%) vs Q5 (≥3.4%) >1.1% point  % of FAs in sc. AT (buttock) 
” SCD Trans18:1 0.59 0.19 1.83 Q1 (≤1.8%) vs Q5 (≥2.8%) >1.0% point  % of FAs in sc. AT (buttock) 
” SCD Trans18:2 0.99 0.35 2.84 Q1 (≤0.5%) vs Q5 (≥0.7%) >0.2% point  % of FAs in sc. AT (buttock) 
Case-control studies with total TFA, t16:1, t18:1, or t18:2 in blood      
Block et al. 2008 57 ACS Total-TFA 1.31 1.11 1.55 1 SD increase ~1.4% point  % of FAs in whole blood 
” ACS Trans18:1 1.24 1.06 1.45 1 SD increase ~0.8% point  % of FAs in whole blood 
” ACS Trans18:2 1.1 0.93 1.3 1 SD increase ~0.1% point  % of FAs in whole blood 
Harris et al. 2007 64 ACS Total-TFA 0.87 0.55 1.37 1 SD increase ~0.8% point  % of FAs in whole blood 
” ACS Trans18:1 0.8 0.51 1.25 1 SD increase ~0.7% point  % of FAs in whole blood 
” ACS Trans18:2 1.41 0.84 2.39 1 SD increase ~0.2% point  % of FAs in whole blood 
Lemaitre et al. 2002 60 SCD Total-TFA 1.47 1.01 2.13 Interquintile range 0.9% point  % of FAs in erythrocytes 
” SCD Trans18:1 0.77 0.48 1.24 Interquintile range 0.8% point  % of FAs in erythrocytes 
” SCD Trans18:2 3.05 1.71 5.44 Interquintile range 0.1% point  % of FAs in erythrocytes 
Lemaitre et al. 2006 65 Fatal IHD Total-TFA 0.94 0.65 1.34 Interquintile range 1.39% point  % of FAs in plasma 
” Fatal IHD Trans16:1 0.95 0.64 1.42 Interquintile range 0.13% point  % of FAs in plasma 
” Fatal IHD Trans18:1 0.38 0.17 0.86 Interquintile range NA  % of FAs in plasma 
” Fatal IHD Trans18:2 1.68 1.21 2.33 Interquintile range 0.13% point  % of FAs in plasma 
Park et al. 2009 290 non-fatal MI Total-TFA 72.7 6.7 790.7 T1 (<0.06%) vs T3 (>0.45%) ~0.4% point  % of FAs in erythrocytes 
” non-fatal MI Trans18:1 50.5 5.3 482.7 T1 (<0.22%) vs T3 (>0.35%) ~0.2% point  % of FAs in erythrocytes 
” non-fatal MI Trans18:2 3.8 0.96 15.4 T1 (<0.19%) vs T3 (>0.29%) ~0.1% point  % of FAs in erythrocytes 
Sun et al. 2007a 62 IHD Total -FA 3.3 1.5 7.2 Q1 (1.2%) vs Q4 (2.2%) 1.0% point  % of FAs in erythrocytes 
” IHD Trans18:1 3.1 1.5 6.7 Q1 (0.8%) vs Q4 (1.6%) 0.8% point  % of FAs in erythrocytes 
” IHD Trans18:2 2.8 1.2 6.3 Q1 (0.3%) vs Q4 (0.5%) 0.2% point  % of FAs in erythrocytes 
Sun et al. 2007b 70 IHD Trans16:1 0.98 0.53 1.83 Q1 (0.1%) vs Q4 (0.2%) 0.1% point  % of FAs in erythrocytes 
AMI; acute myocardial infarction; AT, adipose tissue; ICH, ischemic heart disease; NA, not available; RBC, red blood cells; sc., subcutaneous; SCD, sudden cardiac death.
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Appendix C: Confounders adjusted for in individual case-control studies 
Reference 
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Ascherio et al. 1994 50 •          • 1  •  •  • •  1  • •  •   • 1 • •  1   1   
Aro et al. 1995 63  •  2 2 2      •                     • •       
Roberts et al. 1995 67 •  •  •        •   •                •        
Pedersen et al. 2000 66 • •            •                 • •      •  
Lemaitre et al. 2002 60  •        •   • • •   •         •   •   •       3 
Baylin et al. 2003 69  •         4  •   •  •  • 4     •   •   •     4 
 
Income, years living in the 
house 
Clifton et al. 2004 74                    •      •              
Colon-Ramos 2006, I&II 58 • •          5 •    • • 5 • 5    5 •   •  • •       Income; vit E intake 
Lemaitre et al. 2006 65  •        •   • •                  • •      
 
CVD; clinic site; time of blood 
draw; congestive heart failure; 
history of stroke. 3 
Harris et al. 2007 64  •         •6 • • •     •             •       
 
Race; history of MI or revascu-
larization 
Lopes et al. 2007 54 •         7 • • 7 •   7   •         •   •        
Sun et al. 2007a 62 •           •  • •  •   • • • •  •     8 8         •   •     •     • 8       
Sun et al. 2007b 70 •              •    •   • • • •   •     9 9         •   •     •   • • 9     Total TFA in RBC 
Block et al. 2008 57                 •10 •10 • • • •     • •                           •   •       
  
Personal history of CHD, use of 
statins and antiplatelet drugs. 
Ghahremanpour et al. 2008 59                                 •                             •             Plasma triglycerides; AT PUFA 
Park et al. 2009 290 •                  •     •  •     •                           • •             Blood glucose 
1Further adjustment for these variables and marital status, personality type and intakes of carotene, Vit E and Vit C did not materially change the estimates; 2Further adjustment for these 
variables and socioeconomic status did not materially change the estimates; 3 Blood t18:1 and t18:2 were assessed simultaneously; 4Further adjustment for these variables (plus waist-to-
hip ratio and intake of Vit E and folate) did not materialy change the estimates; 5Further adjustment for these variables (plus weight, height, waist-to-hip ratio, other AT FA, intake of 
folate, margarine, fish and dairy products) did not materialy change the estimates; 6 The adjustment for blood lipids did not materially change the estimates; 7Further adjustment for these 
variables (plus angina pectoris) did not materially change the estimates; 8Further adjustment for these variables (plus folate intake and erythrocyte SFA, MUFA and α-linolenic acid) did 
not materially change the estimates; 9Further adjustment for these variables (plus intake of folate, calcium and Vit D) did not materially change the estimates. 10Excluding blood lipids 
and blood n-3 fatty acids did not change the estimates.
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Appendix D: Risk ratios and 95% confidence intervals for fully adjusted random-effects models exam-
ining the associations of biomarkers of total-TFA (A); trans18:2 (B); trans18:1 (C) and 
trans16:1(D) and risk of CHD 
Study or Subgroup
1.1.1 TFA in blood
Block 2008
Harris 2007
Lemaitre 2002
Lemaitre 2006
Park 2009
Sun 2007a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 22.94, df = 5 (P = 0.0003); I² = 78%
Test for overall effect: Z = 1.83 (P = 0.07)
1.1.2 TFA in adipose tissue
Colon-Ramos 2006; I
Colon-Ramos 2006; II
Ghahremanpour 2008
Lopes 2007
Pedersen 2000
Roberts 1995
Subtotal (95% CI)
Heterogeneity: Tau² = 0.25; Chi² = 22.29, df = 5 (P = 0.0005); I² = 78%
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 45.24, df = 11 (P < 0.00001); I² = 76%
Test for overall effect: Z = 2.01 (P = 0.04)
Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.90), I² = 0%
Weight
14.1%
10.6%
11.7%
11.9%
1.2%
6.8%
56.2%
7.9%
12.4%
13.3%
1.6%
4.1%
4.6%
43.8%
100.0%
IV, Random, 95% CI
1.31 [1.11, 1.55]
0.87 [0.55, 1.37]
1.47 [1.01, 2.13]
0.94 [0.66, 1.34]
72.68 [6.68, 790.95]
3.30 [1.51, 7.20]
1.42 [0.98, 2.07]
3.28 [1.67, 6.43]
1.03 [0.75, 1.42]
1.41 [1.10, 1.80]
0.04 [0.00, 0.32]
1.49 [0.47, 4.69]
0.63 [0.22, 1.84]
1.16 [0.69, 1.95]
1.33 [1.01, 1.74]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.05 0.2 1 5 20
Lower risk with TFA HIgher risk with TFA
Study or Subgroup
4.1.1 t18:2 in blood
Block 2008
Harris 2007
Lemaitre 2006
Park 2009
Sun 2007a
Subtotal (95% CI)
Heterogeneity: Chi² = 11.83, df = 4 (P = 0.02); I² = 66%
Test for overall effect: Z = 3.23 (P = 0.001)
4.1.2 t18:2 in adipose tissue
Colon-Ramos 2006; I
Colon-Ramos 2006; II
Ghahremanpour 2008
Roberts 1995
Subtotal (95% CI)
Heterogeneity: Chi² = 11.96, df = 3 (P = 0.008); I² = 75%
Test for overall effect: Z = 2.60 (P = 0.009)
Total (95% CI)
Heterogeneity: Chi² = 24.68, df = 8 (P = 0.002); I² = 68%
Test for overall effect: Z = 4.03 (P < 0.0001)
Test for subgroup differences: Chi² = 0.90, df = 1 (P = 0.34), I² = 0%
Weight
57.5%
5.7%
14.9%
0.8%
2.4%
81.3%
2.8%
12.7%
1.8%
1.4%
18.7%
100.0%
IV, Fixed, 95% CI
1.10 [0.93, 1.30]
1.41 [0.83, 2.39]
1.68 [1.21, 2.33]
3.80 [0.94, 15.40]
2.80 [1.24, 6.31]
1.26 [1.09, 1.45]
4.76 [2.24, 10.10]
1.15 [0.81, 1.64]
1.85 [0.71, 4.79]
0.99 [0.34, 2.84]
1.47 [1.10, 1.97]
1.30 [1.14, 1.47]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.05 0.2 1 5 20
Lower risk with t18:2 Higher risk with t18:2
A   Total-TFA 
B   trans18:2 
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Study or Subgroup
2.1.1 t16:1in blood
Lemaitre 2006
Sun 2007b
Subtotal (95% CI)
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.24 (P = 0.81)
2.1.2 t16:1 in adipose tissue
Baylin 2003
Ghahremanpour 2008
Subtotal (95% CI)
Heterogeneity: Chi² = 4.05, df = 1 (P = 0.04); I² = 75%
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI)
Heterogeneity: Chi² = 6.19, df = 3 (P = 0.10); I² = 52%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Chi² = 2.14, df = 1 (P = 0.14), I² = 53.3%
Weight
52.1%
21.5%
73.6%
15.2%
11.3%
26.4%
100.0%
IV, Fixed, 95% CI
0.95 [0.64, 1.42]
0.98 [0.52, 1.83]
0.96 [0.68, 1.34]
2.58 [1.23, 5.43]
0.80 [0.34, 1.90]
1.57 [0.89, 2.75]
1.09 [0.82, 1.46]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.05 0.2 1 5 20
Lower risk with t16:1 Higher risk with t16:1
Study or Subgroup
3.1.1 t18:1 in blood
Block 2008
Harris 2007
Lemaitre 2002
Lemaitre 2006
Park 2009
Sun 2007a
Subtotal (95% CI)
Heterogeneity: Chi² = 30.33, df = 5 (P < 0.0001); I² = 84%
Test for overall effect: Z = 2.07 (P = 0.04)
3.1.2 t18:1 in adipose tissue
Aro 1995; Finland
Aro 1995; Germany
Aro 1995; Israel
Aro 1995; Netherlands
Aro 1995; Norway
Aro 1995; Russia
Aro 1995; Spain, Granada
Aro 1995; Spain, Malaga
Aro 1995; Switzerland
Aro 1995; UK
Colon-Ramos 2006; I
Colon-Ramos 2006; II
Ghahremanpour 2008
Roberts 1995
Subtotal (95% CI)
Heterogeneity: Chi² = 44.54, df = 13 (P < 0.0001); I² = 71%
Test for overall effect: Z = 1.69 (P = 0.09)
Total (95% CI)
Heterogeneity: Chi² = 74.87, df = 19 (P < 0.00001); I² = 75%
Test for overall effect: Z = 2.67 (P = 0.008)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.96), I² = 0%
Weight
47.1%
5.8%
5.1%
1.7%
0.2%
2.0%
62.0%
0.6%
1.0%
0.6%
0.8%
1.5%
0.7%
1.0%
0.8%
0.8%
0.6%
3.4%
13.2%
12.1%
0.9%
38.0%
100.0%
IV, Fixed, 95% CI
1.24 [1.06, 1.45]
0.80 [0.51, 1.25]
0.77 [0.48, 1.24]
0.38 [0.17, 0.86]
50.50 [5.28, 482.93]
3.10 [1.43, 6.69]
1.15 [1.01, 1.32]
5.00 [1.27, 19.59]
1.80 [0.62, 5.20]
0.80 [0.20, 3.20]
0.80 [0.25, 2.60]
5.40 [2.23, 13.09]
0.20 [0.06, 0.70]
0.20 [0.07, 0.60]
0.30 [0.09, 1.00]
1.50 [0.46, 4.90]
1.60 [0.39, 6.60]
1.75 [0.97, 3.15]
1.02 [0.76, 1.37]
1.32 [0.97, 1.80]
0.59 [0.19, 1.83]
1.16 [0.98, 1.38]
1.16 [1.04, 1.29]
Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.05 0.2 1 5 20
Lower risk with t18:1 Higher risk with t18:1
C   trans18:1 
D   trans16:1 
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Appendix E:  TFA-feeding studies in animals 
Reference Species Dura
tion 
Diets Diet  composition Body 
weight 
Fat (pad) mass 
or TG content
Hepatic 
TG 
Results 
Kavanagh et 
al. (2007) 22 
Adult male 
green monkeys 
(n=21 per 
group; 17 for 
AT volumes; 8 
y old) 
6 y a) TFA (8E%) from PH 
soybean oil 
b) MUFA  
35 E% fat (17 wt%) 
Amount of feed 
based on body 
weight at baseline. 
Intended to main-
tain weight. 
TFA>MU
FA 
TFA>MUFA - • TFA: body weight ↑ 7% vs 2 % in MUFA ?diff. 
0.45 kg at 6 y. 
• TFA: IAAT ↑ 33% and  VAT↑  29% vs MUFA (ns) 
• TFA: IAAT/SAT ↑  vs. MUFA (p=0.02), adj. for 
body weight. 
• TFA: ↑ 18% fasting insulin (ns) 
• TFA: ↑ 9% fasting glucose (ns) 
• TFA: ↑ 24% HOMA (ns) 
• TFA: ↑ 27% fructosamine 
• TFA: ↑ > 300% insulin at 3h postprandially 
(p=0.02; n=6+6) 
• TFA: Muscle insulin-stimulated Akt phosphoryla-
tion ↓ ~300% (n=3 vs 6 in MUFA) 
• AT Akt activation ↔ 
• Muscle or AT IR activation ↔ 
• AT TNFα protein ↔ (not detectable in muscle) 
Colandre et 
al. (2003) 227
Male Wistar 
rats (n=6 per 
group; weight: 
120 g) 
30 d a) TFA (30 wt% of fat) 
from PH corn oil 
b) SA from hydr. corn oil 
c) OA+LA from corn oil 
38.5%E fat 
Isoenergetic, ad 
libitum 
↔ TFA/SA > 
OA+LA 
 
TFA > SA 
> OA+LA
 
• TFA: Epid. AT weight 87% ↑ vs OA+LA.  
• TFA: Liver weight 26% ↑ vs OA+LA. 
• TFA: Liver TG 126 % ↑ vs. OA+LA and 56 % ↑ vs. 
SA (ns) 
• Carcass fat slightly ↓ on TFA/SA vs OA+LA 
(p=0.05) 
• Serum cholesterol ↔ 
Giudetti et 
al. (2003) 228
Male Wistar 
rats (n=12 per 
group; 6 wk 
old) 
14 d a) TFA (48 wt% of fat) 
from PH soybean oil 
b) SA from hydr. soy-
bean oil/olive oil 
c) OA from olive oil 
20 wt% fat 
Isoenergetic, ad 
libitum 
↔ - OA > 
TFA > SA
• Liver weight ↔ 
• TFA: feed intake ↓ vs OA/SA 
• TFA: Serum cholesterol ↓ 
• TFA vs OA/SA: hepatic enzyme activity:                   
citrate carrier (lipogenic) ↓ (vs SA);                    
CPT-I (FA oxidation)↓;  3-HAD (FA oxidation) ↓      
 
 
 
       (Continued) 
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Appendix E  (continued)        
Reference Species Dura
tion 
Diets Diet  composition Body 
weight 
Fat (pad) mass 
or TG content
Hepatic 
TG 
Results 
Tetri et al. 
(2008) 231 
Male C57BL/6 
mice (n=10 per 
group; 5-6 wk 
old) 
16 wk a) TFA (30 wt% of fat) 
from PH soybean oil  
b) SFA+MUFA  from 
lard 
45E% fat + high-
fructose corn syrup 
 
↔ - TFA> 
SFA+MU
FA (ns) 
• Feed intake ↔ 
• Plasma cholesterol ↔ 
• TFA: liver weight ↑ 
• TFA: liver TG 78% ↑  but ns. 
• TFA: degree of hepatic steatosis ↑. 
• TFA: degree of micro-vesicular steatosis ↑. 
• Glucose tolerance ↔ 
Huang et al. 
(2009) 177 
Male Wistar 
rats (n=10 per 
group; 22-25 d 
old) 
16 wk a) TFA (4.5wt% of feed) 
from margarine 
b) CTR: Corn oil 
16.5 wt% fat ↔ - - • TFA:  Serum total and HDL cholesterol ↓ 
• TFA: Plasma adiponection ↑ resistin ↑ leptin. ↓ 
• Plasma glucose and insulin sensitivity index ↔ 
Koppe et al. 
(2009)188 
Male AKR/J 
mice (n=4-5 
per group;9-10 
wk old) 
8 wk a) TFA (20E%) from 
shortening 
b) CTR: TFA substituted 
by SFA:MUFA:PUFA 
(30:20:50) from lard 
45 E% fat; ad libi-
tum 
TFA<CT
R 
- ↔ • TFA: Serum ALT ↑ 
• Degree of hepatic steatosis ↔ 
• Serum cholesterol ↔ 
• TFA: Leptin ↓ 
• TFA: higher fasting insulin 
• TFA: insulin resistance (QUICKI) ↑ 
• TFA: serum leptin ↓ 
• TFA: hepatic expression of IL-1β ↑,  TNFα ↔, IL6 
↔; IL10 ↔ 
Atal et al. 
(1994) 232 
Male 
C57B1/6J mice 
(n=4-6 per 
group; 0 days 
old) 
2 y a) TFA (25 wt% of fat) 
shortening 
b) OA from olive and 
corn oil 
10 wt% fat 
Isoenergetic, ad 
libitum.  Fed to 
mothers during 
lactation and to 
pubs after 21d 
OA > 
TFA 
OA > TFA - • TFA: epid. and perirenal fat pad mass ↓. 
• TFA: AA ↓and higher LA ↑ in AT 
• TFA: Adipose cell size ↓  
 
 
 
 
 
 
 
       (Continued) 
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Appendix E  (continued)        
Reference Species Dura
tion 
Diets Diet  composition Body 
weight 
Fat (pad) mass 
or TG content
Hepatic 
TG 
Results 
Machado et 
al. (2010) 234
Male 
C57BL/6J 
LDLr-KO 
mice (n=13-14 
per group; 
post-weaning) 
16 wk a) TFA (36wt% of fat) 
from PH soybean oil 
b) PUFA (More OA + 
LA + ALA, less SA 
compared to TFA diet) 
from sunflower and 
canola oil 
c) SFA (More PA + OA 
+ LA, and less SA com-
pared to TFA diet) from 
mostly palm oil 
40 E% fat, ad libi-
tum 
TFA<SF
A<PUFA 
TFA<SFA<PU
FA 
TFA>SFA
/PUFA 
• Feed intake ↔ 
• TFA: 36 % ↓ SAT vs. PUFA and SFA 
• TFA: Epid. fat pad content ↓ 
• TFA: liver weight > 60% ↑ vs. PUFA and SFA 
• TFA: LDL and VLDL cholesterol ↑ 
• TFA: Macrovesicular hepatic steatosis and inflam-
matory infiltrate vs. very mild microvesicular stea-
tosis and minimal inflammatory process in SFA and 
PUFA  
• TFA  vs SFA/PUFA: hepatic gene expression:  
SREBP-1c ↑ PPARγ ↑ (lipid synthesis);  MTP↓ (vs 
PUFA; TG export);  PPARα and CTP-1 ↔ (FA 
oxidation)    
• TFA: Fasting glucose ↑ vs. PUFA, but not SFA 
• Fasting insulin ↔ 
• TFA: Higher HOMA vs PUFA and SFA                     
Tardy et al. 
(2008) 230 
Male wistar 
rats (n=10-14 
per group; 12 
wk old) 
8 wk a) IP-TFA (4 E%) from 
PHVO 
b) R-TFA (4 E%) from 
enriched butter 
b) OA from mix of palm 
stearin/rapeseed/sunflow
er oils 
25 E% fat ↔ ↔ - • Liver weight and energy intake ↔ 
• Muscle oxidative capacity ↔ 
• TFA from either source: Body weight and adipose 
tissue weight slightly ↑ vs. OA, but ns. 
• Insulin and glucose AUC after intraperitoneal glu-
cose tolerance test ↔ 
• TFA: Akt activation in myotubes not different from 
OA, but higher than PA 
Faulconnier 
et al. (2006) 
233 
Male NZ white 
rabbits (n=6 
per group; 10 
wk old) 
12 wk a) TFA, t18:1Δ10 (15 
wt% of fat) from en-
riched butter 
b) SFA (12:0, 14:0, PA) 
from butter 
13 wt% fat 
Isoenergetic, ad 
libitum 
SFA  > 
TFA 
SFA > TFA ↔ • Feed intake ↔ 
• TFA vs SFA: AT enzyme activity:                           
G3PDH ↓;  G6PDH ↓;  LPL ↓(ns) (lipogenic)             
• No effect on hepatic enzyme activity:  G3PDH ↔; 
G6PDH  ↔;   FAS  ↔ (lipogenic)      
 
 
 
       (Continued) 
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Appendix E  (continued)        
Reference Species Dura
tion 
Diets Diet  composition Body 
weight 
Fat (pad) mass 
or TG content
Hepatic 
TG 
Results 
Lessa et al. 
(2010) 229 
Male Wistar 
rats (n=10 per 
group) 
7 wk a) TFA (5 E%) from 
PHVO 
b) PUFA (LA + ALA) 
from soybean oil 
12 wt% fat. Ad 
libitum. Fed to 
mothers during 
gestation and lacta-
tion and to pubs 
from day 23 to wk 7
↔ - TFA>PUF
A 
• TFA: Liver fat deposition in newborns and after 
weanling ↑, but not significantly so in young adult 
rats (p=0.06). 
• TFA: Fasting glucose during young adulthood ↑ 
• TFA: Liver/body weight ratio during young adult-
hood ↑ 
Obara et al. 
(2010) 176 
Femal 
C57BL/6Njcl 
mice (n=6 per 
group; 8-10 wk 
old) 
24 wk a) TFA (29 % of fat), low 
fat (LF) 
b) MUFA/PUFA, LF 
c) TFA (29 % of fat), 
high fat (HF) 
d) MUFA/PUFA, HF 
LF: 12E% fat;  
HF: 64 E% fat. Ad 
libitum. 
 
TFA>MU
FA/PUFA 
on HF 
diets only
- TFA>MU
FA/PUFA 
on HF 
diets only 
• TFA HF: Liver weight ↑ compared to all others 
• TFA HF: Hepatic expression of:  SREBP-1 ↑ 
PPARγ1 ↑ FAS ↑ ACC ↑ 
• TFA LF: Hepatic expression of SREBP-1 ↑ 
• Hepatic expression of PPARα ↔, CTP-1 ↔, MTP-
1 ↔, TNFα ↔ and IL6 ↔ 
Silva et al. 
(2006) 236 
Male Wistar 
rats (n=6 per 
group; 0 d old) 
45 d a) TFA (15% of fat) from 
PHVO 
b) PA from palm oil 
c) OA from canola oil 
d) PUFA from soybean 
oil 
7 wt% fat 
Isoenergetic, ad 
libitum Fed to 
mothers during 
lactation and to 
pubs from day 21 to 
45  
TFA/PA 
> 
OA/PUF
A 
PA >TFA> 
OA/PUFA  
- • TFA: Feed intake vs all others ↓ 
• TFA: Body weight ↑ vs. OA/PUFA 
• TFA: De novo lipogenesis rate in epid. AT ↑ vs. 
OA/PUFA but ↓ vs SA  
• TFA: Lipid content in epid. AT ↑ vs. OA/PUFA but 
↓ vs PA  
• TFA:  level of PUFA in AT ↓. 
• TFA: serum cholesterol ↑, HDL-C ↓ 
• LPL activity ↔ 
Duque-
Guimaraes et 
al. (2009) 178
Female Wistar 
rats 
17 wk a) TFA (15wt% of fat) 
from PHVO 
b) Soybean oil (PA+LA) 
c) Fish oil  
7 wt% fat; 
Ad libitum 
TFA>PA
+LA/fish 
oil 
 Fish oil< 
TFA/PA+
LA 
• TFA: feed intake ↓ vs two other groups until wk 7 
• TFA: Body weight ↑ vs other groups from wk 5-13, 
not from wk 13-17   
• TFA: total/HDL-C ↑ 
• TFA: Insulin ↑ 
• TFA: Plasma adiponectin ↓ 
• TFA: AT expression of resistin ↑; TNFα ↑; adi-
ponectin ↓; PPARγ ↓ vs. the two other groups 
 
 
 
       (Continued) 
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Reference Species Dura
tion 
Diets Diet  composition Body 
weight 
Fat (pad) mass 
or TG content
Hepatic 
TG 
Results 
Dorfman et 
al. (2009) 235
Male Sprague-
Dawley rats 
(n= 8-11 per 
group; 8 wk 
old) 
6 wk 
(8 wk 
for 
IS) 
a) TFA (4.6 E%) from 
addition of  EA to soy-
bean oil 
b) SFA (PA+SA) from 
lard and soybean oil 
10E% fat; 
Ad libitum 
TFA>SF
A 
TFA>SFA TFA>SFA • TFA: Energy intake ↑ 
• TFA: whole body AT gain 50% ↑ vs SFA 
• TFA: primarily gain in IAAT 
• TFA: 6-fold ↑ in hepatic fat 
• Intramuscular fat ↔ 
• TFA: LA and DHA ↓ in AT, liver, muscle 
• TFA: whole-body glucose disposal rate ↓ (clamp) 
• Whole body insulin action (clamp) ↔ 
• TFA: hepatic glycogenesis ↑ 
• Liver glycogen content ↔ 
• Hepatic insulin action ↔ 
• TFA: 2-fold ↑ DAG in soleus muscle 
Cassagno et 
al. (2005) 208
C57B1/6J mice 
(n= 10 per 
group; 8 wk 
old) 
7 wk a) TFA (11 wt% of fat 
from PHVO) 
b) Rapeseed oil (OA + 
LA) 
10 wt% fat - - - • Total-/HDL-C ↔ 
• TFA: plasma triglyceride ↑ 
• TFA: hepatic enzyme expression:                           
FAS ↑ SREBP-1↑ (lipogenic) MTP ↑ apoB100 (TG 
export), LDL-R ↔, cholesteryl 7α-hydroxylase ↔ 
and LXR ↔                                
• Plasma LCAT activity ↔ 
• Reverse cholesterol transport ↔ 
• TFA: 18 % ↑ plasma F2-isoprostanes 
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Appendix E  (continued)        
Reference Species Dura
tion 
Diets Diet  composition Body 
weight 
Fat (pad) mass 
or TG content
Hepatic 
TG 
Results 
Ibrahim et 
al. (2005) 269
WNIN rats 
(n=8 per 
group; 
weanling) 
3 mo a) TFA (3 E% from 
Vanaspati, high LA 
(4E%)) 
b) TFA (3 E% from 
Vanaspati, low LA 
(2E%)) 
c) PA+OA (palmolein) 
d) PUFA (groundnut oil) 
10 wt% fat ↔ ↔ - • TFA: Membrane fluidity ↓ 
• TFA: Fasting insulin ↑ 17%  
• TFA: Anti-lipolytic effect of insulin in adipocytes ↓ 
vs. PUFA and PA+OA 
• TFA: insulin-stimulated glucose transport in adipo-
cytes ↓ vs. PUFA and PA+OA 
• TFA: HDL-cholesterol  ↓ 
• Body weight and epid. fat mass ↔ 
• Insulin and glucose AUC after oral glucose toler-
ance test ↔ 
• No. effect of varying the amount of LA. 
Natarajan et 
al. (2005) 268
Same study as 
above 
      • TFA: FA in diaphragm phospholipids: LA ↑, AA ↓ , 
ratio of AA to LA ↓, and total PUFA ↓ 
• TFA: Diaphragm intramyocellular triglycerides ↑ 
65% vs PUFA and 46% vs. PA+OA 
• TFA: Insulin-stimulated glucose transport in dia-
phragm ↓ 30% vs. PUFA and PA+OA. 
• No. effect of varying the amount of LA. 
Saravanen et 
al. (2005) 187
Same study as 
above 
      • TFA: mRNA expression in AT: PPARγ  ↓ LPL  ↓ 
vs. PUFA and PA+OA, resistin  ↓ vs. PUFA 
• mRNA expression of adiponectin in AT was de-
creased by SFA but not TFA 
ACC, acetyl CoA carboxylase; ALA, alpha-linolenic acid; epid., epididymal; CTP-1, carnitine pamitoyl transferase 1; DHA, docosahexaenoic acid; FAS, fatty acid synthase; G3PDH, 
glycerol-3-phosphate dehydrogenase; G6PDH, glycerol-6-phosphate dehydrogenase; IAAT, intra-abdominal adipose tissue; IR, insulin receptor; LA, linoleic acid; LCAT, lecithin cho-
lesterol acyl transferase; LDLr-KO, LDL receptor knockout; LPL, lipoprotein lipase; MTP, microsomal triglyceride transfer protein; OA, oleic acid; PA, palmitic acid; PH, partially 
hydrogenated; PHVO, partially hydrogenated vegetable oil; PPAR,  peroxisome proliferator-activaeted receptor; SA, stearic acid; SAT, subcutaneous adipose tissue; SREBP-1c, sterol 
regulatory element binding protein-1c; TG, triglyceride; wt, weight. 
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ABSTRACT 
Background and Aims: The aim of this systematic review and meta-analysis was to summarize the 
evidence from observational studies assessing the association between intake of trans fatty acids 
(TFA) and the risk of coronary heart disease CHD), with a specific emphasis on distinguishing be-
tween TFA of industrial and ruminant origin. 
Methods: By searching five bibliographic databases, six published and two unpublished prospective 
cohort studies, assessing the association of intake of TFA with fatal and/or non-fatal CHD, were iden-
tified. Four and three studies reported separate associations for intake of ruminant or industrial TFA, 
respectively. 
Results and Conclusions: The pooled relative risk estimates for comparison of extreme quintiles of 
total-TFA intake (corresponding to intake increments ranging from 2.8 to ~10 g/d) were 1.22 (95% 
confidence interval (CI): 1.08 - 1.38; P = 0.002) for CHD events and 1.24 (CI: 1.07 - 1.43; P = 0.003) 
for fatal CHD.  Ruminant TFA intake (increments ranging from 0.5 to 1.9 g/d) was not significantly 
associated with risk of CHD (RR = 0.92; CI: 0.76 - 1.11; P = 0.36), and neither was industrial TFA 
intake, although there was a trend towards a positive association (RR = 1.21; CI: 0.97 - 1.50; P = 
0.09]. In conclusion, our analysis suggests that industrial TFA is positively related to CHD, whereas 
ruminant TFA is not, but the limited number of available studies prohibits any firm conclusions con-
cerning whether the source of TFA is important. The null association of ruminant TFA with CHD risk 
may be due to lower intake levels. 
Paper I - 2 
INTRODUCTION 
Dietary TFA have long been suspected of increasing the risk of coronary heart disease (CHD), 
especially at high intake levels. No randomized intervention studies evaluating the effect of 
dietary TFA on hard endpoints for CHD have been conducted. However, as several epidemiol-
ogical studies have shown a strong positive association between the intake of TFA and risk of 
CHD1-3, the suspicion of a harmful effect of TFA seems justified. It has been estimated that a 
two percent increase in energy intake from TFA is associated with a 23% increased risk of CHD 
in a previous pooled analysis of four prospective cohort studies with nearly 140,000 subjects4. 
However, TFA is not just TFA. TFA in food originate from two main sources; industrial partial 
hydrogenation of edible oils, and bacterial hydrogenation of unsaturated fatty acids in the rumen 
of ruminants. Today, the industrially produced TFA (IP-TFA) are primarily found in snacks and 
fast food products whereas the ruminant TFA (R-TFA) constitute a part of the fat in meat and 
dairy products. The isomer distribution of the TFA from these two sources is dissimilar. In R-
TFA the predominant isomer is vaccenic acid (trans18:1n-7) whereas IP-TFA generally has a 
Gaussian distribution of trans18:1 isomers with highest levels of elaidic acid (trans18:1n-9)5.  
There has been debate as to whether R-TFA is equally harmful as IP-TFA. Some results from 
epidemiological studies of intake of R-TFA and risk of CHD have indicated that intake of R-
TFA is innocuous or even protects against CHD6.  
We found it fitting and timely to conduct a systematic review and meta-analysis to assess the 
empirical evidence of an association between intake of TFA and the risk of fatal and/or non-
fatal CHD, with a specific emphasis on stratifying results according to industrial or ruminant 
origin of the TFA. We aimed for inclusion of all the available prospective cohort studies which 
have assessed the association between intake of TFA and incident CHD in adult populations.  
SUBJECTS AND METHODS 
We conducted this review in accordance with the PRISMA Statement for Reporting Systematic 
Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions7 on the basis of 
a predefined protocol, which was made publicly available and distributed among interested par-
ties. 
Study selection 
With this work we aimed to review all prospective cohort studies describing the association 
between intake of TFA (industrial and/or ruminant) and the incidence of fatal and non-fatal 
CHD. We conducted a systematic literature search of MEDLINE via Pubmed from 1950 to 
March 2010; EMBASE via Ovid from 1980 to March 2010; Food Science and Technology Ab-
stracts via Ovid from 1969 to March 2010; Web of Science from 1900-14 to March 2010, and 
SciFinder Scholar for studies describing the association between TFA intake and incidence of 
CHD. Two search themes were combined: TFA intake and CHD mortality and morbidity [for 
detailed description of the search strategy please refer to Supplemental Appendix A]. The search 
strategy had no language or study design restrictions. Instead, prospective cohort studies were 
identified from titles and abstracts of the retrieved references. Additionally, we screened the 
reference lists of all identified relevant studies, and of review articles, in order to identify possi-
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ble studies of interest. We contacted authors of included studies for references to studies not 
identifiable by our other searches, including unpublished studies. 
Two reviewers (NTB, investigator, and EMB, Senior Researcher in Biophysics and Research 
Librarian D.B.) independently identified articles eligible for further review by screening of iden-
tified titles and abstracts. Articles were considered for inclusion in the meta-analysis if they 
reported data from an original prospective cohort study with an assumed healthy study popula-
tion of adult men and/or women at study baseline. Studies had to assess intake of one or all of 
IP-TFA, R-TFA and TFA from any source (total-TFA), and one of the outcomes had to be the 
incidence of fatal MI, non-fatal MI, or total CHD-related deaths. Studies were included for fur-
ther screening if one or both reviewers decided the study to be possibly eligible. The second 
screening was based on reading of the full-text versions. Any disagreement between reviewers 
was resolved by consensus. 
Data extraction 
The included studies were scrutinized and reviewed without blinding of reviewers. One investi-
gator (NTB) was responsible for the extraction of data, which was then checked by another re-
viewer (RC). Data was extracted using a customized data extraction form. Relevant data 
included the first author’s name, year of publication, baseline year, name of cohort, country of 
origin, number of participants (men and women) at baseline, participant eligibility criteria, age 
of participants, duration of follow-up, dietary assessment method and validity of the method, 
number of dietary assessments, TFA mean or median intake and extreme quantiles of intake, 
outcome assessment method, number of events, unit of measurement, confounders adjusted for 
in the statistical analysis, relative risks of CHD (from the most adjusted analysis) comparing 
extreme quantiles of TFA intake or per unit of TFA intake, and corresponding 95% confidence 
intervals (CI). 
Statistical analysis 
The most adjusted Risk Ratio (RR) was used as a measure of the association between TFA and 
CHD. Summary estimates were obtained using inverse variance random-effects meta-analysis, 
with the DerSimonian and Laird estimate of the variance τ2 as a measure of heterogeneity be-
tween trials8. We applied random-effects, rather than fixed-effects models to estimate pooled 
RRs in order to take into account the heterogeneity, however small, of the risk estimates and 
thereby be more conservative. Meta-analyses were performed by using Review Manager 5.0 
(The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark; 
http://www.cc-ims.net/RevMan). We assessed homogeneity of effects across studies using the 
Q-test and quantified by I2 index9, which represents the percentage of total variation across stud-
ies that is attributable to inconsistency (heterogeneity) rather than chance10.  
In accordance with the protocol we performed secondary analyses for intake of R-TFA and IP-
TFA, respectively. Sample size was inadequate for analysis stratifying for sex.  
We examined the influence of an individual study on the pooled estimate of RR by excluding 
each study in turn. We specified sensitivity analyses with the aim to evaluate the influence of 
study quality on effect estimates as follows: i) An analysis stratifying for the dietary assessment 
tool (diet records, validated food frequency questionnaire (FFQ), non-validated FFQ, diet his-
tory, 24-h recall) where the former was rated as better, ii) A meta-regression-analysis to exam-
ine if the number of confounders adjusted for in each study affected the effect size; and iii) A 
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meta-regression-analysis to examine if the number of stars obtained in the Newcastle-Ottawa 
Scale quality assessment affected the effect size. The Newcastle-Ottawa Scale is one of the 
more comprehensive instruments for assessing the quality of non-randomized studies in meta-
analyses11. The 8-item instrument consists of three subscales, namely, selection of subjects (4-
item), comparability of subjects (1-item) and assessment of outcome/exposure (3-item). For 
each item each study got a score of zero, one or two stars, with a maximal total score of nine 
stars.  
 
RESULTS 
A total of 257 unique references were identified through the literature search and an additional 
12 from reference lists, giving a total of 269. Of these, only 8 met the selection criteria as shown 
in Figure 1. Three publications pre-
sented results from the Nurses’ Health 
Study (NHS) after 8, 14 and 20 years 
of follow-up, respectively1,12,13. Since 
only the first publication13 presented 
analysis of the association of IP-TFA 
and R-TFA intake with CHD, we 
extracted these data from this publica-
tion. For results on the association of 
total-TFA intake with CHD we ex-
tracted data from the publication with 
the longest follow-up of 20 years1. 
One of the selected studies included 
subjects who were diagnosed with 
diabetes at baseline and adjusted for 
diabetes status in the statistical analy-
ses14. We contacted the authors of all 
the selected studies to request updated 
analysis or additional information. 
The author of one study was able to 
respond to our request6. 
In addition, we contacted the principal 
investigators (PI) of five prospective 
cohort studies who had not published 
data on the association between TFA intake and CHD despite having collected relevant data.  
The PI of the Västerbotten Intervention Program15 and the Womens’ Health Study16 could not 
accommodate our request and the reporting of TFA intake data was judged to be of inadequate 
quality by the PI of the Atherosclerosis Risk in Communities Study17. The Iowa Womens’ Health 
Study (IWHS) performed a relevant analysis on our request (Personal Communication with Dr. 
Kim Robien) and the PI of the Finnish Mobile Clinic Health Examination Survey (FMC) pro-
vided us with the results of an unpublished analysis (Personal Communication with Dr. Paul 
Knekt). Thereby, data from seven peer-reviewed articles were included in this review1-3,6,13,14,18 
as well as unpublished data from two prospective cohort studies.  
Figure 1: Study selection 
References identified 
through literature search; 
n=257
Excluded on basis of ab-
stract/title; n=233 
 - Not a prospective cohort 
study; n=145 
 - Review; n= 86 
 - CHD incidence not an out-
come; n=2  
Articles retrieved for de-
tailed evaluation; n=36 
Excluded; n=28 
 - No data on TFA intake; 
n=20 
 - CHD incidence not an out-
come; n=1 
 - Not a prospective cohort 
study; n=7 
Studies eligible; n=8 
Excluded due to duplicate 
studies; n=1 
Studies included in meta-
analysis; n=9 
- Total-TFA and CHD; n=7 
- R-TFA and CHD; n= 4 
- IP-TFA and CHD; n=3 
Articles identified from refer-
ence lists; n=12 
Unpublished studies; n=2 
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Table 1: Study characteristics of the prospective cohort studies of trans fatty acid (TFA) intake and coronary heart disease (CHD) 
Study Base-
line 
year 
Coun-
try of 
origin
No of par-
ticipants at 
baseline 
Participant eligibility crite-
ria 
Age at 
baseline
Average 
duration 
of follow-
up 
Person 
years of 
follow-
up 
TFA intake Outcome Outcome asses-
sment method
Dietary 
assessment 
method 
No of 
dietary 
asses-
sments 
Validity of 
the dietary 
assessment 
method 
NHS, 
1993 13 
1980 USA 85,095 
women; of 
these 69,181 
did not report 
changes in 
their marga-
rine intake for 
10 y (used in 
subanalyses 
of R-TFA and 
IP-TFA) 
Female nurses. Excluded if:  
left>10 items blank on FFQ, 
improbable energy intake; 
history of angina, MI or 
stroke; high serum choles-
terol or diabetes. Subanaly-
ses of R-TFA and IP-TFA 
also excluded women report-
ing marked changes in mar-
garine intake within previous 
10 y. 
34-59 y 8 y 661,996 
for 
entire 
cohort 
Mean: 4.0 
g/d in entire 
cohort 
Incident 
CHD 
[non-fatal 
MI + CHD 
death] 
Medical re-
cords, hospital 
records, autopsy 
or death certifi-
cate; WHO 
criteria. 
 FFQ 61 food 
items (1 y). 
Specific 
questions 
about type of 
margarine 
and type of 
fat used for 
cooking 
1 (at base-
line)  
Validated for 
this study. 
TFA intake 
was corre-
lated to TFA 
in adipose 
tissue (r=0.5; 
n=115) 
HPFS, 
1996 18  
HPFS, 
2006 4 1 
1986 USA 43,757 men 
(38 461 men 
in updated 
analysis) 
Male health professionals. 
Excluded if:  left>70 items 
blank on FFQ, improbable 
energy intake; previous 
diagnosis of MI, angina, 
coronary artery surgery, 
stroke, transient ischemic 
attack, peripheral arterial 
disease, or diabetes. 
40-75 y 6 y 
(14 y in 
updated 
analysis) 
236,782 Median: 2.7 
g/d 
Total MI 
[non-fatal 
MI + fatal 
CHD] 
& 
Fatal CHD
Medical re-
cords, necropsy 
reports or death 
certificate;WHO 
criteria  
FFQ with 131 
food items (1 
y) 
1 (at base-
line; up-
dated 
dietary 
informa-
tion in 
updated 
analysis) 
Validated 
against two 7-
d food re-
cords 
(n=127); TFA 
intake was 
correlated to 
TFA in adi-
pose tissue, 
r= 0.29 
AT/BC, 
1997 3 
1985-
1988 
Fin-
land 
21,930 men Male smokers. Excluded if:  
history of cancer or other 
serious disease; prior diagno-
sis of MI, angina, stroke or 
diabetes; use of vitamin 
supplements in excess of 
predefined doses; treatment 
with anticoagulating agents; 
missing cardiovascular risk 
factors; exercise-related 
chest pain. 
50-69 y 6.1 y 
(median) 
129,389 
(deaths); 
126,969 
(events)
Median: 2.0 
g/d 
Major 
coronary 
event 
[first non-
fatal MI + 
CHD 
death] 
& 
CHD death
Hospital dis-
charge register; 
death certifi-
cates; ICD-8/9 
codes 410-414 
FFQ w/ 276 
food 
items/dishes 
(1 y). Spe-
cific ques-
tions about 
fat on bread 
and type of 
fat used for 
cooking 
1 (at base-
line)  
Validated 
against 24-d 
food records 
(n=190) in a 
pilot study 
prior to the 
trial 
             (Continued) 
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Table 1 (continued) 
 
          
Study Base-
line 
year 
Coun-
try of 
origin
No of par-
ticipants at 
baseline 
Participant eligibility crite-
ria 
Age at 
baseline
Average 
duration 
of follow-
up 
Person 
years of 
follow-
up 
TFA intake Outcome Outcome asses-
sment method
Dietary 
assessment 
method 
No of 
dietary 
asses-
sments 
Validity of 
the dietary 
assessment 
method 
ZES, 
2001 2 
1985 Nethe
rlands
667 men Excluded if: previous diag-
nosis of MI or angina. 
64-84 y 10 y NA Median: 3.9 
E% 
Incident 
CHD 
[fatal CHD 
+ non-fatal 
MI] 
& 
Fatal CHD
Municipal 
registries; Sta-
tistics Nether-
lands; hospital 
discharge data; 
general practi-
tioners; ICD 
(codes 410-414)
Cross-check 
dietary his-
tory method 
(1mo); inter-
view verified 
against 
checklist of 
foods bought 
per week 
3 (but only 
baseline 
data used 
in analy-
ses) 
Assessment 
of reproduci-
bility after 3 
and 12 
months 
NHS, 
2005 1 
1980 USA 78,778 wo-
men 
Female nurses. Excluded if: 
left>10 items blank on FFQ, 
implausible energy intake; 
history of angina, MI, stroke, 
other CV disease; cancer; 
high serum cholesterol or 
diabetes. 
34-59 y 20 y NA Median: 1.9 
E% 
Incident 
CHD 
[non-fatal 
MI + fatal 
CHD] 
Medical re-
cords, hospital 
records, autopsy 
or death certifi-
cate; WHO 
criteria. 
FFQ (1 y); 61 
food items in 
1980; 116 
food items in 
subsequent. 
Specific 
questions 
about type of 
margarine 
and type of 
fat used for 
cooking. 
6 (in 1980; 
1984, 
1986, 
1990, 
1994, 
1998) 
Validated for 
this study. 
TFA intake 
was corre-
lated to TFA 
in adipose 
tissue (r=0.5; 
n=115) 
SHS, 
2006 14 
 
 
 
 
 
 
1993-
95 
USA 2,938 men 
and women 
American Indians; Excluded 
if: prior MI or CHD, dialysis 
treatment,  kidney transplant 
or liver cirrhosis; improbable 
energy intake; age>79y 
47-79 y 7.2 y 21,101 Mean: 
2.4E% 
Incident 
CHD 
[fatal CHD 
+ first non-
fatal MI]  
& 
Fatal CHD
& 
Non-fatal 
CHD 
Medical re-
cords, fatal 
CHD confirmed 
by review 
committees.  
24-h dietary 
recall (1 d) 
1 (at base-
line)  
NA 
             (Continued) 
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Table 1 (continued) 
 
          
Study Base-
line 
year 
Coun-
try of 
origin
No of par-
ticipants at 
baseline 
Participant eligibility crite-
ria 
Age at 
baseline
Average 
duration 
of follow-
up 
Person 
years of 
follow-
up 
TFA intake Outcome Outcome asses-
sment method
Dietary 
assessment 
method 
No of 
dietary 
asses-
sments 
Validity of 
the dietary 
assessment 
method 
MONI-
CA, 
2008 6 
1974-
1993 
Den-
mark
3,686 (1837 
men) 
Excluded if:  previous diag-
nosis of CHD or diabetes; 
missing data for confound-
ers; implausible dietary 
assessment results. 
30-71 y 18 y NA Median R-
TFA: Men: 
1.8 g/d; 
Women 1.5 
g/d 
Incident 
CHD 
[Fatal + 
non-fatal 
CHD] 
Cause of Death 
Registry and 
National Patient 
Registry; Re-
view of medical 
files; ICD-8 
(codes 410-414) 
until ultimo 
1994; ICD-10 
(codes I20-I25) 
thereafter. 
7-d food 
record (94%) 
or dietary 
history inter-
view (1 m; 
6%) 
1 (at base-
line)  
The two 
methods have 
been vali-
dated against 
each other 
FMC 
(un-
publ.) 
1967-
72 
Fin-
land 
3738 (1956 
men and 1782 
women) 
Excluded if: CHD at baseline 40-69 y 15 y NA Mean: Men: 
2.6 g/d; 
Women: 1.9 
g/d 
Fatal CHD
[Fatal 
CHD + 
CHD 
events] 
Cause of Death 
Registry; ICD-8 
(codes 410-414)
Dietary his-
tory inter-
view, 
structured via 
100-item 
questionnaire
1 (base-
line) 
Assessment 
of short-term 
(4-8 m) and 
long-term (4-
7 y) repro-
ducibility 
IWHS 
(un-
publ.) 
1986 USA 32766 wo-
men 
Postmenopausal women. 
Excluded if: diabetes or 
CHD at baseline, improbable 
energy intake. 
55-69 y 21 y NA Median: 1.6 
E% 
Fatal CHD Cause of Death 
Registry;  ICD-
9 (codes 410-
414 or 429.2) 
 
FFQ with 127 
food items (1 
y) 
1 (base-
line) 
Validated 
against five 
24-h dietary 
recall sur-
veys, but not 
specifically 
for TFA.  
1 An updated analysis after 14 y follow-up with updated dietary data was published in a review in 2006. The principal investigator of the Health Professionals’ Follow-up Study could not 
provide us with more detailed information about this analysis. 2 Data were kindly provided by P. Knekt, A. Reunanen, R. Seppänen, R. Järvinen and A. Aromaa. 3 Data were kindly pro-
vided by K. Robien and S. Motzinger. Abbreviations: AT/BC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; E%, energy %; FFQ, food frequency questionnaire; FMC, the 
Finnish Mobile Clinic Health Examination Survey, HPFS, The Health Professionals' Follow-up Study; ICD, International Classification of Diseases; IP-TFA, industrially produced trans 
fatty acids; IWHS, the Iowa Womens’ Health Study; MI, myocardial infarction; MONICA, The 1914 cohort + The 1936 cohort + MONICA I and III; NA, not available; NHS, The 
Nurses' Health Study; R-TFA, ruminant trans fatty acids; SHS, The Strong Heart Study; ZES, The Zutphen Elderly Study.  
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Table 2: Relative risk estimates for the association of trans fatty acid (TFA) intake with risk of coronary heart disease (CHD) 
Study Outcome N, 
event 
N, total Sex, age Exposure RR 95%CI P for 
trend 
Comparison Comparison 
span 
Total CHD 356 69181 F IP-TFA 1 1.78 1.12 2.83 0.009 Q1 vs Q5 NA NHS, 1993 13 
Total CHD 356 69181 F R-TFA 1 0.59 0.3 1.17 0.23 Q1 vs Q5 NA 
Total CHD 734 43757 M Total-TFA 1 1.21 0.93 1.58 0.2 Q1 (1.5 g/d) vs Q5 (4.3 g/d) 2.8 g/d 
” ” ” ” ” 1.13 0.81 1.58 NA 2 E% increment 2 E% 
Fatal CHD 229 43757 M Total-TFA 1 1.41 0.86 2.32 0.42 Q1 (1.5 g/d) vs Q5 (4.3 g/d) 2.8 g/d 
HPFS, 1996 18 
” ” ” ” ”  0.93 0.52 1.69 NA 2 E% increment 2 E% 
HPFS, 2006 4 2 Total CHD 1702 38461 M Total-TFA 1.26 0.99 1.61 NA 2 E% increment 2 E% 
Total CHD 1399 21930 M Total-TFA 1 1.14 0.96 1.35 0.16 Q1 (1.3 g/d ) vs Q5 (5.6 g/d)  4.3 g/d 
Fatal CHD 635 21930 M Total-TFA 1 1.43 1.12 1.84 0.004 Q1 (0.6 E%) vs Q5 (2.0 E%) 1.4 E% 
Fatal CHD 635 21930 M IP-TFA 1 1.23 0.97 1.55 0.004 Q1 (0.1 g/d ) vs Q5 (5.1) 5.0 g/d 
AT/BC, 1997 3 
Fatal CHD 635 21930 M R-TFA 1 0.83 0.62 1.11 0.035 Q1 (0.6 g/d ) vs Q5 (2.5) 1.9 g/d 
Total CHD 98 667 M Total-TFA 1 2.00 1.07 3.75 0.03 T1 (2.4 E%) vs T3 (6.4 E%) 4 E% 
” ” ” ” ” 1.28 1.01 1.61 NA 2 E% increment 2 E% 
Total CHD 98 667 M IP-TFA (C18:1) 1.05 0.94 1.17 NA 0.5 E% increment 0.5 E% 
Total CHD 98 667 M IP-TFA (other) 1.07 0.99 1.15 NA 0.5 E% increment 0.5 E% 
Total CHD  98 667 M IP-TFA (All) 1,3 1.06 1.0 1.13 NA 0.5 E% increment 0.5 E% 
Total CHD 98 667 M R-TFA 1 1.17 0.69 1.98 NA 0.5 E% increment 0.5 E% 
Fatal CHD 49 667 M Total-TFA 1.33 0.96 1.86 NA 2 E% increment 2 E% 
ZES, 2001 2 
Fatal CHD  49 667 M Total-TFA 1, 4 1.77 0.91 3.45 NA T1 (2.4 E%) vs T3 (6.4 E%) 4 E% 
Total CHD 1766 78778 F Total-TFA 1.33 1.07 1.66 0.01 Q1 (1.3 E%) vs Q5 (2.8 E%) 1.5 E% 
Total CHD 1111 NA F, < 65 y Total-TFA 1 1.5 1.13 2 0.01 Q1 vs Q5 NA 
NHS, 2005 1 
 
Total CHD 655 NA F, > 65 y Total-TFA 1 1.15 0.8 1.66 0.49 Q1 vs Q5 NA 
Total CHD 436 2938 F+M Total-TFA 1 1.06 0.78 1.44 0.88 Q1 (0.9 E%) vs Q4 (3.9 E%) 3.0 E% 
Fatal CHD 46 1659 F+M, 47-59 y Total-TFA 1 1.15 0.49 2.68 0.66 Q1 (0.9 E%) vs Q4 (4.0 E%) 3.1 E% 
” ” ” ” ” 1.73 0.57 5.25 NA 5 E% increment 5 E% 
Fatal CHD 92 1279 F+M, 60-79 y Total-TFA 1 0.83 0.42 1.66 0.54 Q1 (1.0 E%) vs Q4 (3.9 E%) 2.9 E% 
” ” ” ” ” 1.34 0.48 2.46 NA 5 E% increment 5 E% 
SHS, 2006 14 
 
 
 
 
Non-fatal CHD 298 2938 F+M Total-TFA 1.21 0.85 1.74 0.41 Q1 (0.9 E%) vs Q4 (3.9 E%) 3.0 E% 
           (Continued) 
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Table 2 (continued)          
Study Outcome N, 
event 
N, total Sex, age Exposure RR 95%CI P for 
trend 
Comparison Comparison 
span 
Total CHD 374 3686 F+ M R-TFA 1.05 0.92 1.19 NA 0.5 g/d increment 0.5 g/d 
Total CHD 253 1837 M R-TFA 1 1.05 0.94 1.17 NA 0.5 g/d increment 0.5 g/d 
MONICA, 2008 6 
Total CHD 121 1849 F R-TFA 1 0.77 0.55 1.09 NA 0.5 g/d increment 0.5 g/d 
FMC (unpubl.) 5 Fatal CHD 216 1956 M Total-TFA 1 0.73 0.35 1.54 NA Q1 vs Q5  NA 
 Fatal CHD 72 1782 F Total-TFA 1 0.94 0.26 3.40 NA Q1 vs Q5  NA 
IWHS (unpubl.) 6 Fatal CHD 1875 32766 F Total-TFA 1 1.15 0.92 1.43 0.31 Q1 (1.0 E%) vs Q4 (2.5 E%) 1.5 E% 
1 Data included in meta-analysis (Figure 2). 2 These data are from a review providing an updated analysis of data from the Health Professionals’ Follow-up Study after 14 y follow-up 
with updated dietary data. The principal investigator of the study could not accommodate our request for an updated analysis comparing extreme quintiles of intake. 3 Pooled RR calcu-
lated from RRs for IP-TFA (C18:1) and IP-TFA(other). 4 RR calculated based on RR for 2E% increments and intake levels in extreme quintiles. 5 Data were kindly provided by P. 
Knekt, A. Reunanen, R. Seppänen, R. Järvinen and A. Aromaa.  6 Data were kindly provided by K. Robien and S. Motzinger. Abbreviations: AT/BC, Alpha-Tocopherol, Beta-Carotene 
Cancer Prevention Study; F, females; E%, energy %; FMC, the Finnish Mobile Clinic Health Examination Survey, HPFS, The Health Professionals' Follow-up Study; IP-TFA, indus-
trially produced trans fatty acids; IWHS, the Iowa Womens’ Health Study; M, males; MONICA, The 1914 cohort + The 1936 cohort + MONICA I and III; NA, not available; NHS, 
The Nurses' Health Study; R-TFA, ruminant trans fatty acids; SHS, The Strong Heart Study; ZES, The Zutphen Elderly Study.  
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Table 3: Confounders adjusted for in the included studies 
Study 
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NHS, 1993 13 •   •   •   • • 1 •  1   •  •   •  • 1  •  •  •  13 
HPFS, 1996 18 •   •   • • •  •  •  •           •  •     Profession 11 
AT/BC, 1997 3 •  • •  •     • 2 •  •   2     2   •  •     Treatment.group 10 
ZES, 2001 2 •   •       • • •  •     •  • •     •    •  11 
NHS, 2005 1 •   •   •  •  • • •  •  •  • • • • • • • •  • • • • •  22 
SHS, 2006 14 • •  • •     • •  •        •      • •     Study center 11 
MONICA, 2008 6 3 •   • •   • •       • • •   • •       • • • •     • • •         Cohort ID 18 
FMC (unpubl.) 4 • • • •                •  • •     •      8 
IWHS (unpubl.) 5 •   •  •     • • •  •    • • • • •   •  •  •    15 
1 There was no adjustments for physical activity or fiber and cholesterol intake in the extracted sub-analyses of R-TFA and IP-TFA intake. However these covariates did not change the 
estimates in analysis of total-TFA in the whole cohort. 2 Further adjustments for intake of cholesterol, linoleic acid and SFA did not materially change the estimates. 3 A confounder was 
included if it changed the beta-coefficient for the R-TFA variable 10% or more. 4 Data were kindly provided by P. Knekt, A. Reunanen, R. Seppänen, R. Järvinen and A. Aromaa. 5 Data 
were kindly provided by K. Robien and S. Motzinger. Abbreviations: AT/BC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; FMC, the Finnish Mobile Clinic Health Ex-
amination Survey, HPFS, The Health Professionals' Follow-up Study; IP-TFA, industrially produced trans fatty acids; IWHS, the Iowa Womens’ Health Study; MONICA, The 1914 
cohort + The 1936 cohort + MONICA I and III; NHS, The Nurses' Health Study; R-TFA, ruminant trans fatty acids; SHS, The Strong Heart Study; ZES, The Zutphen Elderly Study.  
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The study design characteristics of the nine studies are presented in Table 1. Seven studies 
evaluated the association of total-TFA intake with fatal- and/or total CHD1-3,14,18(+IWHS and 
FMC, unpublished); four examined the association of R-TFA with fatal- or total CHD2,3,6,13 and 
three considered the association of IP-TFA with fatal- or total CHD2,3,13. The studies included 
from 667 to 78,778 participants who were followed for periods ranging from 6 to 21 years. 
Three studies included only men, two studied only women and three studies both men and 
women. The published studies’ quality was given a rating of 6 to 8 (out of 9) when assessed by 
the Newcastle-Ottawa Scale [Supplemental Table 1]. Different methods for assessing dietary 
TFA were applied in the included studies: five used validated FFQs, one used 7-d weighed food 
records, two used the dietary history method, and one study used single 24-h recalls. Only one 
study performed repeated dietary assessments1. The risk estimates for the most fully adjusted 
analysis for the individual studies are presented in Table 2, and the covariates adjusted for in 
Table 3. The number of covariates ranged from 10 to 22. 
We pooled the individual studies’ risk estimates for comparison of extreme quintiles of total-
TFA intake (Figure 2A) and found that total-TFA intake was associated with an increased risk 
of CHD events of 22% (RR = 1.22; 95% confidence interval (CI): 1.08 - 1.38; P = 0.002) and an 
almost similar risk of fatal CHD (RR = 1.24; CI: 1.07 - 1.43; P = 0.003).  The risk estimates for 
the individual studies corresponded to variable intake spans of total-TFA ranging from 2.8 g/d 
to 4 E% (or ~10 g/d), as shown in Table 2. Yet, there was no indication of heterogeneity be-
tween the studies; the I2 value was below 15% for both analyses. When omitting the two unpub-
lished studies, the risk estimate for fatal CHD changed to RR = 1.37 (CI: 1.13 - 1.68; P = 
0.002), and when omitting the study that included subjects diagnosed with diabetes at baseline14, 
the effect estimates increased modestly to 1.25 (CI: 1.09 - 1.45; P = 0.002) and 1.26 (CI: 1.09 - 
1.47; P = 0.003) for total and fatal CHD, respectively.  
There was no significant association between R-TFA intake and risk of CHD events when pool-
ing all available estimates for risk associated with increasing R-TFA intake (one study com-
pared extreme quintiles of intake13, and two studies reported estimates for increments of 0.5 g/d6 
or 0.5 E%2) (RR = 0.93; CI: 0.74 - 1.18; P = 0.56; Figure 2B). Inclusion of one study evaluating 
the risk of fatal CHD (comparing intake quintiles3) did not change this estimate (RR = 0.92; CI: 
0.76 - 1.11; P = 0.36). The test for heterogeneity was not significant and the risk estimates for 
the individual studies corresponded to in R-TFA intake increments ranging from 0.5 to 1.9 g/d 
[Table 2]. 
Only three studies assessed the CHD risk associated with intake of IP-TFA. The pooled effect 
estimate suggested that IP-TFA intake increases the risk of CHD, although this association did 
not reach statistical significance (RR = 1.21; CI: 0.97 - 1.50; P = 0.09; Figure 2C). There was 
an indication of heterogeneity between the studies in this analysis (I2 = 66%; P = 0.05), which 
was reduced when omitting the study of women only (I2 = 29%; P = 0.23) whereby also the 
effect estimate changed (RR = 1.09; CI: 0.98 - 1.22; P = 0.12). The risk estimates for the indi-
vidual studies corresponded to IP-TFA intake increments ranging from ~1.3 g/d (0.5 E%) to 5.0 
g/d [Table 2]. 
To address whether one single study carried most of the effect, we examined the influence of an 
individual study on the pooled RR estimate by excluding each study in turn. When the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study (AT/BC) was omitted from the pooled 
analysis of the risk of fatal CHD associated with intake of total-TFA, the risk estimate decreased 
and was no longer significant, RR = 1.16 (CI: 0.97 - 1.38; P = 0.10). No other study had sub-
stantial influence on the pooled estimates.  
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Figure 2: Risk ratios and 95% confidence intervals for fully adjusted random-effects models examining 
the associations of intake of trans fatty acids from any source (T-TFA) with total coronary heart disease 
(CHD) events and fatal CHD (Figure 2A); for studies examining the associations of intake of ruminant 
trans fatty acids (R-TFA) with total CHD events and fatal CHD (Figure 2B) and  for studies examining 
the associations of intake of industrially produced trans fatty acids (IP-TFA) with total CHD events and 
fatal CHD (Figure 2C). Abbreviations: AT/BC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
Study3; FMC, the Finnish Mobile Clinic Health Examination Survey, HPFS, The Health Professionals' 
Follow-up Study18; IWHS, the Iowa Womens’ Health Study; MONICA, The 1914 cohort + The 1936 
cohort + MONICA I and III6; NHS, The Nurses' Health Study1,13; SHS, The Strong Heart Study14; ZES, 
The Zutphen Elderly Study2.  
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When restricting the analysis to studies assessing TFA intake by means of validated FFQs or 
food records, the effect estimate for the association of total-TFA intake with CHD events or 
fatal CHD did not change considerably (RR = 1.21; CI: 1.07 - 1.37; P = 0.002 and RR = 1.28; 
CI: 1.09 - 1.49; P=0.002 for total and fatal CHD, respectively), neither did the association of R-
TFA with CHD (RR = 0.88; CI: 0.71 - 1.09; P = 0.25). Due to the limited number of identified 
studies, the relatively low degree of heterogeneity and the fact that the studies were rated almost 
equally by means of the New-Castle-Ottawa Scale, we did not find the data suitable for further 
sensitivity analysis.  
 
DISCUSSION 
The present systematic review addresses the question of whether we in year 2010 have enough 
available evidence from prospective cohort studies to evaluate if intake of IP-TFA and R-TFA, 
respectively, affects the risk of CHD. Our comprehensive literature search of published and 
unpublished results identified limited new data, whereby data from a total of only eight prospec-
tive cohort studies could be pooled.  
In accordance with a previous analysis19, we found that total-TFA intake is associated with an 
increased risk of fatal and total CHD of more than 20% when comparing extreme quintiles of 
intake. Inclusion of unpublished data from two cohort studies resulted in a slightly lower risk 
estimate of fatal CHD (RR = 1.24), compared to that found previously (RR = 1.32)19. We did 
not calculate a risk estimate for CHD events associated with incremental TFA intake, since our 
literature search did not identify new data that would complement recent meta-analyses estimat-
ing that an increased TFA intake of 2 E% is associated with an RR of CHD events of 1.23 (CI: 
1.11 - 1.37) based on data from NHS, AT/BC, the Health Professionals’ Follow-up Study 
(HPFS) and the Zutphen Elderly Study (ZES)4,19.  
Our pooled analyses of the risk associated with R-TFA and IP-TFA intake, respectively, were 
compromised by a very limited number of available studies, which indeed prohibits any firm 
conclusions about whether the source of TFA is important. The pooled estimates suggested that 
while dietary IP-TFA increases the risk of CHD, R-TFA intake doses not. Two studies showed 
strong positive association of total-TFA with CHD: the ZES which included elderly men with a 
very high TFA intake2 and the NHS1. Whereas the association could be ascribed to IP-TFA 
intake in the NHS, the ZES did not indicate that R-TFA is less harmful than IP-TFA. 
The validity of any meta-analysis highly depends on the quality of the included studies.  Both 
the quality of the dietary assessment and the confounders adjusted for in the statistical analysis 
are central features. The lack of an effect in the Strong Heart Study (SHS)14 and the FMC (un-
published) could be due to the fact that blood lipids were adjusted for in the analyses from these 
studies. It is indeed problematic when potential metabolic effects of TFA intake are adjusted for, 
as the effects of intake of TFA on risk of CHD may be mediated through the effect of these 
intermediate factors. In the study by Ascherio et al.18, fiber intake was shown to be an important 
confounder eliminating an otherwise positive association between TFA intake and CHD. There-
fore it is positive that all studies but the FMC and the SHS14 took this dietary factor into ac-
count. Whereas all studies adjusted for smoking, age, body mass index and intake of energy and 
alcohol, only five of the included studies adjusted for other subclasses of dietary fat1,2,6(+IWHS 
and FMC, unpublished).  
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Of the included studies, the Nurses’ Health Study had the most powerful design with repeated 
dietary assessments using a FFQ which specifically addressed the type and brand of margarine 
and a continuously updated food composition database specifically constructed for assessment 
of TFA composition of foods20. In contrast, the validity of single 24-h recalls to estimate usual 
intakes of TFA is questionable and may explain why no association of TFA intake with CHD 
was found in the SHS14.  
In epidemiological studies, the assessment of intake of TFA is potentially affected by substantial 
random measurement error due to a number of factors such as i) participant recall bias; ii) insuf-
ficiently updated values in food composition tables and iii) substantial changes in the TFA con-
tent of foods over time21. During the 1960s margarine became viewed as the healthy alternative 
to butter because it was lower in SFA20 and many food manufacturers and restaurants replaced 
tallow and lard with TFA based products. However, during the 1990s the food industry in many 
countries made efforts to reduce the TFA content of margarines and shortenings and in recent 
years a drastic decline in the industrial TFA content of most foods in Western countries has 
been reported22. These changes can only be accounted for by performing repeated assessment of 
dietary intake.  
Also, a problem of confounding by indication may arise in dietary surveys, and this is difficult 
to correct for: A subject with symptoms of CHD or family history of MI may be more aware of 
consuming a healthy diet, which in the 1970s meant replacing butter with margarine. Thereby 
subjects at higher risk may have increased their margarine and with this their IP-TFA consump-
tion while reducing their butter, and R-TFA, consumption.  
Considering the difficulties in assessing TFA intake and the fact that very few prospective co-
hort studies have investigated the association between R-TFA or IP-TFA intake and CHD, data 
from other types of studies may add important evidence. The results from a case-control study 
by Ascherio et al.23 are in support of the results from the pooled analyses of cohort studies by 
indicating that IP-TFA was associated with increased risk, but only at intake levels above 3.3 
g/d, whereas R-TFA was neutral (when comparing intakes up to 1.8 g/d).  
Whereas IP-TFA intake has consistently been shown to adversely affect risk markers for CHD 
in controlled trials4, very few intervention studies have examined the effect of R-TFA on car-
diovascular risk markers. One study showed that when men consumed R-TFA in high amounts 
(3.7 E% or 10.2 g/d), the effect on blood lipids was comparable to the effects of IP-TFA by 
increasing the low-density lipoprotein cholesterol (LDL-C) and decreasing the high-density 
lipoprotein cholesterol (HDL-C) concentrations in plasma. However, when R-TFA was con-
sumed in moderate amounts (1.5E% or 4.2 g/d) the effect on blood lipids was not significantly 
different from that of a control diet with low TFA content (0.8 E% or 2.2 g/d from any 
source)24. Recently, an intervention study also found no difference in the effect of IP-TFA and 
R-TFA on blood lipids or insulin sensitivity at low intake levels (5 g/d) in overweight women25. 
A third intervention study suggested that R-TFA intake could affect women and men differ-
ently. Among women, total cholesterol, HDL-C and LDL-C were higher after intake of 5 E% 
(~11-12 g/d) R-TFA compared to equivalent intakes of IP-TFA, whereas only minor differences 
were observed in men26. In accordance no significant difference between the effects of TFA 
from the two sources (P=0.37) on the LDL- to HDL-C ratio was found in the quantitative re-
view by Brouwer et al.27 who compiled the evidence from 29 and 6 treatments with IP-TFA and 
R-TFA intake, respectively.  
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In summary, the observational evidence suggests that in contrast to dietary IP-TFA, R-TFA 
intake does not affect the risk of CHD or may even be slightly protective. However, this could 
be ascribed to the fact that R-TFA generally is consumed i) in much lower quantities than IP-
TFA, and ii) together with dairy products, which may be heart protective28.  Alternatively, the 
weak tendency for a risk reduction seen with R-TFA, may relate to the fact that vaccenic acid 
may be converted endogenously to the conjugated linoleic acid isomer cis9, trans11-18:229, the 
adipose tissue content of which has been shown to be inversely associated with MI risk30.  
Denmark introduced legislation, effective from 1 January 2004, restricting the use of TFA to a 
maximum of 2% in oils and fats destined for human consumption. R-TFA were excluded from 
this legislation. The results of this systematic review support the notion that TFA intake is det-
rimental to the heart. However, the limited number of available studies prohibits any firm con-
clusions concerning whether the source of TFA is important. Any legislative discrimination 
between TFA from the two sources must therefore be the result of a pragmatic decision based 
on: i) the low risk of achieving high daily intakes of R-TFA when consuming normal foods vs. 
the risk of consuming considerable amount of IP-TFA with high intakes of certain food products 
such as fast food and snacks (or with hydrogenated vegetable oil in non-Western countries31); ii) 
the difficulties in removing R-TFA from natural food sources vs. the achievable elimination of 
IP-TFA from most foods32; and iii) the belief that R-TFA-containing foods are often otherwise 
healthy, whereby the consumption of these should not be restricted vs. the notion that IP-TFA 
are nutritionally unnecessary.  
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Supplemental Appendix A: Search Strategy 
For searches in MEDLINE and EMBASE the following search strategy was be applied: 1) trans 
fatty acid*; 2) elaidic acid; 3) vaccenic acid*; 4) ruminant fat*; 5) animal fat*; 6) hydrogenated 
fat*; 7) hydrogenated oil*  (1-7 all as free text, and where applicable as exploded MESH/Key 
Words); 8) 1 or 2 or 3 or 4 or 5 or 6 or 7; 9) myocardial infarction; 10) cardiovascular disease; 
11) Sudden death; 12) Ischemic heart disease; 13) Coronary heart diseas* (9-13 as free text and 
where applicable as exploded MESH/Key Words); 14) 9 or 10 or 11 or 12 or 13; 15) 8 and 14. 
A similar search strategy was applied for Food Science and Technology Abstracts (FSTA), with 
use of Key Words where applicable. In Web of Science we searched for the following terms 
(trans fatty acid* or elaidic acid or vaccenic acid* or ruminant fat* or animal fat* or hydrogen-
ated oil* or hydrogenated fat*) AND (myocardial infarction* or cardiovascular diseas* or vas-
cular diseas* or ischemic heart diseas* or sudden death). In SciFinder Scholar we searched for 
relevant references by using the phrase “trans fatty acids and cardiovascular disease”. The 
search was refined by specifying the document type (Book, Clinical trial, Conference, Disserta-
tion and Journal) and by using the phrase “human not animal”. 
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Supplemental Table 1: Assessment of risk of bias in published prospective cohort studies according to the New-Castle/Ottawa Scale.  
  
NHS, 
1993 13 
HPFS, 
1996 18 
AT/BC,  
1997 3 
ZES, 
2001 2 
NHS, 
2005 1 
SHS, 
2006 14 
MONICA, 
2008 6 
Selection  [one mark in each section]        
1. Representativeness of the intervention cohort         
a) truly representative of the average free-living adult subject *    *   * 
b) somewhat representative of the average free-living adult subject *        
c) selected group of subjects √ (Nurses) √ (Health 
profs) 
√ (Male 
smokers) 
 √ (Nurses) √ (American 
Indians) 
 
d) no description of the derivation of the cohort        
2. Selection of the non intervention cohort        
a) drawn from the same community as the intervention cohort   * * * * * * * * 
b) drawn from a different source        
c) no description of the derivation of the non intervention cohort        
3. Ascertainment of intervention          
a) secure record (diet records) *       * 1 
b) structured interview  (validated FFQ) * * * *  *   
c) written self report (non-validated FFQ)        
d) other / no description (e.g. diet history / 24-hour recall)    √  √  
4. Demonstration that outcome of interest was not present at start of study          
a) yes  * * * * * * * * 
b) no           
Comparability  [one or two marks as appropriate]        
1. Comparability of cohorts on the basis of the analysis        
a) study controls for age, sex, BMI, energy intake * * * * * * * * 
b) study controls for Intake of SFA, MUFA, PUFA, fiber  * * 1   * *  * 
       (Continued) 
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Supplemental Table 1 (continued)        
  
NHS, 
1993 13 
HPFS, 
1996 18 
AT/BC,  
1997 3 
ZES, 
2001 2 
NHS, 
2005 1 
SHS, 
2006 14 
MONICA, 
2008 6 
Outcome [one mark in each section]        
1. Assessment of outcome        
a) independent blind assessment  (e.g. link to health records) * * * * * * * * 
b) record linkage (e.g. ICD codes on database records) *        
c) self report        
d) other / no description        
2. Was follow up long enough for outcomes to occur          
a) yes, if median duration of follow-up >= 6 years * * * * * * * * 
b) no, if median duration of follow-up < 6 years        
3. Adequacy of follow up of cohorts          
a) complete follow up: all subjects accounted for  *        
b) subjects lost to follow up unlikely to introduce bias  
( number lost <= 20%,  or description of those lost suggesting no differ-
ent from those followed) * 
* (98% on 
deaths) 
* 2  *  * (99.8% on 
deaths) 
 
c) follow up rate < 80%  and no description of those lost        
d) no statement   √  √  √ 
Total no of stars 8 7 6 8 7 6 8 
1 (in 94% of subjects). 2 94% of subjects returned questionnaire in each two year follow-up cycle. Abbreviations: AT/BC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; 
FMC, the Finnish Mobile Clinic Health Examination Survey, HPFS, The Health Professionals' Follow-up Study; IWHS, the Iowa Womens’ Health Study; MONICA, The 1914 cohort + 
The 1936 cohort + MONICA I and III; NHS, The Nurses' Health Study; SHS, The Strong Heart Study; ZES, The Zutphen Elderly Study.  
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ABSTRACT 
Background: Intake of industrially produced trans fatty acids (TFA) is, according to observational 
studies, associated with an increased risk of cardiovascular disease, but the causal mechanisms have 
not been fully elucidated. Besides inducing dyslipidemia, TFA intake is suspected of promoting ab-
dominal and liver fat deposition. 
Objective: We examined the effect of a high intake of TFA as part of an isocaloric diet on whole-
body, abdominal and hepatic fat deposition and blood lipids in postmenopausal women.  
Methods: In a 16-wk double-blind parallel intervention study, 52 healthy overweight postmenopausal 
women were randomized to receive either partially hydrogenated soybean oil providing 15.7 g/d of 
TFA or a control oil with mainly oleic and palmitic acid. Before and after the intervention, body com-
position was assessed by dual-energy x-ray absorptiometry, abdominal fat by magnetic resonance 
(MR) imaging, and liver fat by 1H MR spectroscopy.  
Results: Compared to the control fat, TFA intake decreased plasma HDL-cholesterol by 10%, in-
creased LDL-cholesterol by 18%, and resulted in an increased LDL/HDL-cholesterol ratio [baseline 
adjusted mean (95%CI) difference between diet groups 0.41 (0.22; 0.60); P<0.001]. TFA tended to 
increase body fat [0.46 (-0.20; 1.17) kg; P = 0.16] and waist circumference [1.1 (-0.1; 2.4) cm; 
P=0.08] more than the control fat, whereas neither abdominal nor liver fat deposition was affected by 
TFA.  
Conclusion: The adverse effect of dietary TFA on cardiovascular disease risk involve induction of 
dyslipidemia, and perhaps body fat, whereas weight gain-independent accumulation of ectopic fat 
could not be identified as a contributory factor during short-term intake. 
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INTRODUCTION 
A high intake of industrially produced trans fatty acids (TFA) has in observational studies con-
sistently been shown to be associated to an increased risk of coronary heart disease (CHD). In a 
meta-analysis of four prospective cohort studies it was estimated that that an isocaloric substitu-
tion of two percent of the total energy intake (E%) of carbohydrates with TFA corresponds to a 
23% increase in the risk of cardiovascular events1. 
It has been well established that TFA increase the ratio of total cholesterol (TC) to HDL-
cholesterol (HDL-C) in the blood. A recent meta-analysis estimated that an absolute increase of 
two E% in the intake of TFA is associated with an increase in the TC/HDL-C ratio of ~0.1 unit, 
when replacing cis monounsaturated fatty acids (MUFA)2. An increase of this size is estimated 
to increase the risk of CHD by ~5%3, suggesting that TFA exert harmful effects beyond those 
affecting cholesterol concentrations. Even when taking into account the possible unfavorable 
effects of TFA on lipoprotein (a), triglycerides, apolipoprotein (Apo) B/ApoAI ratio and C-
reactive protein a considerable explanatory gap persists2. We hypothesize that this gap might be 
partly explained by adverse effects of TFA on body fat deposition.  
Abdominal fat deposition is an established risk factor for cardiovascular disease and emerging 
evidence suggests that liver fat should be considered one as well4. TFA intake was positively 
associated with a modest increase in waist circumference during nine years of follow-up in the 
Health Professional’s Follow-up Study, even after adjustment for body mass index (BMI)5, and 
with weight change during 8 years of follow-up in the Nurses’ Health Study6.  Moreover, a re-
cent intervention study in non-human primates suggested that TFA might stimulate intra-
abdominal fat deposition irrespective of weight gain when consumed in considerable amounts 
over a long period of time7, and rodent studies have shown that a high TFA intake may lead to 
increased deposition of fat in the liver8,9. In humans, it has yet to be examined whether TFA 
intake affects abdominal or liver fat deposition.  
We conducted a long-term dietary intervention study with the objective to examine the effect of 
a high intake of industrially produced TFA on lipid deposition in liver and in the abdominal 
region in TFA-depleted overweight postmenopausal women. Also, we wanted to confirm previ-
ous findings of the effect of TFA on blood lipids. 
 
SUBJECTS AND METHODS 
The present work examined the effect of a high intake of TFA from partially hydrogenated soy-
bean oil on risk markers for cardiovascular disease, with the primary endpoints being LDL-
cholesterol (LDL-C)/HDL-C ratio and liver fat deposition. 
Study design 
We conducted a 16-wk double-blind, parallel dietary intervention study, where 52 women were 
randomized to two test diets stratified by waist circumference. The cut-off waist circumference 
was set at 96 cm for separation into strata. For each stratum a randomization sequence with 
random permuted blocks of four was computer generated by a third party prior to initiating the 
randomization. A coding list was given to the department’s kitchen staff. The investigators 
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responsible for seeing the study subjects allocated the next available number on entry into the 
trial, and each woman collected her experimental diet directly from the kitchen. Thereby the 
code was kept undisclosed for the investigators until after study completion.  
All study personnel and participants were blinded to the treatment assignment for the duration 
of the study. Information about which diet was assigned to which group was not disclosed to the 
researcher responsible for the statistical analyses before completion of the analyses.   
The women visited the department for 4 examinations during the study; at screening (1-8 weeks 
prior to baseline), baseline (wk 0), mid-intervention (wk 8), and at end of treatment (wk 16). In 
addition, the subjects attended the department for control weighing at wk 4 and wk 12. The ha-
bitual activity level during the last year was assessed at baseline using the questionnaire by 
Baecke et al.10 and subjects were instructed to maintain their habitual activity level throughout 
the dietary intervention period. Subsequent to the dietary intervention period the subjects par-
ticipated in a 12-wk dietary weight loss program after which they came in for follow-up exami-
nations. Data from these examinations will be reported elsewhere.  
Subjects attended all visits after an overnight fast of at least 10h. The subjects were requested to 
avoid vigorous exercise and alcohol consumption on the day before and on the day of examina-
tions at wk 0, 8 and 16. Also, subjects were instructed to consume similar evening meals on the 
evening before each of the visits at wk 0 and 16. 
Subjects 
The participating women were recruited from Copenhagen and the surrounding areas by adver-
tisements posted on university web pages and in the local media. Subject inclusion criteria were: 
healthy; moderately overweight (BMI between 25 and 32 kg/m2); waist circumference > 80 cm; 
postmenopausal (self reported) for the last 12 months; and aged 45-70 y, extremes included. The 
exclusion criteria were diabetes or other chronic diseases (active cancer, psychiatric disorders, 
moderate to severe rheumatologic disorders, active gastrointestinal disorders, chronic lung dis-
ease); history of cardiovascular disease; smoking (current and within six months prior to screen-
ing); hypertension (>160/100 mmHg); fasting plasma triglycerides >3 mmol/L; fasting plasma 
LDL-C >6 mmol/L; fasting plasma glucose >7 mmol/L; use of hormones or anti-hypertensive, 
anti-lipidemic or anti-cholesterolemic drugs; weight changes >3 kg for two months prior to 
screening; participation in strenuous physical activity >10 h/week; and abnormalities in routine 
biochemical and haematological tests. The subjects were not allowed to donate blood during the 
study and three months prior to screening or to use fish oil as dietary supplements during the 
study and one month prior to commencement.  
To assess how adversely the metabolism of the intervention group was affected by their elevated 
weight, the study included 19 lean reference subjects (BMI = 19-24 kg/m2; waist circumference 
≤ 80 cm), who underwent baseline examinations only. These reference subjects fulfilled all 
other inclusion and exclusion criteria as the intervention subjects.  
The subjects were given both verbal and written information, whereupon all gave written con-
sent. The study was carried out at the Department of Human Nutrition, Faculty of Life Sciences, 
University of Copenhagen, Frederiksberg, Denmark, between April 2008 and March 2009 and 
was approved by the Municipal Ethical Committee of The Capital Region of Denmark in accor-
dance with the Helsinki-II declaration (H-B_2007-089). Subjects received ~900 US$ as com-
pensation on completion of all the tests. Lean reference subjects received ~500 US$. The trial 
was registered at clinicaltrials.gov as NCT00655902. 
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Study diets 
In this study, the physiological effect of consuming 15.7 g/d of industrially produced TFA from 
26 g/d partially hydrogenated soybean oil was assessed and a 50/50% mix of palm oil and high 
oleic sunflower oil was used as the control. Both test fats were supplied by AarhusKarlshamn, 
Denmark. The fatty acid (FA) composition of the two test fats was analyzed chemically as 
described below for red blood cell FA composition. The two fats mainly differed in the content 
of TFA, palmitic (16:0), oleic (cis18:1n-9) and linoleic acid (cis,cis18:2n-6) (Table 1). The test 
fats were incorporated into carrot bread rolls, baked in the department’s metabolic kitchen by 
experienced kitchen staff. The study participants were instructed to consume two bread rolls per 
day providing 26 g/d of test fat and a total of 2500 kJ (approximately 7 E% protein, 41 E% fat 
and 51 E% carbohydrate, calculated using the Dankost 3000® dietary assessment software (Da-
nish Catering Center, Herlev, Denmark)). Frozen rolls were handed out to the women every 1-4 
weeks from the department for consumption at home.  
The intervention was not intended to pro-
mote weight gain; hence a clinical dieti-
cian instructed the participants how to let 
the bread rolls iso-calorically substitute 
food items from their habitual diets. The 
subjects were weighed every 4 weeks 
during the dietary intervention. They were 
offered an additional dietary session if 
their weight increased more than 2 kg 
from baseline; three subjects from the 
TFA group and two from the control 
(CTR) group accepted the offer.  
Compliance 
At baseline, the study subjects were 
handed a diary in which they were to re-
port whether or not both test rolls were 
consumed each day. Also, they were to 
weigh back and report amounts not eaten. 
As an objective compliance measure the 
incorporation of FA into phospholipids of 
red blood cells (RBC) was assessed at wk 
0, 8, and 16. For determination of FA 
composition, saline washed RBCs were 
spiked with tri-heptadecenoylglyceride, solubilized in 9:1 methanol/toluene, and centrifuged. 
Fatty acid methyl esters in supernatant aliquots were prepared by sequential treatment with an-
hydrous methanolic sodium methoxide and methanolic hydrochloric acid11.  Fatty acid methyl 
esters were back extracted into hexane, enriched with methyl tricosanoate (23:0) as an internal 
standard, and quantified by gas chromatography (GC) on high polarity cyano-silica columns and 
a flame ionization detector (FID) (see also Supplemental Method Description). 
Due to co-chromatography of interference with variable relative retention times on the two 
chromatographic systems used during this study, an accurate quantitative assessment of TFA 
Fatty acid (w/w%) Control fat 
TFA 
fat 
C14:0 0.7 0.2 
C16:0 26.7 12.7 
C16:1-trans (n-7) 1 < 0.1 < 0.1 
C16:1-cis (n-7) < 0.1 < 0.1 
C17:0 < 0.1 0.1 
C18:0 3.8 6.2 
Total C18:1-trans < 0.7 59.0 
trans (n-12) / trans (n-11) / trans (n-10) < 0.1 9.6 
trans (n-9) < 0.1 12.7 
trans (n-8) < 0.1 12.7 
trans (n-7) < 0.1 10.7 
trans (n-6) < 0.1 7.8 
trans (n-5) < 0.1 3.9 
trans (n-4)  < 0.1 1.6 
Total C18:1-cis 61.4 19.6 
cis (n-12) / cis (n-11) / cis (n-10) < 0.1 2.9 
cis (n-9) 60.2 6.8 
cis (n-8) < 0.1 3.2 
cis (n-7) 0.6 3.4 
cis (n-6) 0.6 3.2 
C18:2-trans, trans (n-6) < 0.1 1.4 
C18:2-cis, cis (n-6) 6.6 0.2 
C20:0 0.4 0.4 
C22:0 0.4 0.3 
Total trans fatty acids < 0.7 60.4 
Table 1: Fatty acid composition of the two test fats
1 Positions of double bonds are counted from the methyl end of 
the fatty acid. 
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concentrations could unfortunately not be made.  However, a qualitative ranking of the presence 
and abundance of the TFA profile relative to cis18:1n-7 was possible (Supplemental Figure 1).  
Dietary intake 
The dietary intake was assessed by 3-day weighed food records before the intervention and in 
the last week of the intervention. The records were coded, and the energy intake and macronu-
trient composition were calculated by using a national food database (National Food Agency, 
Søborg, Denmark12) with the Dankost 3000® dietary assessment software (Danish Catering 
Center, Herlev, Denmark).  
Anthropometrics and blood pressure 
Body weight and waist and hip circumference were measured at all visits. Body weight was 
measured in kilograms with one decimal by a Lindeltronic 8000 scale (Sweden). Height was 
assessed at screening to the nearest 0.5 cm using a Seca stadiometer (Hultafors, Sweden). Waist 
circumference was measured at the midpoint between the lower part of the last rib and the top of 
the hip, and hip circumference at the maximal width over the greater trochanters, using a non-
extendable linen tape measure to the nearest 0.5 cm. Sagittal abdominal diameter (SAD) was 
measured in the supine position as the maximal distance between the top of the examination 
table and a horizontally placed spirit level placed above the abdomen at the level of the iliac 
crest (in expiration phase).  
Blood pressure measurements were performed in the seated position after 10 minutes of rest, 
with an automatically inflated cuff (UA-787, A & D Co Ltd, Saitama, Japan) at wk 0, 8, and 16.  
Body composition was measured by dual-energy x-ray absorptiometry (DXA) using a GE Lunar 
Prodigy Advance DXA scanner (GE Medical Systems Lunar, Madison, WI, USA). A diagonal 
line passing through the middle of the femoral neck separated the lower-body and trunkal re-
gions for determination of trunk fat in percentage of total tissue mass. 
Magnetic resonance scans 
We assessed total, subcutaneous and intra-abdominal adipose tissue (AAT) volumes by mag-
netic resonance (MR) imaging technique and measured lipid content of the liver by 1H MR 
spectroscopy. MR-examinations were performed on all subjects at wk 0 and wk 16 one to three 
days after the other examinations (but at a similar day and time of day for each subject at both 
visits). The subjects were instructed to refrain from alcohol consumption and vigorous physical 
activity for 24 h prior to each scan. At the baseline visit, subjects recorded all food and drinks 
consumed the evening before the scan and on the morning of the day of the scan. At the subse-
quent visit this intake was to be replicated. 
All MR measurements were performed using Achieva 3.0 T MR imaging system (Philips Medi-
cal Systems, Best, the Netherlands) and a sense cardiac coil. In the beginning of the MR exami-
nation T2w TSE coronal and axial slices through the abdomen were acquired for positioning the 
spectroscopy volumes of interest (VOI). The spectroscopy VOI (11 mm x 11 mm) was posi-
tioned within liver avoiding major blood vessels and intrahepatic bile ducts. A single voxel 
PRESS sequence with respiratory triggering was used for acquisition.  The MR scanner’s soft-
ware was used to fit the acquired spectrum to relative content of water and lipid. Thereby, he-
patic lipid content was expressed as lipid relative to water (%)13. 
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A fast T1w TFE MR sequence in transverse plane was used for obtaining data for estimating 
adipose tissue volumes. A transverse slice with 10 mm thickness was acquired for all subjects in 
the middle of the third lumbar vertebra (L3). Image analysis to determine the total and the intra-
AAT fat volumes was carried out on Philips ViewForum workstation using "segmentation tool" 
in "volume analysis".  
Blood sampling and analysis 
Fasting blood was sampled from an antecubital vein after minimum 10 min of rest. Routine 
haematological and biochemical analyses including blood lipids were performed at the Depart-
ment of Clinical Biochemistry, Gentofte University Hospital, Denmark.  Fasting plasma TC, 
HDL-C, and triglycerides were measured by dry chemistry slides on Vitros 5.1 FS (Johnson & 
Johnson, Rochester, NY, USA). The coefficients of variation (CV%) were 4.4, 6.0 and 9.6 for 
TC, HDL-C, and triglycerides, respectively.  All tests were performed in accordance with ISO 
15189 accreditation. Plasma LDL-C concentration was estimated by the Friedewald equation14.   
Statistical analyses 
The study size was estimated based on the effect of TFA on the LDL-C/HDL-C ratio. Based on 
data from two meta-analyses we assumed a within-subject standard deviation of 0.6 for this 
ratio1,15. We estimated that a minimum of 48 subjects was required to detect an absolute differ-
ence of 0.5 in the LDL-C/HDL-C ratio between diet groups with a statistical power of 80%, and 
a two-sided significance level of 5%. Assuming a standard deviation for liver fat of 6.5% in 
moderately obese women16 a difference between diet groups of approximately 6% point liver fat 
could be detected with at statistical power of 80%, a two-sided significance level of 5% and 24 
expected completers in each group. To allow for an estimated 10% drop out rate, 52 participants 
were recruited.  
Data were analyzed using Statistic Analysis Package, SAS© version 9.1 (SAS Institute, Cary, 
NC, USA). The primary analysis included participants who completed the intervention (n=49). 
The statistical significance level is defined as P<0.05.  
At baseline, characteristics of participants in the two diet groups were compared with the use of 
unpaired t-tests or Kruskal-Wallis tests for skewed data. Baseline values for the overweight 
intervention subjects were compared to values for the lean reference subjects by similar tests.   
Analysis of covariance (ANCOVA) was used to assess the baseline-adjusted difference between 
diet groups for variables measured at wk 0 and 16, i.e. the baseline value was included as a co-
variate. For variables measured at wk 0, 4, 8, 12 and 16 and wk 0, 8 and 16, respectively, a 
mixed model of repeated measures examining the effect of diet and time (wk 4, 8, 12, and 16) 
and their interactions was applied, again with the baseline value as a covariate, and with “sub-
ject” treated as a random effect. Variance homogeneity and normality were investigated by re-
sidual plots, histograms and Shapiro-Wilk’s test and data were log transformed when needed. 
Analyses were performed with and without adjustment for changes in body weight.  
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RESULTS 
49 subjects (24 in the TFA group and 25 in the CTR group) completed the intervention (Figure 
1). One subject withdrew immediately after baseline examinations (she felt medicalized by the 
study) and two subjects dropped out after a few weeks due to lack of time.  
Baseline characteristics of the subjects in the two diet groups were comparable and the lean 
reference subjects were adequately matched for age and height (Table 2). 
Table 2:  Baseline characteristics for subjects in the trans fat (TFA; n=24) and control (CTR; n=25) 
groups and for lean references (n=19) 1 
  TFA              CTR       Lean references  P2 
Age (y) 58.5 ±  4.6 58.8 ±  5.5 60.1 ±  5.9 ns 
Height (cm) 165.3 ±  5.5 166.9 ±  5.2 166.7 ±  4.3 ns 
Weight (kg) 78.7 ±  7.1 78.4 ±  8.6 59.4 ±  4.8 <0.001 
BMI (kg/m2) 28.8 ±  1.7 28.1 ±  2.2 21.3 ±  1.4 <0.001 
Waist circumference (cm) 97.1 ±  7.3 95.5 ±  6.8 74.9 ±  3.8 <0.001 
Blood pressure      
Systolic  (mmHg) 118 ±  12 118 ±  11 120 ±  14 ns 
Diastolic (mmHg) 81 ±  8 82 ±  6 80 ±  10 ns 
Physical activity index10 7.5 ±  1.4 7.9 ±  1.6 8.6 ±  1.4 0.02 
1 Values are means ± SD, completers only. 2 P value refers to difference between overweight intervention subjects 
(diet groups combined) and lean reference subjects by unpaired t-tests (ns, non significant; P>0.05). 
Figure 1: CONSORT flow diagram displaying subjects recruited into the dietary intervention. Subjects were ran-
domly assigned into two diet groups: a trans fatty acid (TFA) group and a control (CTR) group. 
Assessed for eligibility (n = 64) 
Excluded (n = 12) 
  Not meeting inclusion criteria (n = 8) 
  Refused to participate (n = 4) 
Analyzed (n = 24) 
Excluded from analysis (n = 0) 
Lost to follow-up (n = 1) 
Discontinued intervention (n = 0) 
    
Allocated to intervention (n = 25) 
Received allocated intervention (n = 24) 
Did not receive allocated intervention (n = 1) 
 - one subject withdrew immediately after baseline. 
Lost to follow-up (n = 2) 
Discontinued intervention (n = 2) 
 - 2 withdrew after 1-3  weeks due to lack of time. 
Analyzed (n = 25) 
Excluded from analysis (n = 0) 
Allocation 
Analysis 
Follow-Up 
Enrollment
Allocated to intervention (n = 27) 
Received allocated intervention (n = 27) 
Did not receive allocated intervention (n = 0) 
   
CTR TFA
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Compliance with the study diets 
The test diets provided on average 28% of the subjects’ energy requirements. Self reported com-
pliance assessed using study diaries showed that 98% of all test bread rolls were consumed, with 
no difference between diet groups. The 
presence of elevated trans18:1 residues in 
RBC phospholipids determined by GC/-
FID was used as an objective compliance 
measure.  Due to an analytical interference, 
accurate quantification of trans18:1 iso-
mers was not possible. Instead a qualitative 
intensity scale was established and used to 
assign a value of TFA enrichment to each 
sample (Supplemental Figure 1). These re-
sults were transformed to ranks and 
showed that subjects in the TFA group all 
had elevated trans18:1 residue levels at 
both 8 and 16 wk of intervention, whereas 
the control subjects did not (Figure 2). 
The intervention modestly decreased the 
relative abundance of saturated fatty acids 
(SFA) and increased that of polyunsatu-
rated fatty acids (PUFA) in the RBCs of 
both diet groups after 16 wk. Oleic acid 
increased in the control group only (Sup-
plemental Table 1). 
Dietary intake 
The energy intake in the last week of the intervention (representing the intake during the dietary 
period) was not different between diet groups (Supplemental Table 2). The only significant die-
tary differences between diet groups during the intervention were the contributions of energy 
from MUFA and TFA, indicating that the diets were overall comparable apart from the FA 
composition. TFA constituted 7% of the energy intake in the TFA group.  
Anthropometrics 
Contrary to the intention, body weight increased slowly but steadily in both diet groups during 
the dietary intervention with no difference between groups (P= 0.002 for effect of time in base-
line adjusted repeated measures analysis testing for interaction between diet and time) (Figure 
3). At wk 16 mean (± SEM) weight changes from baseline in the TFA and CTR group were 1.1 
± 0.2 kg and 1.1 ± 0.3 kg, respectively. Waist circumference tended to increase more in the TFA 
group after adjustment for baseline values [mean difference (95% confidence interval (CI) be-
tween diets 1.1 cm (-0.1 to 2.4); P = 0.08]; adjusting for weight change had no effect on this 
estimate (Figure 3). There was no difference between groups in hip circumference (data not 
shown). 
Figure 2: Semi-quantitative assessment of trans fatty acids 
(TFA) in red blood cell (RBC) phospholipids assessed by gas 
chromatography.  Based on semi-quantitative assessments of 
RBC trans18:1 profiles, including the scores 0, 0.5, 1, 1.5 
and 2 (where 2 signifies full enrichment) [Supplemental 
Figure 1], maximal TFA-enrichment was observed by wk 8 
and was generally sustained at wk 16 in the TFA group 
(n=24), whereas the subjects in the control group experienced 
no TFA-enrichment (n=25). Changes from baseline TFA 
profiles were assessed by repeated measures ANOVA. Due 
to the non-normal distribution of the semi-quantitative data, 
the analyses were performed on ranked data. asignificantly 
different from the baseline value (P<0.001). bsignificantly 
different from the control group (P<0.001).  
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Fat deposition 
The changes in whole body and trunk fat mass assessed by DXA were in line with the trend for 
waist circumference. The fat gain was numerically greater in the TFA group, although not sig-
nificantly so when compared to controls (Table 3).  The baseline adjusted mean difference in 
body fat between diets at wk 16 was 0.46 kg (CI: -0.20 to 1.17; P = 0.16).   
Due to technical reasons, the liver fat was obtained by 1H MR spectroscopy only in 23 subjects 
in each diet group, and fat distribution was obtained by MR imaging in 19 subjects in each diet 
group. The dietary intervention did not significantly affect liver fat. The between-subject vari-
ability for liver fat changes was large (Figure 4), and thereby the estimate of the liver fat con-
centration being 7% lower in the TFA group at week 16 compared to controls, came with a wide 
confidence interval (CI: -61 to 120%; P = 0.87; Table 3). According to MR imaging, the dietary 
intervention affected neither total, subcutaneous, intra-AAT nor the ratio of intra- to subcutane-
Figure 3: Development in mean 
(±SEM) body weight (figure 3A) and 
waist circumference (figure 3B) in the 
trans fat (TFA; n=24) and control 
(CTR; n=25) groups during the 16-wk 
dietary intervention. Baseline values 
were not significantly different (un-
paired t-test, P>0.05). Note that the y-
axes have been truncated. In spite of 
the isocaloric study design, body 
weight increased significantly in both 
diet groups (P=0.002 for effect of time 
in repeated measures analysis of co-
variance testing for interaction between 
diet group and time (wk 4, 8, 12, 16) 
with wk 0 as a covariate; there was no 
significant interaction between diet and 
time, nor effect on diet). Waist circum-
ference tended to increase more in the 
TFA group (P=0.08 for effect of diet; 
there was no significant interaction 
between diet and time, nor effect of 
time). 
Figure 4: Liver fat percentage in the trans fat 
group (TFA; n=23) and in the control group 
(CTR; n=23) before and after 16 wk of dietary 
intervention and in lean references (n=19) 
obtained by 1H MR spectroscopy. Bars show 
geometric means (95% confidence intervals). 
There was no significant effect of diet, P=0.87 
for differences between diet groups at wk 16 
with wk 0 as a covariate, by analysis of covari-
ance performed on log transformed data. The 
liver fat % in lean references was significantly 
lower than in overweight intervention subjects 
(diet groups combined) by Kruskal-Wallis test 
for skewed data; P<0.01. 
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ous AAT (Table 3). As expected, the liver fat percentage, as well as the subcutaneous and intra-
AAT volumes, was significantly greater in overweight subjects compared to lean references.  
Table 3: Body composition and abdominal fat deposition in the trans fat (TFA) and con-
trol (CTR) groups and in lean references 1 
  Week 0 2 Week 16 Pdiet3 
Fat mass (kg)     0.16 
TFA (n=24) 33.4 ± 1.0 34.6 ± 1.1  
CTR (n=25) 31.8 ± 1.1 32.7 ± 1.0  
Lean references (n=19) 16.8 ± 0.8 4 n/a   
Fat free mass (kg)     0.20 
TFA (n=24) 45.6 ± 0.7 45.6 ± 0.8  
CTR (n=25) 47.0 ± 1.0 47.3 ± 0.9  
Lean references (n=19) 43.3 ± 0.6 4 n/a   
Whole body fat (%)     0.12 
TFA (n=24) 42.1 ± 0.7 43.0 ± 0.7  
CTR l (n=25) 40.2 ± 0.9 40.7 ± 0.8  
Lean references (n=19) 27.8 ± 0.9 4 n/a   
Trunk fat  (%)     0.17 
TFA (n=24) 43.2 ± 0.9 44.2 ± 0.8  
CTR (n=25) 41.3 ± 1.0 42.0 ± 0.9  
Lean references (n=19) 25.5 ± 1.1 4 n/a   
Sagittal diameter (cm)     0.57 
TFA (n=24) 22.2 ± 0.3 22.8 ± 0.4  
CTR (n=25) 22.1 ± 0.3 22.5 ± 0.3  
Lean references (n=19) 17.2 ± 0.2 4 n/a   
Total AAT (cm3) 5     0.85 
TFA (n=19) 446 ± 20 458 ± 20  
CTR (n=19) 390 ± 21 407 ± 21  
Lean references (n=19) 138 ± 10 4 n/a   
Subcutaneous AAT (cm3) 5     0.46 
TFA (n=19) 313 ± 15 317 ± 15  
CTR (n=19) 255 ± 16 261 ± 14  
Lean references (n=19) 106 ± 7.6 4 n/a   
Intra-AAT (cm3) 5     0.58 
TFA (n=19) 133 ± 9 141 ± 10  
Control (n=19) 135 ± 14 146 ± 17  
Lean references (n=19) 33 ± 4 4 n/a   
Intra/subcutaneous AAT 5, 6     0.67 
TFA (n=19) 0.45 ± 0.04 0.46 ± 0.05  
CTR (n=19) 0.56 ± 0.08 0.60 ± 0.10  
Lean references (n=19) 0.31 ± 0.03 4 n/a   
Liver fat (%) 6    0.87 
TFA (n=23) 2.7 (1.3; 5.7) 1.9 (0.8; 4.6)  
CTR (n=23) 2.4 (1.0; 5.6) 1.8 (0.6; 5.1)  
Lean references (n=19) 0.1 (0.07; 0.3) 4 n/a   
1Values are means ± SEM or geometric means (95% confidence interval) for skewed data, com-
pleters only. n/a, not applicable; AAT, abdominal adipose tissue. 2There were no significant differ-
ences in baseline values between diet groups (unpaired t-test). 3P value refers to differences 
between diet groups at wk 16 with wk 0 as a covariate, by analysis of covariance (ANCOVA). 
Adjusting for weight change did not affect the results. 4Significantly different from overweight 
intervention subjects (diet groups combined) by unpaired t-test or Kruskal-Wallis test for skewed 
data; P<0.05. 5Obtained from MR imaging. 6ANCOVA performed on log10-transformed values. 
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Plasma lipids 
TFA adversely affected blood cholesterol by increasing LDL-C and decreasing HDL-C (Table 
4). Hereby, the ratio between the two was significantly greater in the TFA diet group at both wk 
8 and 16 compared to the control group [baseline adjusted mean (95%CI) difference between 
diets 0.41 (0.22 to 0.60); P<0.001]. Accordingly, the TC/HDL-C ratio was also significantly 
increased by TFA [difference between diets 0.45 (0.24 to 0.65); P<0.001]. There was no effect 
of diet on fasting plasma triglycerides.   
Table 4: Blood lipids in the trans fat (TFA; n=24) and control (CTR; n=25) groups and in lean references 
(n=19) 1 
                  ANCOVA 3 
  Week 0 2 Week 8 Week 16 Ptime*diet Pdiet Ptime 
Total cholesterol (mmol/L)          0.16 0.03 0.88 
TFA  5.44 ± 0.19 6.07 ± 0.21 5.95 ± 0.19    
CTR l  5.54 ± 0.20 5.77 ± 0.18 5.86 ± 0.21    
Lean references  5.46 ± 0.18 n/a   n/a      
HDL cholesterol (mmol/L)          0.23 0.03 <0.001 
TFA  1.54 ± 0.06 1.54 ± 0.05 1.38 ± 0.04    
CTR  1.65 ± 0.07 1.69 ± 0.08 1.59 ± 0.06    
Lean references  1.69 ± 0.05 n/a   n/a      
LDL cholesterol (mmol/L)         0.24 0.002 0.01 
TFA  3.39 ± 0.18 3.91 ± 0.19 4.01 ± 0.18    
CTR  3.36 ± 0.20 3.46 ± 0.16 3.72 ± 0.19    
Lean references  3.47 ± 0.17 n/a   n/a      
LDL/HDL-cholesterol ratio          0.23 <0.001 <0.001 
TFA  2.31 ± 0.16 2.64 ± 0.17 3.02 ± 0.20    
CTR  2.20 ± 0.20 2.20 ± 0.17 2.45 ± 0.16    
Lean references  2.08 ± 0.11 n/a   n/a      
Total/HDL-cholesterol ratio          0.22 <0.001 <0.001 
TFA  3.65 ± 0.19 4.08 ± 0.22 4.45 ± 0.23    
CTR  3.54 ± 0.23 3.60 ± 0.21 3.83 ± 0.20    
Lean references  3.25 ± 0.12 n/a   n/a      
Triglycerides (mmol/L) 4          0.78 0.39 0.09 
TFA  1.13 ± 0.10 1.39 ± 0.15 1.24 ± 0.09    
CTR  1.19 ± 0.10 1.35 ± 0.12 1.23 ± 0.11       
Lean references  0.67 ± 0.04 5 n/a   n/a      
1 Values are means ± SEM, completers only. n/a, not applicable. 2 There were no significant differences in baseline 
values between diet group (unpaired t-test, P>0.05). 3 P values were derived by repeated measures analysis of co-
variance testing for interaction between diet group and time (wk 8, 16) with wk 0 as a covariate. P values for effects 
of diet and time, respectively, were derived from analyses omitting the interaction term. 4 ANCOVA performed on 
log10-transformed values. 5 Significantly different from overweight intervention subjects (diet groups combined) by 
unpaired t-test; P<0.05.  
Safety assessments 
Blood pressure was stable in both diet groups during the entire study period (data not shown). 
Hematological (hemoglobin, thrombocytes, leucocytes and erythrocytes) and biochemical (al-
bumin, bilirubin, creatinin, sodium, and potassium) blood parameters did not change during the 
course of the study. Nor did plasma liver enzymes (alanine aminotransferase, aspartate amino 
transferase and alkaline phosphatase; data not shown). 
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DISCUSSION  
The present study aimed at decreasing the explanatory gap between the harmful effect of indus-
trially produced dietary TFA seen in observational studies and the affirmed effects on individual 
risk markers for cardiovascular disease. Due to the Danish legislation, which went into force in 
2003 and practically eliminated industrially produced TFA from food products sold in Den-
mark, the study population was depleted of industrially produced TFA. In metabolically vulner-
able women the present intervention study found that a high intake of TFA from partially 
hydrogenated soybean oil for 16 weeks increased the ratio of plasma LDL- to HDL-C but had 
no detectable effect on hepatic and abdominal fat deposition.  
In dietary interventions examining the effect of a specific FA composition, it is always a chal-
lenge to decide on an appropriate control fat. For the present study, a fat containing predomi-
nantly MUFA but also SFA and PUFA was chosen, because fast food products and snacks 
produced without TFA have higher levels of all three FA classes compared to similar products 
high in TFA17. Also, a recent report has documented that when products high in TFA are refor-
mulated to eliminate TFA, the TFA is mainly replaced by unsaturated FA18. 
TFA intake led to an increase in LDL-C as well as a decrease in HDL-C concentrations, result-
ing in a mean difference between diet groups in the LDL/HDL-C ratio of 0.41, or 0.059 per E% 
TFA. This is comparable to the results from a recent quantitative review of 23 dietary trials 
estimating that a 1 E% increase in industrially produced TFA would result in an increase in the 
LDL/HDL-C ratio of 0.055 when replacing cis MUFA19. However, in the present study the con-
trol fat did not solely consist of cis MUFA.  
The mean difference between diet groups in the TC/HDL-C ratio of 0.45 was somewhat larger 
than what could have been expected from a recent meta-analysis by Mozaffarian & Clarke2 
estimating that a replacement of 1 E% TFA by SFA, MUFA and PUFA increases  the TC/HDL-
C ratio by 0.031, 0.054 and 0.067, respectively2. The present study used a blend of palm oil and 
high oleic sunflower oil as a control fat whereby 7 E% from TFA in the TFA group was com-
pared to an intake of 1.6 E% from SFA, 4.7 E% from MUFA and 0.7 E% from PUFA in the 
control group. According to the estimates from the study by Mozaffarian & Clarke, a difference 
in the TC/HDL-C ratio of 0.35 between the TFA and control diet was expected. The effect of 
TFA on blood lipids in the present study is also considerably greater than that observed in our 
previous 8-wk study with similar design but with normal weight young men20. The fact that only 
moderately overweight women above the age of 45 y were enrolled may help to explain the 
more pronounced effect of TFA on plasma cholesterol in the present study. It has previously 
been suggested that a high TFA intake may be more detrimental towards women than men21,22. 
The TC/HDL-C ratio is twice as informative of cardiovascular risk as TC or LDL-C alone3. The 
increase in the TC/HDL-C ratio in the TFA group of 0.45 compared to the control subjects, may 
translate into an increase in the risk of CHD of approximately 20%3. An intake of 15 g/day of 
TFA may be a likely scenario in selected communities or subpopulations around the world. E.g., 
in an Iranian population the mean TFA intake was as high as 12.3 g/day in year 2001-200323 
and in 1989-91, the mean TFA intake in the US population was 5.3 g/day and 10% of the popu-
lation was estimated to have an intake above 9.4 g/d24. However, although more recent intake 
estimates are lacking, the TFA intake in the US has most likely declined in recent years as in-
creased trans fat awareness has forced the food industry to limit the content of TFA25. Still, it is 
a matter of concern that one may obtain an intake of TFA beyond 15 g in a single serving of fast 
food from international fast food restaurants in selected countries, as assessed in 200626. 
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In prospective cohort studies TFA intake has been positively associated with changes in weight 
and waist circumference5,6. In our study, women in both diet groups experienced slight weight 
gains during the course of the intervention, implying that they did not succeed in isocalorically 
substituting the test food for food items from their habitual diets. We observed weak trends to-
wards greater increases in waist circumference and total fat mass in the TFA group compared to 
controls independent of body weight changes. However, these trends were not reflected by the 
observed changes in abdominal fat deposition. We saw no differences between the diet groups 
in either intra-abdominal or subcutaneous abdominal fat deposition, nor in the ratio between the 
two. Thereby, the present study could not substantiate the findings from a study in green mon-
keys observing an increase in the ratio of intra-to subcutaneous AAT volume irrespective of 
weight gain after 6 y of isocaloric TFA feeding7. It is likely that 16 weeks of exposure was too 
short a period of time to detect changes in abdominal fat deposition independent of body weight 
even with high daily TFA intakes. Indeed body weight gain may be an intermediary step leading 
to TFA induced increases in abdominal fat deposition, which we may not have been able to 
detect with our isocaloric study design. However, in comparison, conjugated linoleic acid sup-
plementation of 4.5 g/d has been shown to significantly decrease fat mass (assessed by DXA) in 
postmenopausal women within 16 weeks on iso-caloric diets27. Also, isocaloric diets high in 
PUFA have been found to significantly decrease subcutaneous AT (assessed by single-slice 
MRI) compared to diets high in SFA within 5 wk, despite no changes in body weight28. This 
confirms that abdominal fat distribution can be affected by dietary fat manipulations within the 
timeframe of our study.  
Since a long-term dietary intervention study providing high daily amounts of TFA is not feasi-
ble, it is questionable if an effect on abdominal fat will ever be established in humans. Con-
versely, potential changes in liver fat due to high intakes of TFA might be detected within a 
reasonable period of time. Liver fat is thought to be a more sensitive marker of a deleterious fat 
deposition pattern29 and is suggested to be a more important risk factor for obesity-related meta-
bolic disorders than intra-AAT30.  
We are the first to report on the influence of a high TFA intake on liver fat deposition in hu-
mans. The data from the present study were consistent with liver fat being from 61% lower to 
140% higher in the TFA group at wk 16 when compared to controls. Given the geometric mean 
liver fat concentration of approx. 2.5% at baseline, the confidence limits may translate into an 
absolute mean decrease in liver fat of 1.5% or an absolute increase of 3.5%. Therefore, our re-
sults cannot discount the possibility that TFA intake may exert effects on liver fat smaller than 
this, prohibiting firm conclusions on minor changes. However, no detectable trend in liver fat, 
was observed in either direction in either diet group and plasma liver enzymes remained un-
changed, arguing that if TFA induced changes in liver fat concentration, they were small indeed.  
In several rodent studies, TFA feeding has been shown to increase liver fat by more than 100% 
compared to animals fed cis FA8,9,31, although this is not a consistent finding32,33. Yet, extrapola-
tion from animal studies is problematic. While it has been documented that liver fat deposition 
in humans is affected by intake of energy and fat (liver fat increased 100% (from 2 to 4% and 
from 11 to 22%) after 3-4-day hypercaloric high-fat diets34,35 and 35% (from 10 to 14%) after 
14-day eucaloric high-fat diets36), the influence of dietary FA composition on liver fat deposi-
tion in humans has yet to be evaluated in controlled trials. It has however been documented that 
intake of specific FAs can affect liver fat accumulation; consumption of n-3 long chain PUFA 
supplements (2-4 g/d) for 8 - 26 wk has been shown to reduce liver fat in subjects with hepatic 
steatosis (liver fat contents of at least 5%)37,38.  
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Also, liver fat is affected by body weight changes and has been shown to decrease by 30-60% in 
obese subjects after ~6-11 kg weight loss39,40. In accordance, we observed significant decreases 
of about 40% in liver fat mean values after a 12-wk dietary weight loss period (mean weight 
loss ~4 kg) subsequent to the dietary intervention (data not shown).  
In conclusion, our research confirms that part of the increase in risk of cardiovascular disease 
seen with increased TFA consumption in observational studies is likely to be due to dyslipide-
mia. The magnitude of the observed impact of TFA intake on blood cholesterol levels suggests 
that older and overweight populations may be more susceptible to TFA-induced metabolic 
changes than young and lean ones. Conversely, weight gain-independent induction of liver or 
intra-abdominal fat deposition could not be identified as contributory explanatory mechanisms.  
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Supplemental table 1: Fatty acid composition of phospholipids in red blood cell (RBC) membranes 
expressed as a mole percent of total quantified lipids with mean intensities >1% in the trans fat (TFA; 
n=24) and control (CTR; n=25) groups and in lean references (n=19) 1. 
                    ANCOVA3 
  Week 0 2 Week 8 Week 16 Ptime*diet Pdiet Ptime 
C16:0          0.99 0.29 <0.001
TFA  40.22 ± 0.71 41.18 ± 0.93 37.84 ± 0.71    
CTR  41.98 ± 1.19 40.44 ± 0.94 37.10 ± 0.71    
Lean references  40.78 ± 0.92 n/a   n/a      
C16:1, n-7 4, 5           0.58 0.47 0.002 
TFA  0.83 ± 0.07 1.09 ± 0.08 0.82 ± 0.07    
CTR  1.04 ± 0.08 1.18 ± 0.09 1.04 ± 0.15    
Lean references  0.77 ± 0.08 n/a   n/a      
C18:0          0.86 0.04 <0.001
TFA  20.85 ± 0.39 18.98 ± 0.61 17.05 ± 0.40    
CTR  21.04 ± 0.61 19.93 ± 0.52 18.18 ± 0.41    
Lean references  23.56 ± 0.67 6 n/a   n/a      
C18:1, n-9          0.63 0.04 <0.001
TFA  17.74 ± 0.65 18.18 ± 0.47 16.25 ± 0.48    
CTR 16.92 ± 0.59 19.36 ± 0.49 16.99 ± 0.38    
Lean references  15.70 ± 0.72 n/a   n/a      
C18:1, n-7          0.38 0.02 0.74 
TFA  1.51 ± 0.13 1.33 ± 0.06 1.43 ± 0.09    
CTR  1.30 ± 0.15 1.20 ± 0.08 1.16 ± 0.07    
Lean references  1.24 ± 0.11 n/a   n/a      
C18:2, n-6          0.41 0.04 <0.001
TFA  10.51 ± 0.56 11.25 ± 0.57 13.08 ± 0.41    
CTR 10.23 ± 0.85 10.40 ± 0.46 11.56 ± 0.49    
Lean references  9.68 ± 0.76 n/a   n/a      
C20:3, n-6 5          0.20 0.37 <0.001
TFA  0.93 ± 0.10 0.59 ± 0.08 1.08 ± 0.09    
CTR  1.16 ± 0.12 0.79 ± 0.14 1.64 ± 0.20    
Lean references  0.76 ± 0.08 n/a   n/a      
C20:4, n-6 5          0.40 0.50 <0.001
TFA  4.95 ± 0.49 4.68 ± 0.56 7.74 ± 0.49    
CTR  4.12 ± 0.48 4.25 ± 0.65 7.68 ± 0.46    
Lean references  4.97 ± 0.48 n/a   n/a      
C22:5, n-3 7          0.72 0.90 0.02 
TFA  0.79 ± 0.12 0.92 ± 0.09 1.18 ± 0.14    
CTR  0.80 ± 0.11 0.88 ± 0.10 1.22 ± 0.13    
Lean references  0.85 ± 0.09 n/a   n/a      
C22:6, n-3 5          1.00 0.98 <0.001
TFA  1.69 ± 0.23 1.83 ± 0.31 3.55 ± 0.36    
CTR  1.40 ± 0.25 1.62 ± 0.28 3.47 ± 0.36    
Lean references  1.65 ± 0.35 n/a   n/a      
∑SFA 5          0.98 0.97 <0.001
TFA  61.07 ± 0.81 60.15 ± 1.42 54.89 ± 0.74    
CTR   63.02 ± 1.48 60.38 ± 1.24 55.27 ± 0.94    
Lean references  64.34 ± 1.45 n/a   n/a      
         
(Continued) 
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Supplemental table 1 (Continued)      
                    ANCOVA3 
  Week 0 2 Week 8 Week 16 Ptime*diet Pdiet Ptime 
∑MUFA          0.66 0.08 <0.001
TFA  20.08 ± 0.71 20.60 ± 0.48 18.50 ± 0.53    
CTR  19.26 ± 0.65 21.74 ± 0.53 19.19 ± 0.46    
Lean references  17.72 ± 0.76 6 n/a   n/a      
∑PUFA          0.81 0.56 <0.001
TFA  18.87 ± 0.91 19.27 ± 1.45 26.61 ± 0.90    
CTR  17.71 ± 1.28 17.94 ± 1.40 25.57 ± 0.95    
Lean references  17.92 ± 1.28 n/a     n/a           
1 Values are means ± SEM, completers only. n/a, not applicable; MUFA, monounsaturated fatty acids; SFA, saturated 
fatty acids; PUFA, polyunsaturated fatty acids; TFA, trans fatty acids. Accurate quantitative determination of RBC 
C18:1 trans fatty acids was prevented by the presence of an analytical interference with variable relative retention 
times on the gas chromatographs used in this study, see Figure 2 and Supplemental Figure 1 for details. 2 There were 
no significant differences between diet groups at baseline (unpaired t-test; P>0.05). 3 P values were derived by repeated 
measures analysis of covariance testing for interaction between diet group and time (wk 8 and 16) with wk 0 as a 
covariate. P values for effects of diet and time, respectively, were derived from analyses omitting the interaction term. 
4All double bonds have cis configuration. Positions of double bonds are counted from the methyl end of the fatty acid. 
5ANCOVA analysis performed on log 10 transformed values. 6 Significantly different from overweight intervention 
subjects (diet groups combined) by unpaired t-test, P<0.05). 7 ANCOVA analysis performed on square root trans-
formed values. 
 Paper II - 19 
Supplemental Table 2: Dietary intake estimated using 3-d weighed food 
records in the trans fat (TFA; n=24) and control groups (CTR; n=25) 1 
  Week 0 2 Week 16 P2 
Energy (MJ/d)     ns 
TFA  7.35 ± 0.30 a 8.30 ± 0.34 b  
CTR l  8.26 ± 0.48 8.01 ± 0.43  
Protein (E%)     ns 
TFA  18.3 ± 0.6 a 14.5 ± 0.4 b  
CTR  17.0 ± 0.7 16.0 ± 0.8  
Carbohydrate (E%)     ns 
TFA  47.3 ± 1.5 a 44.2 ± 1.0 b  
CTR  45.0 ± 1.7 44.0 ± 1.6  
Fat (E%)     ns 
TFA  31.0 ± 1.2 a 37.1 ± 1.0 b  
CTR  30.8 ± 1.8 33.9 ± 1.4  
SFA (E%)     ns 
TFA  11.3 ± 0.6 11.2 ± 0.5  
CTR  11.3 ± 0.9 11.8 ± 0.6  
cisMUFA (E%)     <0.001 
TFA  9.8 ± 0.5 10.3 ± 0.4  
CTR  9.7 ± 0.7 a 13.9 ± 0.8 b  
cisPUFA (E%)     ns 
TFA  5.0 ± 0.2 a 4.5 ± 0.3 b  
CTR  5.1 ± 0.3 4.3 ± 0.3  
TFA (E%)     <0.001 
TFA  0.4 ± 0.0 a 7.0 ± 0.2 b  
CTR 0.5 ± 0.1 a 0.3 ± 0.0 b  
Cholesterol (mg/d)     ns 
TFA  331 ± 27 a 257 ± 24 b  
CTR  310 ± 23 281 ± 32  
Alcohol (g/d)     ns 
TFA  8.7 ± 2.0 14.4 ± 4.1  
CTR  19.3 ± 3.3 18.1 ± 3.6  
Fiber (g/d)     ns 
TFA  21.2 ± 1.2 a 18.6 ± 1.0 b  
CTR  21.4 ± 1.6 a 18.7 ± 1.6 b   
1 Values are means ± SEM. ns, non significant (P>0.05). Means in a row with super-
scripts without a common letter differ; P<0.05 (paired t-test). 2 There were no sig-
nificant differences in baseline values between diet groups (unpaired t-test), except 
for alcohol (P<0.05). 3 P value is for differences between diet groups at wk 16, un-
paired t-test.  
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 Value trans18:1 Assessment Criterion 
0 Not present a & c, or a & d not observed 
0.5 Indeterminate a & c, or a & d < 3x background & a < 0.5 b  
1 Low a & c, or a & d > 3x background, and b < 0.5 18:1n7c  
2 High a & c, or a & d > 3x background & b > 0.5 18:1n7c 
Supplemental figure 1: Semi-quantitative analysis of red blood cell (RBC) trans fatty acid (TFA) pro-
files. A representative chromatogram showing “high” C18:1 TFA profiles observed in RBC sample ex-
tracts of TFA fed subjects run on two different gas chromatographers and an authentic standard.  A peak 
interfering with the trans-C18:1 profile (indicated by hatching) impeded quantitative analysis. Rather, four 
peaks (a, b, c, and d) from the trans profile were used to indicate the presence or absence of an industrial 
TFA profile, while the relative abundance to cis-C18:1(n-7) was used as an indication of TFA intensity. 
Peak relative retention times to cis-C18:1(n-9) and cis-C18:1(n-7) were used as positive identification. 
Peaks b and c, respectively co-eluted with trans-C18:1(n-9) and trans-C18:1(n-7) in authentic standards. 
A value of 0 was applied if a & c or a & d were not observed, indicating that trans-C18:1 was not present; 
a value of 0.5 was applied if a & c, or a & d < 3x background and a < 0.5 b, indicating that the presence of
trans-C18:1 was indeterminate; a value of 1 was applied if a & c, or a & d > 3x background and b < 0.5 
18:1n7c indicating low presence of trans-C18:1; a value of 2 was applied if a & c, or a & d > 3x back-
ground and b > 0.5 18:1n7c indicating high presence of trans-C18:1.
 Paper II - 21 
Supplemental Method Description 
Fatty acid methyl ester (FAME) analysis gas chromatography conditions  
Esterified lipids were separated by gas chromatography (GC) on Agilent 6890 GCs with split/-
splitless inlets run in splitless mode with a 0.8 min purge delay.  The resolution of eighteen car-
bon cis/trans MUFA isomers was equivalent under these two described chromatographic 
conditions.  
Dietary FAMEs were separated on a 100m x 0.25mm id x 0.25µm CP-Select capillary column 
(Varian, Inc.; Walnut Creek, CA).  The oven temperature gradient was as follows: 2min at 
80ºC; 75ºC/min to 160ºC; 25min hold; 1ºC/min to 225ºC; 8 min hold; 75ºC/min to 80ºC; 2min 
hold (total run time 104 min). The column helium flow gradient was as follows: Initial flow 
1.5mL/min, held 10min; 1mL/min² to 0.8L/min, held 77min: 1mL/min² to 1.5mL/min.  
Co-elution of some trans and cis C18:1 isomers could not be resolved and therefore the assump-
tion that the 11-trans/11-cis-ratio established the relative abundance for all cis/trans pairs in the 
trans test fat was applied.  
RBC FAMEs were separated on a 100m x 0.25mm id x 0.2µm SP-2380 capillary column (Var-
ian, Inc.; Walnut Creek, CA). The oven temperature gradient was as follows: 1 min at 80ºC; 
35ºC/min to 150ºC; 25min hold; 2ºC/min to 205ºC; 1ºC/min to 211ºC; 0.7ºC/min to 219ºC; 
0.4ºC/min to 223ºC; 32min hold; 35ºC/min to 80ºC; 2min hold (total run time 120 min). The 
column helium flow gradient was as follows: Initial flow 1.2mL/min, held 4min; 1mL/min² to 
0.8L/min, held 60min: 1mL/min² to 1.2mL/min, held 0min.  
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ABSTRACT 
Background and aim: Intake of industrially produced trans fatty acids (TFA) has been linked to 
increased risk of type 2 diabetes in observational studies. We investigated the causality of this associa-
tion by examining if a high intake of TFA impairs measures of glucose homeostasis and induces in-
tramuscular lipid deposition in abdominally obese women.  
Methods: In a double-blind parallel dietary intervention study, 52 healthy but overweight postmeno-
pausal women were randomised to receive either partially hydrogenated soybean oil (15 g/d TFA) or a 
control oil (mainly oleate/palmitate) for 16 weeks. Three markers of glucose homeostasis and four 
markers of lipolysis were derived from glucose, insulin, C-peptide, nonesterified fatty acid (NEFA) 
and glycerol concentrations during a 3-hour frequent sampling oral glucose tolerance test (OGTT). 
Intramuscular lipids were assessed by magnetic resonance spectroscopy. 
Results:  Forty-nine women completed the study. Insulin sensitivity (assessed by ISIcomposite), beta-cell 
function (the disposition index) and the metabolic clearance rate of insulin were not significantly 
affected by the dietary intervention. Neither was the ability of insulin to suppress plasma NEFA and 
glycerol during oral glucose ingestion nor the intramuscular lipid deposition.  
Conclusions: Our study did not find any effect of high TFA intake on glucose metabolism over 16 
weeks. A study population with a stronger predisposition to insulin resistance and/or a longer duration 
of exposure may be required for insulin sensitivity to be affected by intake of industrial TFA.  
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INTRODUCTION 
Intake of trans fatty acids (TFA) is associated to an increased risk of type 2 diabetes mellitus 
according to data from the prospective Nurses’ Health Study. Replacement of 2 energy% (E%) 
TFA by polyunsaturated fatty acids (PUFA) was estimated to decrease the risk of type 2 diabe-
tes mellitus by 40%1. Whereas others have failed to find such an association in large prospective 
cohort studies with slightly lower median TFA intakes (~1.3 E% vs. 2 E% in the Nurses’ Health 
Study)2,3, an Iranian cross-sectional study points in the same direction4. 
A few controlled intervention studies have investigated the effect of TFA intake on measures of 
glucose homeostasis, but the results are inconclusive. In lean and healthy young subjects a high 
intake of neither ruminant nor industrial TFA seems to impair insulin and glucose metabolism 
in short-term studies of 4 to 5 weeks duration5-7. Recently, it was shown that ~5 g/d of TFA 
(ruminant as well as industrial) did not affect peripheral insulin sensitivity in moderately over-
weight women either8. In contrast, meals with high TFA contents have been shown to produce 
higher postprandial insulin and C-peptide concentrations than similar meals with cis fatty acids 
in overweight subjects and type 2 diabetic patients9,10.  
We hypothesized that industrial TFA may affect substrate metabolism in several ways that 
would increase the risk of developing type 2 diabetes mellitus: A high TFA intake might i) in-
duce peripheral insulin resistance, possibly through increased deposition of intramuscular 
lipids11,12; ii) impair beta-cell function; and iii) increase lipolysis by decreasing the inhibitory 
action of insulin.  
To explore these hypotheses, we conducted a dietary intervention study examining the effect of 
long-term exposure to high daily amounts of industrial TFA on glucose homeostasis and mark-
ers of lipolysis in healthy but abdominally obese postmenopausal women. We anticipated that a 
16-week intervention period would be sufficiently long to allow for incorporation of TFA into 
muscle structural lipids with possible influence on development of insulin resistance13 and for 
induction of intramuscular lipid accumulation11. 
 
MATERIALS AND METHODS 
The present work examines the effect of high intakes of industrial TFA on insulin sensitivity, 
beta-cell function, markers of lipolysis and intramuscular lipids.  The measurements reported 
here were collected at baseline (week 0) and at the end of the dietary intervention (week 16). 
Study design  
This dietary intervention study had a randomized, double-blind, parallel design. Fifty-two 
healthy, moderately overweight postmenopausal women were allocated to 26 g/d of partially 
hydrogenated soybean oil with ~60% TFA or control oil for 16 weeks. The participants were 
randomized to the two diets stratified by waist circumference. The computer generated ran-
domization sequences with random permuted blocks of four, was kept undisclosed for the inves-
tigators until after study completion. All study personnel and participants were blinded to the 
treatment assignment for the duration of the study.  
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The subjects were recruited from Copenhagen and the surrounding areas by advertising in the 
local media. Subject inclusion criteria were: healthy; body mass index between 25 and 32 
kg/m2; waist circumference >80 cm; postmenopausal (self reported) for the last 12 months; and 
aged 45-70 years. The exclusion criteria were known diabetes or other chronic diseases; history 
of cardiovascular disease; smoking; hypertension (>160/100 mmHg); fasting plasma triglyc-
erides >3 mmol/L; fasting plasma LDL-cholesterol >6 mmol/L; fasting plasma glucose >7 
mmol/L; use of hormones or anti-hypertensive, anti-lipidemic or anti-cholesterolemic drugs;  
weight changes >3 kg for two months prior to screening; participation in strenuous physical 
activity >10 h/week; and abnormalities in routine biochemical and haematological tests. The 
subjects were not allowed to donate blood during the study and three months prior to screening 
or to use fish oil as dietary supplements during the study and one month before commencement.  
All participants gave their informed consent to the study, which was carried out at the Univer-
sity of Copenhagen, Denmark and was approved by the Municipal Ethical Committee of The 
Capital Region of Denmark (H-B_2007-089), and registered at clinicaltrials.gov as NCT-
00655902.  
Intervention and compliance 
We compared the effect of consuming 15.7 g/d of TFA from partially hydrogenated soybean oil 
with that of a control oil consisting of a 50/50% mix of palm oil and high oleic sunflower oil. 
The test fats (kindly supplied by AarhusKarlshamn, Denmark) mainly differed in the content of 
TFA, palmitic, oleic and linoleic acid. The TFA fat consisted of 60.4% TFA (of which ~98% 
was trans18:1 and 2% trans18:2 isomers) 19.6% cis18:1, 12.7% C16:0 and 6.2% C18:0, and the 
control fat consisted of 61.4% cis18:1, 26.7% C16:0, 6.6% cis18:2 and 3.8% C18:0. Both fats 
contained minor amounts of C14:0, C20:0 and C22:0. 
The fats were incorporated into bread rolls providing a total of 600 kcal/d (41 E% fat) equiva-
lent to 28% of the subjects’ energy requirements on average. A clinical dietician instructed the 
participants how to let the bread rolls iso-calorically substitute food items from their habitual 
diets.  
Dietary intake was measured using 3-day weighed food records at baseline and in the last week 
of the intervention. The only significant dietary differences between diet groups during the in-
tervention were the contributions of energy from monounsaturated fatty acids (MUFA) and 
TFA, indicating that the diets were overall comparable apart from the fatty acid composition. 
The intake of TFA was higher in the TFA group (7.0 ± 0.2 E% (mean±SEM) vs. 0.3 ± 0.0 E%) 
and the intake of MUFA lower compared to the control (CTR) group (10.3 ± 0.4 E% vs. 13.4 ± 
0.8 E%).  
Self reported compliance as assessed by means of study diaries showed that 98% of all test 
bread rolls were consumed with no difference between diet groups. Incorporation of fatty acids 
into phospholipids of red blood cells (RBC) was used as an objective compliance measure. 
RBCs from all TFA fed subjects were enriched in trans18:1 residues after the dietary 
intervention, whereas those of control subjects were not (data not shown).  
Measurements 
At each visit the subjects were told to be 10 h fasted (except for 0.5 l water). They were 
instructed to avoid vigorous exercise and alcohol consumption on the day before and to con-
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sume similar carbohydrate-rich evening meals on the evening before each visit. Body weight 
and height were measured by standard procedures.  
We assessed insulin sensitivity by use of frequent sampling 3 hour glucose tolerance tests 
(OGTT) where subjects ingested a solution of 75 g glucose dissolved in 300 ml water. Venous 
blood samples were collected before and during the OGTT for measurement of plasma glucose, 
and serum insulin and C-peptide at the following time points -10, 0, 10, 20, 30, 45, 60, 75, 90, 
105, 120, 150, and 180 min. Samples for measurement of plasma glycerol and non-esterified FA 
(NEFA) were collected at -10, 0, 30, 60, 90 and 120 min. 
Intra- and extra-myocellular lipids (in psoas major) were measured by 1H magnetic resonance 
spectroscopy14 using Achieva 3.0 T MRI system (Philips Medical Systems) and a sense cardiac 
coil. A single voxel PRESS sequence with the spectroscopy volumes of 11 mm x 11 mm x 11 
mm was used for acquisition.  The MR scanner’s software was used to fit the acquired spectrum 
to obtain spectroscopic areas of water, intra- and extra-myocellular lipids. Consequently, con-
tent of the lipids in % relative to water was calculated.  
Laboratory analyses 
Fasting and OGTT plasma glucose concentrations were analysed by a colorimetric assay (Or-
tho-Clinical Diagnostics, Johnson & Johnson, Birkerød, Denmark) for the Vitros 5.1 
FS analyzer (intra-assay CV: 5.1%). Fasting and OGTT serum insulin and C-peptide concentra-
tions were analysed by a solid-phase, enzyme-labeled chemiluminescent immunometric assay 
and a solid-phase, two-site chemiluminescent immunometric assay, respectively (Siemens 
Medical Solutions Diagnostics, Ballerup, Denmark)  for the IMMULITE 2500 analyzer (intra-
assay CVs: 4.2% and 2.6%, respectively).  
Fasting and OGTT plasma glycerol concentrations were analyzed by a direct colorimetric assay 
(Randox, Crumlin, UK) and plasma NEFA concentrations were measured by an enzymatic col-
orimetric assay (Trichem, Frederikssund, Denmark) both for the Pentra 400 Analyzer (Horiba 
ABX Diagnostics). 
The fatty acid composition of dietary fats as well as of phospholipids in RBC membranes was 
analyzed by gas chromatography (on an Agilent 6890 GC) of fatty acid methyl esters on high 
polarity cyano-silica columns (Varian, Inc.; Walnut Creek, CA) and a flame ionization detector.  
Calculations 
Areas under the curves (AUC) were calculated by means of the trapezoidal rule, and incre-
mental AUC (iAUC) represent AUC above the fasting value. 
Three central parameters to describe insulin sensitivity, clearance of insulin and beta-cell func-
tion, respectively, during oral glucose ingestion were chosen:  
i) Insulin sensitivity was estimated by use of the insulin sensitivity index ISIcomposite as proposed 
by Matsuda & DeFronzo, which has been shown to correlate closely with the M value of the 
glucose clamp in individuals displaying a range of glucose tolerance15. ISIcomposite was calculated 
as = 10 000 / (fasting glucose x fasting insulin x mean glucoset0-30-60-90-120 x mean insulint0-30-60-90-
120)½, where glucose is measured in mg/dl and insulin in μU/ml.   
ii) The insulin metabolic clearance rate (MCRi) was estimated as the changes in prehepatic insu-
lin secretion relative to plasma insulin concentration during the OGTT. The calculation of 
Paper III - 5 
MCRi has previously been described in detail16 and is based on the following principle: As C-
peptide is co-secreted equimolarly with insulin from the pancreatic beta-cells, but is not ab-
sorbed by the liver prior to entering the blood stream, the C-peptide concentrations during the 
OGTT allows for the estimation of the prehepatic insulin secretion rate (ISR). The estimation 
was performed by deconvolution of the C-peptide concentration using the computer program 
ISEC17, which has been validated to calculate prehepatic ISR during intravenous glucose toler-
ance tests18 meal tests19 and OGTT20. The ISR-AUC is an expression of the total amount of pre-
hepatic insulin secreted during the OGTT. Since the insulin-AUC represents both insulin secre-
tion and clearance, the MCRi can be calculated as the ratio of ISR-AUC to insulin-AUC.  
iii) Beta-cell function was expressed by the Disposition Index that estimates the beta-cell re-
sponsiveness taking into account ambient insulin sensitivity. A detailed description of these 
endpoints has been given by Haugaard et al.16. Briefly, the index for beta-cell responsiveness (or 
insulin secretory capacity) Btotal was calculated as the change in ISR per unit change in glucose 
concentration by performing cross-correlation analysis between plasma glucose concentrations 
and ISR during the OGTT. The Disposition Index was calculated as the product of Btotal and 
ISIcomposite.  
Four integrated parameters to measure and describe lipolysis during oral glucose ingestion were 
chosen. First, the plasma concentrations of NEFA and glycerol at their most suppressed period 
during the OGTT (90 -120 min), NEFAmean, 90-120 min, and Glycerolmean, 90-120 min, were taken as 
independent markers of remnant lipolysis. Second, the ability of insulin to suppress both NEFA 
and glycerol during oral glucose ingestion was estimated as the change in NEFA and glycerol, 
respectively, relative to the integer of changes in insulin concentration during the OGTT 
(∆NEFA/InsuliniAUC   and ∆Glycerol/InsuliniAUC). The change in NEFA and glycerol during the 
OGTT, (∆NEFA and ∆Glycerol) were calculated as the change from t=0 min to the mean of 
values at t=90 and 120 min as percentage of t=0 min value.  
Statistical analyses 
The study size was estimated based on the effect of TFA on the LDL/HDL-cholesterol ratio, 
which was one of the 3 primary endpoints of this study (the others being hepatic fat and insulin 
sensitivity). The results for blood lipids and hepatic fat will be reported elsewhere. It was esti-
mated that a minimum of 48 subjects was required to detect an absolute difference of 0.5 in the 
LDL-C/HDL-C ratio between diet groups with a statistical power of 80%, and a two-sided sig-
nificance level of 5%. Fifty-two participants were recruited to allow for an estimated drop out 
rate of 10%. 
Data were analyzed using Statistic Analysis Package, SAS© version 9.1 (SAS Institute, Cary, 
NC, USA). The primary analysis included participants who completed the intervention (n=49). 
The statistical significance level is defined as P<0.05. 
At baseline, characteristics of participants in the two diet groups were compared with the use of 
2-tailed unpaired t-tests or Kruskal-Wallis’ χ2 tests for skewed data. Analysis of covariance 
(ANCOVA) was used to assess the baseline-adjusted difference between diet groups for vari-
ables measured at week 0 and 16. For variables with repeated measures over time (OGTT data) 
a mixed model of repeated measures examining the effect of diet and time (with time denoting 
the measurement time points during the OGTT) and their interactions was applied, again with 
the baseline value as a covariate. A Gaussian covariance structure was used for all variables. 
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Variance homogeneity and normality were investigated by residual plots, histograms and 
Shapiro-Wilk’s test and data was log transformed when needed.   
RESULTS 
Baseline characteristics for the 49 completers of the study (24 out of 25 randomized to the TFA 
group and 25 out of 27 randomized to the CTR group) are presented in Table 1. Body weight 
increased by 1.1 ± 0.2 kg in both diet groups during the dietary intervention. 
Table 1: Subject characteristics at baseline for completers in the trans fat (TFA) and control (CTR) 
groups. 
  TFA  CTR  
n 24  25  
Age (years) 58.5 ±  4.6 58.8 ±  5.5 
Height (cm) 165.3 ±  5.5 166.9 ±  5.2 
Weight (kg) 78.7 ±  7.1 78.4 ±  8.6 
Body mass index (kg/m2) 28.8 ±  1.7 28.1 ±  2.2 
Waist circumference (cm) 97.1 ±  7.3 95.5 ±  6.8 
Systolic blood pressure (mmHg) 118 ±  12 118 ±  11 
Diastolic blood pressure (mmHg) 81 ±  8 82 ±  6 
No of NFG / IFG / T2D 1 18 / 6 / 0 20 / 5 / 0 
No of NGT / IGT / T2D 2, 3 11 / 11 / 2 19 / 6 / 0 
Fasting blood parameters    
p-Glucose (mmol/l) 5.2 ±  0.6 5.3 ±  0.4 
s-Insulin (pmol/l) 24 (16; 37) 37 (25; 54) 
s-C-Peptide (pmol/l) 563 (471; 674) 598 (505; 708) 
p-Glycerol (pmol/l)  96 ±  38 84 ±  42 
p-NEFA (μmol/l) 732 ±  162 693 ±  195 
p-Triglycerides (mmol/l) 1.13 ±  0.50 1.19 ±  0.50 
p-Cholesterol (mmol/l) 5.4 ±  0.9 5.5 ±  1.0 
OGTT derived parameters    
ISIcomposite 3 7.3 (5.0; 10.7) 5.3 (3.8; 7.4) 
Btotal 3 2.3 ±  0.2 3.0 ±  0.3 4 
Disposition Index 3 14.9 (9.6; 23.2) 14.6 (11.1; 19.1) 
MCRi (l/min) 3 3.4 ±  0.3 2.7 ±  0.2 4 
NEFAmean, 90-120 min (μmol/l)  37 (28; 50) 42 (35; 53) 
∆NEFA/InsuliniAUC (% min-1 pmol-1 l)  4.2 (3.2; 5.5) 2.9 (2.1; 4.0) 4 
Glycerolmean, 90-120 min (pmol/l)  21 ±  3 28 ±  4 
∆Glycerol/InsuliniAUC (% min-1 pmol-1 l) 5 3.7 ±  0.5 2.4 ±  0.3 4 
Intramuscular lipids    
Intramyocellular lipids (%) 6 1.6 (1.1; 2.3) 1.5 (1.1; 1.9) 
Extramyocellular lipids (%) 6 5.2 (4.0; 6.7) 4.3 (3.5; 5.4) 
Total myocellular lipids (%) 6  7.3 (6.0; 9.0) 6.0 (5.0; 7.2) 
Values are means ± SD or geometric means (95%CI) for skewed data, completers only. 1 NFG, normal fasting glu-
cose (defined as fasting plasma glucose <5.6 mmol/l); IFG, impaired fasting glucose (≥5.6 to 6.9 mmol/l); T2D, type 
2 diabetes (fasting glucose ≥7.0 mmol/l) 28;  2 NGT, normal glucose tolerance (defined as plasma 2-hour glucose <7.8 
mmol/l during an oral glucose tolerance test); IGT, impaired glucose tolerance (2h glucose ≥7.8 and <11.1 mmol/l); 
T2D (2h glucose ≥11.1 mmol/l) 28. No significant difference between groups by Fisher’s Exact Test, P>0.05. 3 n = 23 
in the TFA group. 4 P<0.05 vs. TFA group.  5 n = 22 in the TFA group. 6 Assessed by magnetic resonance spectros-
copy of psoas major; n = 23 in the TFA group and n = 22 in the control group due to a few erroneous scans. Btotal, 
beta-cell responsiveness; ISI, insulin sensitivity index; MCRi, metabolic clearance rate of insulin; NEFA, non-
esterified fatty acids: p, plasma; s, serum. 
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There was no effect of diet on fasting concentrations of glucose, insulin, C-peptide, glycerol and 
NEFA (Table 2). Responses for glucose, insulin, C-peptide and ISR during the 3h OGTT, be-
fore and after the intervention, are depicted in Figure 1. At week 16 there were neither signifi-
cant diet by time (in min) interactions, nor significant effects of diet in repeated measures 
analysis for any of these variables when adjusting for the response at baseline. The AUC values 
were not significantly different either (Figure 1).  
As expected, the baseline relationship between ISIcomposite and Btotal fitted a hyperbola (n=30, 
r=0.52, P=0.004) for subjects with normal glucose tolerance (defined as 2h glucose <7.8 
mmol/L) whereas a shift to the left (P=0.06) was seen for subjects with impaired glucose toler-
ance (2h glucose ≥7.8 mmol/L). 
None of the OGTT-derived parameters describing glucose homeostasis or lipolysis changed 
significantly in either diet group during the 16 weeks of intervention. Thereby, after the inter-
vention there was no difference between diet groups in either ISIcomposite, Disposition Index, 
Figure 1: Glucose and insulin metabolism during oral glucose tolerance test (OGTT) 
Mean (±SEM) glucose (A), insulin (B) and C-peptide (C) concentrations and insulin secretion rates 
(ISR) during the 3-hour OGTT performed at baseline (week 0; dotted lines) and after the dietary inter-
vention (week 16; solid lines), in subjects who consumed 15.7 g/d trans fatty acids (TFA; n=24; black 
squares); and a control oil (control; n=25; white triangles). The corresponding areas under the curves 
(AUC) are also depicted (black bars = TFA; white bars = control). No diet x time interaction was 
observed for either glucose (P=0.81), insulin (P=1.00) C-peptide (P=0.98) or ISR (P=0.90) by repeated 
measures analysis, nor were the AUCs significantly different in baseline-adjusted analyses (P>0.39). 
The insulin response was slightly higher in the control group at baseline (significant diet x time inter-
action in repeated measures analysis (P<0.001), with no significant difference between diets at indi-
vidual time points after Bonferroni correction), however, the AUC value was not statistically different 
from the TFA group (P= 0.11 by unpaired t-test). There were no significant baseline differences be-
tween the two groups for the other variables. Wk, week. 
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MCRi, nadir concentrations of NEFA/glycerol or the ability of insulin to suppress NEFA/-
glycerol, when adjusting for baseline values (Table 2).  
Intra- and extra-myocellular lipids did not change during the dietary intervention in either study 
group (Table 2); neither did the ratio between the two (data not shown). 
 
DISCUSSION  
The present study investigated if the positive association between intake of industrially pro-
duced TFA and risk of type 2 diabetes mellitus observed in the Nurses’ Health Study1 might be 
explained by adverse effects on insulin sensitivity and beta-cell function. We found that in me-
tabolically vulnerable postmenopausal women a high intake of TFA from partially hydrogen-
ated soybean oil for 16 weeks had no measurable effect on any of the examined diabetes related 
end points compared to intake of a control oil where TFA was replaced by mainly oleic but also 
palmitic and linoleic acid.  
We did not find an effect of TFA exposure on insulin sensitivity in this study, despite high self- 
reported compliance with the intervention diet (98% of bread rolls consumed), reflected by in-
corporation of TFA isomers in the red blood cell membrane of all subjects in the TFA group. 
Also, the fact that the TFA group experienced a significant 34% increase in the plasma 
LDL/HDL-cholesterol ratio (Bendsen et al. 2010, submitted observations), is indicative of good 
compliance. Dietary TFA has consistently been shown to increase this ratio compared to all 
other FA classes21. We assessed insulin sensitivity by use of the OGTT-derived ISIcomposite. This 
index of whole-body insulin sensitivity has been shown to correlate well with the rate of insulin-
mediated glucose disposal during the euglycemic insulin clamp15. An advantage of the OGTT is 
that it reflects physiological stimulation of insulin secretion. Also, the few studies that have 
suggested an insulin-raising effect of TFA have employed meal tests9,10,22 suggesting that the 
entero-insular axis may be of relevance. 
However, it is a limitation of this study that sample size calculations were not based on insulin 
sensitivity. The relative mean difference between diets in ISIcomposite was -4% (95% confidence 
interval: -23 to 20) after the intervention, indicating that we would not have been able to detect 
TFA-induced changes in ISIcomposite smaller than 20%. Nevertheless, within-group changes were 
very small, which strongly indicates that TFA intake do not induce a clinically relevant change 
in insulin sensitivity in this metabolically sensitive population.  
To examine possible effects of TFA on glucose metabolism beyond those on whole-body insu-
lin sensitivity, we calculated additional indices derived from the OGTT data. The metabolic 
clearance rate of insulin, MCRi, was assessed because a decrease in this measure would reflect a 
compensatory mechanism to comply with increased insulin resistance23; the Disposition Index 
was calculated, since insulin secretion should be compared to the insulin sensitivity of the indi-
vidual in order to reflect beta-cell function24; and finally, we assessed the ability of insulin to 
suppress both NEFA and glycerol during oral glucose ingestion as it is suggested to reflect the 
sensitivity of adipose tissue to the antilipolytic effect of insulin, which has been shown to be 
impaired in healthy subjects with muscle insulin resistance25. Neither of these indices was sig-
nificantly affected by the dietary intervention.  
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Table 2: Glucose, insulin and lipid metabolic data and intramuscular lipids in the trans fat (TFA) and control (CTR) groups after the 16-week dietary intervention 
 TFA (n=24) CTR (n=25)  TFA - CTR   
 Week 16 1  Change from 
baseline 2 
 Week 16 1 Change from base-
line 2 
 Mean difference at 
week 16 3 
P 4 
Fasting blood parameters            
p-Glucose (mmol/l) 5.3 (5.2; 5.4)  0.02 ± 0.05  5.2 (5.1, 5.3) -0.10 ± 0.07  0.13 (-0.04; 0.30) 0.13 
s-Insulin (pmol/l) 5 32 (25; 39)  0.0 (-5.3; 9.9)  33 (27; 41) 1.1 (-3.6; 8.8)  -4 (-30; 31) % 0.77 
s-C-Peptide (pmol/l) 5 605 (550; 665)  22 (-54; 127)  584 (532; 641) 22 (-63; 108)  4 (-9; 18) % 0.60 
p-Glycerol (pmol/l) 5 73 (61; 88)  -9 (-38; 0)  82 (69; 98) 2 (-25; 19)  -11 (-31; 15) % 0.37 
p-NEFA (μmol/l) 626 (550; 702)  -100 ± 31  673 (599; 748) -25 ± 55  -47 (-153; 60) 0.38 
OGTT derived parameters           
ISIcomposite 5, 6 5.8 (5.0; 6.8)  -0.5 (-2.0; 0.5)  6.0 (5.2; 7.0) -0.1 (-0.7; 0.5)  -4 (-23; 20) % 0.72 
Btotal  6 2.7 (2.3; 3.1)  0.2 ± 0.2  2.4 (2.0; 2.8) -0.4 ± 0.2  0.3 (-0.3, 0.8) 0.36 
Disposition Index 5, 6 14.2 (11.8; 17.1)  -0.7 (-3.0; 3.0)  12.5 (10.4; 14.9) -1.1 (-2.7; 1.2)  14 (-12; 47) % 0.31 
MCRi (l/min) 5 2.8 (2.5; 3.0)  -0.5 ± 0.3  2.6 (2.3; 2.8) -0.2 ± 0.1  0.2 (-0.2; 0.6) 0.35 
NEFAmean, 90-120 min (μmol/l) 5 41 (31; 56)  10 (-15; 26)  41 (30; 55) 3 (-18; 7)  2 (-34; 56) % 0.94 
∆NEFA/InsuliniAUC (% min-1 pmol-1 l) 5 3.2 (2.7; 3.9)  -0.2 (-1.2; 0.4)  3.4 (2.8; 4.1) 0.1 (-0.7; 0.5)  -5 (-27; 23) % 0.68 
Glycerolmean, 90-120 min (pmol/l)  29 (23; 36)  6.1 ± 4.0  24 (17; 31) -3.8 ± 4.5  5.5 (-4.5; 15.4) 0.27 
∆Glycerol/InsuliniAUC (% min-1 pmol-1 l) 7 2.4 (1.8; 2.9)  -1.0 ± 0.4  2.9 (2.4; 3.4) 0.2 ± 0.2  -0.5 (-1.2; 0.3) 0.38 
Intramuscular lipids           
Intramyocellular lipids (%) 5, 8 1.8 (1.6; 2.1)  0.0 (-0.9; 1.1)  1.6 (1.4; 1.9) -0.1 (-0.4; 0.6)  12 (-11; 42) % 0.30 
Extramyocellular lipids (%) 5, 8 4.7 (4.0; 5.6)  -0.2 (-0.8; 1.0)  4.2 (3.5; 5.0) -0.6 (-1.3; 0.4)  12 (-11; 42) % 0.33 
Total myocellular lipids (%) 5, 8  6.7 (5.8; 7.7)  0.5 (-1.0; 1,3)  6.1 (5.3; 7.0) -0.9 (-1.4; 0.5)  10 (-10; 35) % 0.33 
1 Values are least squares means (95%CI). 2 Values are means ± SEM or medians (interquartile range) for skewed values, completers only. 3 Mean baseline-adjusted difference (or 
relative difference) between diet groups at week 16 (TFA – CTR); 4 P value is for differences between diet groups at week 16 with week 0 as a covariate, by ANCOVA. 5 AN-
COVA performed on log10-transformed values. 6 n = 23 in the TFA group. 7 n=22 in the TFA group. 8 Assessed by magnetic resonance spectroscopy of psoas major; n = 23 in the 
TFA group and n = 22 in the control group due to a few erroneous scans. Btotal, beta-cell responsiveness; ISI, insulin sensitivity index; MCRi, metabolic clearance rate of insulin; 
NEFA, non-esterified fatty acids, p, plasma; s, serum. 
 Paper III - 10 
Also, we hypothesized that TFA might affect glucose metabolism through induction of ectopic 
intramuscular lipid accumulation, as previously observed in rats12. Intramuscular fat (in combi-
nation with diminished mitochondrial lipid oxidation) is thought to be a major contributor to 
obesity-associated insulin resistance as reviewed by Corcoran et al.11 However, TFA did not 
increase the deposition of intramuscular lipids in this study. In contrast, 12 weeks of supplemen-
tation with conjugated linoleic acid (1.2 wt%) significantly increased the intramuscular fat con-
tent in growing pigs’ longissimus dorsi by 19%26. This indicates that relatively small amounts of 
specific fatty acids may affect muscle lipid accumulation, at least during growth; unfortunately 
insulin sensitivity was not assessed in this study. 
Our results are in agreement with findings from previous studies of shorter duration (≤ 5 weeks) 
in lean and overweight subjects, finding no effect of industrial TFA on pancreatic insulin secre-
tion or insulin sensitivity5,6,8. We hypothesized that the failure of these studies to show an effect 
was either due to i) too short study durations not allowing time for TFA to be incorporated into 
myocellular membrane lipids with possible influence on insulin sensitivity13, ii) too low TFA 
intake levels, and/or iii) too young and healthy study populations.  Lovejoy et al.6 found a trend 
towards a decrease in insulin sensitivity after TFA intake only in overweight subjects and Vega-
Lopez et al.27 reported that TFA consumption modestly increased fasting insulin levels in older 
and moderately hyperlipidemic subjects.  
In accordance, in moderately overweight subjects consumption of a single meal with 10 E% 
TFA resulted in increased postprandial levels of insulin and C-peptide compared to a meal with 
cis MUFA9, and the same picture emerged in type 2 diabetic patients after consumption of a diet 
very high in industrial TFA (20 E%)10. In the latter study an increase of 59% in postprandial 
insulin response was seen after TFA compared to MUFA intake, whereas the response did not 
differ from that seen after consumption of saturated fatty acids.  
This raises the question of whether TFA intake only will exert adverse effects on glucose me-
tabolism at very high intake levels in subjects with a strong underlying predisposition to insulin 
resistance, and only when compared to MUFA. Alternatively, very long exposures may be re-
quired. After 6 years on a diet with 8 E%, TFA-increased postprandial insulin concentrations 
were found in green monkeys compared to monkeys fed MUFA22. However, the question has 
not previously been sought answered by studies using adequate insulin sensitivity assessment 
methodology. In the present study we failed to find an effect in abdominally obese, older 
women after a relatively long period of high TFA exposure employing the validated OGTT-
derived ISIcomposite.  
As no detrimental effects on glucose metabolism were seen in metabolically vulnerable subjects 
after 16 weeks of high daily amounts of TFA in the present study, we conclude that either i) 
unrealistically high intake levels and/or a longer duration of exposure may be required for insu-
lin sensitivity to be affected by intake of industrial TFA or ii) the observational data showing 
associations to risk of type 2 diabetes are potentially flawed by confounding. It may indeed be 
difficult to separate the effects of industrial TFA intake per se from that of an unhealthy life 
style with high fast food consumption.  
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ABSTRACT 
Background: Intake of industrial trans fatty acids (TFA) has been positively associated to systemic 
markers of low-grade inflammation and endothelial dysfunction in cross-sectional studies, but results 
from intervention studies are inconclusive. 
Objective: To examine the effect of a high intake of TFA on systemic biomarkers of inflammation 
and endothelial dysfunction; adipose tissue expression of adipokines and content of ceramide; and 
urinary markers of oxidative stress. 
Design: A 16-weeks double-blind parallel intervention study where 52 healthy overweight postmeno-
pausal women were randomized to receive either partially hydrogenated soybean oil providing 15.7 g 
per day of TFA or a control oil where TFA was replaced by mainly oleic and palmitic acid.  
Results: After 16 weeks, TFA exposure resulted in an increase in baseline-adjusted serum tumor 
necrosis factor (TNF) α of 12% (95% confidence interval (CI): 5 – 20; P=0.002) compared to controls. 
Plasma soluble TNF receptors 1 and 2 were also increased by TFA [155 pg/ml (CI: 63 – 247); 
P<0.001 and 480 pg/ml (CI: 72 – 887); P=0.02, respectively]. Serum C-reactive protein, interleukin 
(IL) 6 and adiponectin and subcutaneous abdominal adipose tissue mRNA expression of IL6, IL8, 
TNFα and adiponectin and ceramide content were not affected by the dietary intervention, neither was 
the urinary marker of oxidative stress 8-iso-prostaglandin-F2α.  
Conclusions: This dietary trial shows that the mechanisms linking dietary TFA to cardiovascular 
disease is likely to involve induction of low-grade systemic inflammation, although this is not mir-
rored in subcutaneous adipose tissue mRNA expression within 16 weeks. 
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INTRODUCTION 
Intake of industrially produced trans fatty acids (TFA) is in cross-sectional studies positively 
associated to systemic concentrations of various inflammatory markers such as C-reactive pro-
tein (CRP), tumor necrosis factor α (TNFα) and interleukin 6 (IL6)1-3. Recently, similar associa-
tions to inflammatory markers were found with intake of partially hydrogenated vegetable oil, 
which is the primary source of industrial TFA4. Consequently, induction of low-grade systemic 
inflammation has been suggested as a mechanism by which TFA intake increases the risk of 
cardiovascular disease (CVD) and type 2 diabetes, as seen in large prospective cohort studies5,6. 
However, the evidence from randomized studies is limited; one study has shown increased pro-
duction of TNFα and IL6 in stimulated mononuclear cells from humans after high TFA con-
sumption7 and two studies found increased CRP blood concentrations8,9, whereas several others 
have failed to find an effect of dietary TFA on inflammatory markers10-12.  
TFA intake has also been positively associated with markers of endothelial dysfunction, such as 
E-selectin and adhesion molecules, in a cross-sectional analysis of the Nurses’ Health Study3, a 
finding which causality was strengthened by a randomized trial showing higher concentrations 
of plasma E-selectin after TFA consumption8. In concordance with this, a study by de Ross et 
al.13 suggested that TFA decrease flow-mediated vasodilation, which is a more direct measure 
of endothelial function, although this finding failed to be confirmed in our hands14. 
Furthermore, TFA intake has been suggested to increase oxidative stress in humans, which 
might accelerate diseases such as CVD and type 2 diabetes15. An increase in the urinary concen-
tration of 8-iso-prostaglandin-F2α (8-iso-PGF2α), a marker of the whole-body level of oxidative 
stress in vivo16, has previously been documented after high intakes of conjugated linoleic acid 
(CLA), and the TFA isomers trans18:1n-7 and trans18:1n-617-19.  
In the present dietary intervention study we examined the effect of a high intake of industrial 
TFA on systemic and adipose biomarkers of inflammation. Also, we wished to investigate pos-
sible effects on markers of endothelial dysfunction and oxidative stress. 
 
SUBJECTS AND METHODS 
This work presents data from a dietary intervention study examining the effect of a high intake 
of TFA on a range of risk markers for CVD and type 2 diabetes. Here we report the results for 
systemic markers of low-grade inflammation and endothelial dysfunction, urinary markers of 
oxidative stress as well as adipokine expression and ceramide content in subcutaneous abdomi-
nal adipose tissue (AT).  
The details of this 16-week (wk) double-blind, parallel dietary intervention study has been re-
ported previously20. In brief, 52 women were randomized to two test diets by using a computer-
generated randomization sequence. Subjects in the TFA group were given 26 g/d of partially 
hydrogenated soybean oil (providing 15.7 g/d TFA) incorporated into 2 daily bread rolls (2500 
kJ), whereas subjects in the control (CTR) group received bread rolls with a low TFA oil con-
sisting of a 50/50% mixture of palm oil and high oleic sunflower oil. The test fats were kindly 
supplied by AarhusKarlshamn, Denmark. The fatty acid (FA) composition of the two test fats 
mainly differed in the content of TFA, palmitic (16:0), oleic (cis18:1) and linoleic acid (cis18:2) 
as shown in Table 1. The data were collected at wk 0 (baseline), 8 and 16. 
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Subject were healthy; moderately overweight (body mass index (BMI) 25 - 32 kg/m2); waist 
circumference > 80 cm; postmenopausal for the last year; and aged 45-70 years. Criteria for 
exclusion were diabetes or other chronic diseases; history of CVD; smoking; hypertension; hy-
perlipidemia, hypercholesterolemia; hyperglycemia; use of hormones or anti-hypertensive, anti-
lipidemic or anti-cholesterolemic drugs;  recent weight changes; strenuous physical activity; and 
abnormalities in routine biochemical and haematological tests.  
To assess the effect of body weight on the inflamma-
tory markers, the study included 19 lean reference 
women (BMI = 19-24 kg/m2; waist circumference ≤ 
80 cm) who underwent baseline examinations only. 
These reference subjects fulfilled the same inclusion 
and exclusion criteria as the intervention subjects, 
apart from the limits for BMI and waist.  
After having received both verbal and written infor-
mation, all participants gave written consent. The 
study was approved by the Municipal Ethical Com-
mittee of The Capital Region of Denmark in accor-
dance with the Helsinki-II declaration (H-B_2007-
089) and was registered at clinicaltrials.gov as 
NCT00655902. 
Sample collection and analysis 
At all visits subjects were fasted for 10h. After minimum 10 min of rest, blood was sampled 
from an antecubital vein into Vacutainer lithium heparin gel tubes and silicone coated serum 
tubes (BD Medical Systems, Franklin Lakes, NJ, USA). Serum was obtained after 30 minutes 
clotting at room temperature and 10 min centrifugation at 3000 G. Samples were stored at -80˚C 
before analysis. 
C-reactive protein (#6801739) was analyzed on a Vitros 5.1 (Johnson & Johnson, Rochester, 
NY, USA) with an inter-assay variation coefficient (CV) of 5.0% and a detection limit of 0.1 
mg/L (minimum detectable concentration + 2 x standard deviation). Samples (2%) that were 
below the CRP detection limit (DL) of 0.1 mg/L were defined as 0.05 mg/L. A total of seven 
CRP values (four at baseline, two at week 8 and one among the reference subjects) were ex-
cluded due to CRP concentrations >10 mg/L, indicating acute inflammation. Serum adiponectin 
(CV: 7.3%) was analyzed by a human enzyme-linked immunosorbent assay (ELISA) kit (B-
Bridge International, California, USA). Serum TNFα (CV: 4.7% , DL: 0.11 pg/mL) and IL6 
(CV: 9.8%, DL: 0.039 pg/mL) concentrations were also measured by using human ELISA kits 
(Quantikine HS #HSTA00D & #HS600B, ELISA, R&D Systems, Abingdon, UK). 
Concentrations in plasma and serum of soluble TNF receptor 1 (sTNF-R1) (CV:5.3%, DL: 60 
pg/ml) and soluble TNF receptor 2 (sTNF-R2) (CV:7.6%, DL:79 pg/ml) were measured by 2-
plex immunoassays (#HSCR-32K) using fluorescently labeled microsphere beads kits (Milli-
pore, Billerica, MA, USA) and analysis on BioPlex 200® (Biorad, Hercules, CA, USA);  as 
well as by ELISA (#DRT100 & DRT200, R&D Systems) (CV:2.8%, DL:1.14 pg/mL & 
CV:2.4%, DL:0.78 pg/mL, respectively). A 3-plex kit (Millipore #HCVDI-67AK) was used for 
measurement in plasma and serum of soluble E-selectin (sE-selectin) (CV:11.8%, DL:2.1 
Table 1: Fatty acid composition of the 
trans fat (TFA) and the control fat 
Fatty acid (w/w%) CTR   TFA  
C14:0 0.7 0.2 
C16:0 26.7 12.7 
C18:0 3.8 6.2 
C18:1-trans < 0.7 59.0 
C18:1-cis 61.4 19.6 
C18:2-trans  < 0.1 1.4 
C18:2-cis  6.6 0.2 
C20:0 0.4 0.4 
C22:0 0.4 0.3 
Total trans fatty acids < 0.7 60.4 
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ng/ml), soluble vascular cell adhesion molecule 1 (sVCAM-1) (CV:4.1%, DL:1.1 ng/ml), and 
soluble intercellular adhesion molecule 1 (sICAM-1) (CV:7.6%, DL:1.8 ng/ml).  
The concentration of free 8-iso-PGF2α was analyzed in 24-hour urine samples, with the use of a 
highly specific and sensitive radioimmunoassay as previously described by Basu21, and was 
adjusted for creatinine value measured with a commercial kit (IL Test; Monarch Instrument, 
Amherst, NH). 
A subcutaneous AT biopsy was taken from the abdominal region under local anaesthesia (1% 
lidocaine) on the left or right side of the abdomen about 5 cm lateral from the umbilicus using a 
Hepafix Luer lock syringe (Braun Medical, Bethlehem, PA) and a 2.10 x 80 mm Braun Medical 
Sterican needle. The biopsy (~500 mg) was washed in physiological saline, divided into 3 sterile 
cryo tubes, immediately frozen in liquid nitrogen and stored at -80 °C until analysis.  
AT (200 mg) were homogenized in TriZol reagent (Gibco BRL, Life Technologies, Roskilde, 
Denmark) and total RNA was extracted following the manufacturer’s protocol. RNA was quan-
tified by measuring absorbance at 260 and 280 nm using a NanoDrop 8000 (NanoDrop prod-
ucts, Bancroft, DE, USA), and there was a ratio ≥1.8. The integrity of the RNA was checked by 
visual inspection of the two ribosomal RNAs, 18S and 28S, on an agarose gel. 
For real-time reverse transcriptase polymerase chain reaction (PCR), complementary DNA was 
constructed using random hexamer primers as described by the manufacturer (Verso cDNA kit, 
Abgene, Epsom, UK). Then KAPA SYBR FAST qPCR mastermix (Kapa Biosystems, Inc. Wo-
burn, MA, USA) and the following primer pairs were added:  
IL6: AAATGCCAGCCTGCTGACGAAG and AACAACAATCTGAGGTGCCCATGCTAC, 
TNFα: CGAGTGACAAGCCTGTAGC and GGTGTGGGTGAGGAGCACAT,  Adiponectin: 
CATGACCAGGAAACCACGACT and TGAATGCTGAGCGGTAT,  IL8: 
TTGGCAGCCTTCCTGATTTC and AACTTCTCCACAACCCTCT-G,  ß-actin: 
TGTGCCCATCTACGAGGGGTATGC and GGTACATGGTGGTGCCGCCAGACA.  
Real-time quantification of genes was performed using an ICycler from Bio-Rad (Bio-Rad 
Laboratories, Hercules, CA, USA).  Each gene was amplified in separate tubes, and the increase 
in fluorescence was measured in real time. The threshold cycle was calculated, and the relative 
gene expression was calculated essentially as described in the User Bulletin no. 2, 1997, from 
Perkin-Elmer. All samples were amplified in duplicate. A similar set-up was used for negative 
controls, except that the reverse transcriptase was omitted and no PCR products were detected 
under these conditions.  
AT ceramide content was analyzed basically as have been described22. In brief, AT was ex-
tracted using the Folch procedure, ceramide with C17 long-chained base (LCB) was added dur-
ing the extraction procedure. Glycerolipids were hydrolyzed using mild alkaline hydrolysis and 
ceramide was isolated from other sphingolipids using amino-propyl cartridges. The isolated 
ceramide were hydrolyzed to LCB and free FA, the LCB was derivatized with o-phtalaldehyde 
and analyzed using an HPLC-system equipped with an amino-propyl column. Ceramide content 
was determined from fluorescence intensity of the endogenous LCB-peaks in relation to the 
internal standard. 
For assessment of AT triglyceride FA composition, lipids were spiked with extraction surro-
gates and solvent extracted23. Triglycerides were isolated from 50-100μg of lipid with amino-
propyl solid phase extraction columns using modification of published procedures24.  Samples 
were transesterified and isolated FA methyl esters were analyzed by gas chromatography on 
high polarity cyano-silica columns with flame ionization detection20.  
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Statistical analyses 
The study size was estimated based on the effect of TFA on the LDL-cholesterol to HDL-
cholesterol ratio, as reported previously20. 
Data were analyzed using Statistic Analysis Package, SAS© version 9.1 (SAS Institute, Cary, 
NC, USA). The analysis included those participants who completed the intervention (n=49). 
The statistical significance level is defined as P<0.05. 
Baseline values for the overweight intervention subjects were compared to values for the lean 
reference subjects by 2-tailed unpaired t-tests or Kruskal-Wallis’ χ2 tests for skewed data.   
Analysis of covariance (ANCOVA) was used to assess the baseline-adjusted difference between 
diet groups for variables measured at wk 0 and 16, i.e. the baseline value was included as a co-
variate. For variables measured at wk 0, 8 and 16 a mixed model of repeated measures examin-
ing the effect of diet and time (wk 8 and 16) and their interactions was applied, again with the 
baseline value as a covariate and with “subject” as a random effect. Variance homogeneity and 
normality were investigated by residual plots, histograms and Shapiro-Wilk’s test and data was 
log transformed when needed. Changes within groups from baseline to wk 16 were evaluated by 
2-tailed paired t-tests or Signed Rank tests for skewed data. 
 
RESULTS 
Baseline characteristics of the 24 completers in the TFA group were comparable to those of the 
25 completers in the control group, and lean references were adequately matched for age and 
height (Table 2). 
Table 2: Baseline characteristics for subjects in the trans fat (TFA; n=24) and control (CTR, n=25) 
groups and for lean references (lean ref.; n=19). 
  TFA CTR Lean ref. 
Age (y) 58.5 ±  4.6 58.8 ±  5.5 60.1 ±  5.9 
Height (cm) 165.3 ±  5.5 166.9 ±  5.2 166.7 ±  4.3 
Weight (kg) 78.7 ±  7.1 78.4 ±  8.6 59.4 ±  4.8 1 
BMI (kg/m2) 28.8 ±  1.7 28.1 ±  2.2 21.3 ±  1.4 1 
Waist circumference (cm) 97.1 ±  7.3 95.5 ±  6.8 74.9 ±  3.8 1 
Urine 8-iso-PGF2α (nmol/mmol creatinine) 2 0.28 (0.24; 0.32) 0.31 (0.24; 0.43) 0.35 (0.28; 0.41) 
Values are means ± SD or geometric means (95%CI) for skewed data, completers only. 1 Significantly different from 
overweight intervention subjects (diet groups combined) by 2-tailed unpaired t-tests (P<0.05). 2 n=18 in lean refer-
ence group due to exclusion of one outlier. 
Systemic markers of low-grade inflammation  
The serum TNFα concentration increased by 10 ± 3% in the TFA group during the intervention 
(P= 0.02 for within-group change) while decreasing by 2 ± 2% in the CTR group (non-
significant (ns)), whereby the mean baseline-adjusted TNFα concentration was 12% (95% con-
fidence interval (CI): 5 – 20) higher at week 16 compared to controls (P=0.002; Figure 1A).  
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The plasma concentration of sTNF-R1, as assessed by Bead array, increased by 22 ± 7% in the 
TFA group (P= 0.0003 for within-group change by paired t-test) vs. a decrease of 3 ± 6% (ns) in 
the CTR group during the 16-wk intervention, resulting in a baseline adjusted mean difference 
between diets of 155 pg/ml (CI: 63 – 247; P<0.001). The Bead array-assessed plasma concen-
tration of sTNF-R2 also increased more on the TFA diet: 14 ± 3% (P= 0.0007) vs. 2 ± 4% (ns) 
in the CTR group (mean baseline adjusted difference between diet groups: 480 pg/ml; CI: 72 – 
887; P=0.022).   
Figure 1: Systemic concentrations of markers of inflammation and endothelial dysfunction 
before and after 8 and 16 weeks (wk) of supplementation with 15.7 g/d trans fatty acids 
(TFA; dark grey bars; n=24) or a control oil (CTR; white bars; n=25), and in lean references 
(light grey bars; n = 19). Figure 1A: Tumor necrosis factor (TNF) α assessed by ELISA and 
soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1 and sTNF-R2) assessed by Bead 
array technology. Figure 1B: C-reactive protein (CRP; n=23, 22 and 18 in the TFA and CTR 
group and lean references, respectively, due to exclusion of CRP values > 10 mg/l), inter-
leukin 6 (IL6) and adiponectin, assessed by ELISA. Figure 1C: Soluble E-selectin (sE-
selectin), soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular adhesion 
molecule 1 (sVCAM-1) assessed by Bead array technology.   
Bars represent means (95% confidence intervals (CI)) for TNF-R1 and TNF-R2 and geomet-
ric means (CI) for all other variables. P-values are for effect of diet, by baseline-adjusted 
ANCOVA. *Significantly different from overweight intervention subjects (diet groups com-
bined); P<0.05 by 2-tailed t-tests or Kruskal-Wallis’ χ2 test. 
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As no randomized study previously has documented this effect of dietary TFA on soluble TNF 
receptor concentrations in plasma, we decided to further explore these finding by repeating the 
analyses using antibodies from a different provider and another platform (ELISA, see Methods 
section). For sTNF-R2 we obtained a similar difference between diets with ELISA, suggesting a 
robust difference([257 pg/ml; CI: 93 – 421; P=0.003; note that concentration were generally 
lower with ELISA due to different calibrations). For sTNF-R1 there was a trend in the ELISA-
assessed data similar to the that observed with Bead array, but the difference between diets did 
not remain significant (56 pg/ml; CI: -14 – 125; P=0.11). These differences between diet groups 
in plasma sTNF receptor concentrations were not present when the same analyses were carried 
out in serum (Supplemental Figure 1). 
While serum CRP tended to increase from baseline in both diet groups (P=0.12 in both groups), 
but with no difference between diets, neither serum adiponectin nor IL6 concentrations were 
affected by the dietary intervention (Figure 1B). 
Systemic markers of endothelial dysfunction  
Serum sE-selectin increased by 19 ± 4% in the TFA group during the intervention (P= 0.004). 
However, the baseline-adjusted relative difference between diets at wk 16 was not significant: 
8% (CI: -2 – 19; P=0.13; Figure 1C), since the serum sE-selectin concentration also increased 
in the CTR group (12 ± 5%; P=0.04). In plasma, the difference between diets in sE-selectin 
reached statistical significance (10%; CI: 1 – 21; P=0.04; data not shown). Serum sVCAM-1 
and sICAM-1 concentrations were not affected by the intervention and neither were plasma 
concentrations.  
Oxidative stress  
During the 16-wk intervention the concentration of the urinary marker of oxidative stress 8-iso-
PGF2α changed little in either diet group  (-7 ± 11% and  -3 ± 13% in the TFA and CTR groups, 
respectively) with no significant baseline-adjusted difference between diet groups (P=0.50).  
Fatty acid composition, mRNA expression of adipokines and ceramide content in adipose 
tissue  
In the TFA group there was an almost 2-fold increase in the AT content of the sum of the 
trans18:1n-9 and trans18:1n-7 isomers (from 0.47 ± 0.03% to 0.97 ± 0.06% of FA), which was 
not seen in the CTR group (P<0.01). There were no significant differences between diet groups 
in the sum of saturated, monounsaturated or polyunsaturated FA, respectively, nor were there 
differences in AT content of individual FA (Supplemental Table 1).  
The TFA intervention had no effect on the mRNA expression of IL6, IL8, TNFα or adiponectin 
in subcutaneous abdominal AT (Figure 2). The AT mRNA expressions of IL6, TNFα and adi-
ponectin were not significantly correlated to the respective serum concentrations at baseline in 
the overweight intervention subjects, nor were the changes in AT and serum over the course of 
the intervention correlated (P>0.20 for all).  
Paper IV - 8 
Baseline AT ceramide content was lower in lean references (176 ± 7 pmol/mg tissue protein) 
compared to in overweight subjects (320 ± 7 pmol/mg tissue protein). AT ceramide tended to 
decrease in the TFA group (by 8 ± 5%; P=0.09 for within-group change), but the change was 
not significantly different from the 1 ± 4% decrease in the CTR group (P=0.23 by baseline-
adjusted ANCOVA).  
 
DISCUSSION  
In addition to the previously described adverse effects of TFA on plasma cholesterol concentra-
tions20, we found that high TFA intakes (~7% of energy (E%)) increase the TNF system activity 
as shown by elevated circulating concentrations of TNFα and its soluble receptors TNF-R1 and 
TNF-R2. Thereby, the results of our study support the notion that the findings from previous 
cross-sectional analyses1-4,25 are causal, and suggest that part of the increased incidence of heart 
disease related to dietary TFA is due to induction of low-grade systemic inflammation.  
We are the first to report increased systemic concentrations of TNFα after TFA supplementa-
tion, and we substantiate our findings by showing concomitant increases in the soluble TNF 
receptors. TNFα, as well as other cytokines, is known to induce shedding of the soluble recep-
tors, and these may thereby be biomarkers of local TNFα activation or mirror overall systemic 
inflammation26. The soluble receptors affect the local and systemic availability of TNFα and 
appear to act as a buffer system either prolonging or attenuating the biological effects of 
TNFα26.  
Figure 2: Subcutaneous abdominal adipose tissue mRNA expression before and after 16 weeks (wk) 
of supplementation with 15.7 g/d trans fatty acids (TFA; dark grey bars; n=24; n= 23 for IL8) or a 
control oil (CTR; white bars; n=25), and in lean references (light grey bars; n = 17). mRNA expres-
sions are expressed relative to β-actin and bars represent geometric means (95% confidence inter-
vals). There were no differences between diet groups at wk 16 by ANCOVA with baseline value as a 
covariate (P>0.10). *Significantly different from overweight intervention subjects (diet groups com-
bined); P<0.001 by Kruskal-Wallis’ χ2 test.  IL6, interleukin 6; IL8, interleukin 8; TNFα, tumor 
necrosis factor α. 
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Soluble TNF receptors were positively associated with CHD risk in the Nurses’ Health Study, 
but not after adjustment for lipid and other cardiovascular risk factors27. When we adjusted for 
the TFA-induced 34% increase in the LDL-cholesterol to HDL-cholesterol ratio (as reported 
previously20), the difference between diets in TNFα and sTNF-R1 became more pronounced, 
suggesting that the effect of TFA was not mediated through blood lipid changes. The effect of 
diet for sTNF-R2 was attenuated slightly by adjustment for lipid concentrations.  
Others have examined the effect of TFA consumption on TNFα with discordant results. Han et 
al.7 showed increased production of TNFα (and IL6) in stimulated mononuclear cells of mildly 
hypercholesterolemic, older and overweight subjects after 32 days of 7 E% TFA intake from 
stick margarine compared to intake of soybean oil. In contrast, in two studies in young, lean and 
healthy subjects, supplementation with a mix of trans18:1n-7 and trans18:1n-6 (~3 E%) for 6 
weeks had no effect on plasma concentrations of TNFα, IL6, IL8 or adiponectin10, and 5 weeks 
consumption of 10 E% TFA from hydrogenated soybean oil did not affect the serum TNFα (or 
IL6) concentration when compared to palm stearin or high oleic palm olein9. It is possible, that 
the TNF system is more susceptible to TFA-induced activation in older and overweight subjects.  
The effect of the TFA-rich diet on sTNF-Rs was visible in heparinized plasma but not in serum. 
Hypothetically, the incorporation of TFA into cell membranes and ensuing change in cellular 
lipid rafts may have imposed conformational changes on the extra-cellular domains of mem-
brane-bound TNF receptors28, which may have persisted after shedding from the membrane. 
The coagulation cascade occurring during serum formation activates several proteases that may 
alter the sTNF-R molecules. A difference in configuration between sTNF-Rs exposed to TFA or 
control fat could affect the extent to which the molecules are modified and thereby their recog-
nition by specific antibodies.  
Wong et al. described great differences in cytokines between serum and plasma29, and hypothe-
sized that this might be due to i) degradation of the cytokines during the clotting process, ii) ex 
vivo degranulation of granulocytes and platelets, and/or iii) non-specific interference related to 
the protein matrix. For sTNF-R we observed a difference between concentrations in plasma and 
serum, but more importantly we found that the sTNF-R response to TFA exposure is detectable 
in plasma but not in serum. Whatever the explanation, our observations suggest that plasma is 
the material of choice for studying the effect of dietary fats on sTNF-R. Notably, cross-sectional 
associations between TFA intake and sTNF-Rs were detected in studies analyzing plasma1-3, but 
not in one using serum samples25.  
Previous intervention studies examining the effect of TFA on systemic CRP concentrations are 
limited and contradictory. In studies providing healthy subjects with 8 or 10 E% TFA, the con-
centration of CRP increased compared to provision of carbohydrate and oleic acid8 or compared 
to oleic acid/polyunsaturated FA or palmitic/oleic acid9. In contrast, CRP was unaffected by 
dietary TFA in a study comparing diets with four types of margarine (up to 5.2 E% TFA),  but-
ter or soybean oil11, in a study comparing intake of partially hydrogenated soy bean oil (4 E% 
TFA) to corn oil12 and in a study comparing stick margarine intake (3.6 E% TFA) with a but-
ter/canola oil mix30. It is possible that very high dietary TFA levels are needed before CRP is 
affected, or more likely, that most studies have simply been underpowered to detect the small 
changes induced by TFA; the difference between diets in CRP in the two crossover studies 
showing significant effects of TFA was only 0.12 mg/l  (n=41)9 and 0.20 mg/l (n=50)8, respec-
tively. In our study, the baseline-adjusted mean values for CRP at wk 16 in the TFA and CTR 
groups were 1.93 mg/l (CI: 1.53 – 2.43) and 1.91 mg/l (CI: 1.50 – 2.42), respectively. Consis-
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tent with the width of these confidence intervals, we were not able to detect a difference be-
tween diet groups of the size previously reported.  
We did not see a clear pattern for the effect of TFA on systemic markers of endothelial dysfunc-
tion. Serum sE-selectin increased in the TFA group, but not significantly more than in controls. 
In contrast, sVCAM-1 and sICAM-1 concentrations remained unchanged. An increase in E-
selectin after 5 weeks of 8 E% TFA consumption (compared to carbohydrate, stearic acid, oleic 
acid and a mix of lauric, myristitic and palmitic acid) has been reported in a previous trial8.  
Others have documented that urinary 8-iso-PGF2α, a validated marker of oxidative stress in vivo, 
is increased by intake of CLA and the TFA isomers trans18:1n-7 and trans18:1n-617-19. How-
ever, a mixture of TFA isomers, as provided to the subjects in the present study, had no detect-
able effect on the urinary concentration of 8-iso-PGF2α and we hypothesize that the increase in 
oxidative stress markers previously seen with trans18:1n-7 consumption may be ascribed to 
endogenous conversion to CLA18.  
The dietary intervention did not affect mRNA expression of inflammatory markers and cera-
mide content in subcutaneous AT. This may be due to limited incorporation of TFA into AT 
during the 16 weeks of intervention; the AT content of the two predominant TFA isomers dou-
bled in the TFA group, but still only constituted ~1% of total FA. The low degree of TFA incor-
poration is not surprising given the half life of subcutaneous AT FA of 6-18 months31,32. 
However, as the visceral depot FA turnover is higher than that of the subcutaneous33 and since 
meal FA uptake is relatively larger in the former depot34, more TFA may have been incorpo-
rated here. Previously, the TFA concentration was shown to be higher in visceral compared to 
subcutaneous AT35. Also, the subcutaneous AT depot may not adequately reflect an effect of 
TFA on AT inflammation; macrophage infiltration is higher in visceral than in subcutaneous 
AT36 and in obese subjects, the mRNA of TNFα was found to be considerable higher in visceral 
compared to subcutaneous AT37,38.  
The facts that cytokines are also produced by other tissues/cells, e.g. skeletal muscle39, and that 
transcript and protein turnover is different40, would also explain why mRNA expression did not 
correlate with serum levels.  
In conclusion, our research indicates that the TFA-associated increase in cardiovascular risk, 
beyond the adverse effect explained by changes in blood lipids, is likely to be due to induction 
of systemic low-grade inflammation.  
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Supplemental Figure 1: Mean concentrations of soluble tumor necrosis factor receptor 1 
(sTNF-R1) in plasma (panel A) and serum (panel B) and of soluble tumor necrosis factor 
receptor 2 (sTNF-R2) in plasma (panel C) and serum (panel D) assessed by Bead array and 
ELISA technology.  
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Supplemental Table 1: Fatty acid composition in subcutaneous abdominal adipose tissue (AT) triglyc-
erides in the trans fat (TFA; n=23) and control (n=25) groups and in lean references (n=18). 
Fatty acid  
(nmol/g AT) Week 0 Week 16 ∆Week 0-16 
Group mean dif-
ference (95%CI) 1 
C14:0          -50 (-201; 101) 
TFA 773 ± 36 705 ± 49 -71 ± 52   
CTR 732 ± 37 745 ± 56 12 ± 64   
Lean ref. 737 ± 41         
C16:0          -663 (-1742; 415) 
TFA 5812 ± 296 5023 ± 279 -739 ± 335   
CTR 5477 ± 219 5606 ± 446 129 ± 474   
Lean ref. 4974 ± 246 2         
C18:0          116 (-59; 292) 
TFA 525 ± 51 788 ± 58 255 ± 76   
CTR 498 ± 53 670 ± 63 172 ± 81   
Lean ref. 732 ± 65 2         
C20:0          0 (-9; 9) 
TFA 26 ± 3 30 ± 3 4 ± 4   
CTR 29 ± 3 29 ± 3 0 ± 5   
Lean ref. 43 ± 4 2         
C16:1n-7trans          5 (-16; 27) 
TFA 34 ± 4 3 29 ± 3 -6 ± 6   
CTR 25 ± 2 29 ± 9 3 ± 10   
Lean references 19 ± 3 2       
C16:1n-7cis          -119 (-469; 230) 
TFA 1742 ± 172 1457 ± 126 -219 ± 150   
CTR 1655 ± 99 1571 ± 124 -83 ± 165   
Lean ref. 1585 ± 110         
C18:1n-9trans        32 (10; 55) 4 
TFA 51 ± 6 96 ± 7  46 ± 11   
CTR 58 ± 7 62 ± 8 4 ± 11   
Lean references 69 ± 6       
C18:1n-7trans        32 (9; 54) 4 
TFA 71 ± 6 111 ± 8  41 ± 11    
CTR 74 ± 7 79 ± 8 5 ± 11   
Lean references 80 ± 7         
C18:1n-12cis&C18:1n-5trans?          27 (9; 45) 4 
TFA 72 ± 6 99 ± 7 27 ± 7   
CTR 79 ± 6 76 ± 7 -3 ± 7   
Lean ref. 79 ± 7         
C18:1n-9cis          -537 (-2497; 1422)
TFA 11565 ± 571 9728 ± 615 -1598 ± 619   
CTR 10694 ± 461 10162 ± 728 -532 ± 914   
Lean ref. 10530 ± 455         
C18:1n-7cis          -34 (-126; 59) 
TFA 566 ± 46 468 ± 25 -76 ± 41   
CTR 514 ± 25 499 ± 37 -15 ± 46   
Lean ref. 446 ± 31 2         
C18:2n-6cis          49 (-548; 642) 
TFA 3403 ± 150 2685 ± 166 -667 ± 195   
CTR 3230 ± 156 2635 ± 234 -595 ± 294   
Lean ref. 3242 ± 169         
C20:3n-6cis          2 (-18; 21) 
TFA 76 ± 7 61 ± 6 -12 ± 9   
CTR 69 ± 5 59 ± 7 -10 ± 9   
Lean ref. 67 ± 8         
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Supplemental Table 1 (continued)    
Fatty acid  
(nmol/g AT) Week 0 Week 16 ∆Week 0-16 
Group mean dif-
ference (95%CI) 1 
C20:4n-6cis          24 (-28; 76) 
TFA 174 ± 14 176 ± 17 5 ± 25   
CTR 143 ± 12 149 ± 18 6 ± 18   
Lean ref. 155 ± 14         
C22:4n-6cis          -2 (-14; 11) 
TFA 70 ± 6 38 ± 3 -30 ± 7   
CTR 61 ± 4 41 ± 5 -21 ± 7   
Lean ref. 38 ± 5 2         
C18:3n-3&C20:1n-9cis          14 (-101; 128) 
TFA 540 ± 29 486 ± 33 -53 ± 31   
CTR 530 ± 29 470 ± 46 -60 ± 54   
Lean ref. 657 ± 51 2         
C20:5n-3cis          4 (-13; 21) 
TFA 58 ± 6 3 57 ± 6 0 ± 9   
CTR 79 ± 8 53 ± 5 -26 ± 10   
Lean ref. 78 ± 10         
C22:5n-3cis          4 (-25; 33) 
TFA 155 ± 11 110 ± 10 -43 ± 16   
CTR 159 ± 13 107 ± 10 -53 ± 14   
Lean ref. 121 ± 13 2         
C22:6n-3cis          9 (-26; 44) 
TFA 188 ± 14 127 ± 14 -60 ± 21   
CTR 215 ± 20 120 ± 11 -95 ± 20   
Lean ref. 160 ± 22         
ΣSFA          -589 (-1910; 733) 
TFA 7135 ± 349 6545 ± 348 -551 ± 424   
CTR 6736 ± 278 7050 ± 538 313 ± 583   
Lean references 6486 ± 264         
ΣMUFA-cis          -604 (-2974; 1766)
TFA 14100 ± 776 11988 ± 750 -1786 ± 795   
CTR 13098 ± 564 12477 ± 882 -621 ± 1109   
Lean references 12808 ± 582         
ΣPUFAn-6cis          76 (-567; 718) 
TFA 3724 ± 164 2960 ± 180 -704 ± 220   
CTR 3504 ± 161 2884 ± 251 -620 ± 311   
Lean references 3503 ± 179         
ΣPUFAn-3cis          39 (-137; 215) 
TFA 942 ± 51 780 ± 58 -156 ± 69   
CTR 983 ± 55 749 ± 65 -234 ± 80   
Lean references 1016 ± 88         
n-6:n-3 PUFA          -0.1 (-0.4; 0.2) 
TFA 4.0 ± 0.1  3 3.9 ± 0.1 -0.1 ± 0.1   
CTR 3.7 ± 0.1 3.9 ± 0.1 0.2 ± 0.1   
Lean references 3.7 ± 0.2         
Values are means ± SEM, completers only. AT, adipose tissue; MUFA, mono-unsaturated fatty acids; PUFA, poly-
unsaturated fatty acids; SFA, saturated fatty acids. 1Baseline-adjusted least square mean difference (95% CI) between 
diet groups at week 16. 2Significantly different from overweight interventions subjects (diet groups combined) by 
two-tailed t-test (P<0.01). 3Significantly different from CTR group by two-tailed t-test (P<0.05). 4Significant differ-
ence between diets by baseline-adjusted ANCOVA (P<0.01).  
 
 
 
